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Abstract 
The pleiotropic cytokine granulocyte-colony stimulatory factor (G-CSF) is mainly 
required for the generation of neutrophils, but its role in macrophage generation has 
also been reported. In addition, G-CSF is effective for the down-regulation of 
inflammatory cytokines and ameliorating gut disorders, such as colitis. However, the 
G-CSF function in macrophage generation and gut immunity remains unclear. The 
first focus of this thesis was to assess the role of G-CSF in macrophage generation 
and its contribution to gut immunity. G-CSF was found to promote the generation of 
Gr-1high/F4/80+ macrophages in macrophage (M)-CSF-treated bone marrow cells, 
most likely through suppressing cell death. Gr-1high macrophages showed anti-
inflammatory/regulatory macrophage (M2)-like cytokine and surface marker profiles. 
G-CSF receptor deficient (G-CSFR-/-) mice harbored less gut macrophages, but had a 
similar number of neutrophils in the gut. In addition, adoptive transfer of G-CSF-
treated bone marrow-derived macrophages (G-BMDM) showed a dominant gut-
homing phenotype. G-CSFR-/- mice were also more susceptible to dextran sulfate 
sodium (DSS)-induced colitis than wild-type mice and adoptive transfer of G-BMDM 
protected these mice from DSS-induced colitis. The second focus of this thesis was to 
explore the signaling mechanism(s) controlling the preferential G-CSF production 
over inflammatory cytokines in probiotic bacteria-exposed BMDM. Lactobacillus 
rhamnosus GR-1 (GR-1) renders several immunomodulatory effects, at least in part, 
through preferentially inducing G-CSF in macrophages. However, the mechanism(s) 
by which GR-1 induces preferential G-CSF production in macrophages is still 
unknown. Among 84 genes tested, G-CSF was the cytokine induced at highest levels 
in GR-1-treated BMDM, but the induction of inflammatory cytokines, such as TNF-α, 
was minimal. The signaling pathway of GR-1-preferential G-CSF production was 
TLR2-, NF-κB-, ERKs- and PI3K/Akt-dependent. A secreted protein-like molecule(s) 
was found to be responsible for GR-1-preferential G-CSF production.  
Collectively, these results demonstrated the immune regulatory function of G-CSF on 
macrophages in gut immunity and a potential mechanism of action of certain 
probiotics. 
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1.1 THE IMMUNE SYSTEM 
The main and crucial function of the immune system is to prevent or limit microbial 
infections using an interactive network of organs and hematopoietic cells. The 
immune system consists of several organs and cell types that monitor foreign 
antigens, as well as abnormal tissues or cells, and function to eliminate those that are 
considered a health threat [1]. The immune system is divided into two arms: the 
innate immune system and the adaptive immune system.  
The innate immune system is evolutionary ancient and consists of cells, such as 
macrophages, that respond rapidly to pathogens through recognizing the presence of 
conserved constituents of microorganisms. This pivotal subsystem of the body’s 
immune system comprises cells known as leukocytes that include natural killer cells, 
mast cells, eosinophils, basophils, neutrophils, dendritic cells (DCs) and 
macrophages. The innate immune system provides the first line of defense against 
infections and also initiates the development of an adaptive immune response. 
Cytokines play an important role in such innate immune response and those involved 
in this process are mainly produced by macrophages. In fact, macrophages regulate 
responses in both arms of immunity by participating in the anti-infectious function, 
antigen presentation and co-activation of lymphocytes that all employ cytokine 
release [2]. Macrophages, as a major source of many cytokines, are therefore 
important immune cells in shaping overall immune responses. In contrast, the 
adaptive immune system contains B and T lymphocytes and is more evolutionary 
recent and can provide lifelong immunity to the host, but this is not immediate [1, 3, 
4]. The combined effects of innate and adaptive immune systems represent the main 
defense mechanism of the host against infectious agents [3].  
Cells of both innate and adaptive arms of the immune system communicate with each 
other through cytokines, soluble mediators and cell surface ligands, to shape proper 
immune responses. To date, various types of cytokines have been found, including 
interleukins (ILs), chemokines, and growth factors (such as colony-stimulating 
factors; CSFs). ILs, which are mainly produced by immune cells, act on immune cells 
to regulate their function; however, chemokines, which are produced by many 
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different cell types, are involved in recruitment or movement of immune cells [5]. 
Growth factors stimulate the survival or development of lineage-specific precursor or 
differentiated cells. The effects of cytokines are complex, as each cytokine by itself or 
in combined with other cytokines has different functions on target cells. Abnormal 
production of cytokines has shown to be associated with various inflammatory 
diseases, such as inflammatory bowel diseases (IBD) [6].   
1.2 MACROPHAGES 
Macrophages, as key innate immune cells, fulfill a wide range of tissue- and organ-
specific functions, including developmental, metabolic and inflammatory actions [7, 
8]. These cells represent the mononuclear phagocytic system (MPS), which also 
comprises circulating monocytes, DCs and bone marrow progenitor cells [9].  
Macrophages are distributed through all body tissues and acquire specific phenotypes 
to fulfill tissue-specific functions in response to the tissue cytokine milieu. They are 
located in the gut (lamina propria macrophages), lymph nodes, spleen, liver (Kupffer 
cells), kidney (mesangial cells), lung (alveolar macrophages), eye (intraocular 
macrophages), connective tissues (histocytes), serous cavities (pleural and peritoneum 
macrophages), bone (osteoclast), synovium, skin, and central nervous system 
(microglia) [10].  
1.2.1 Macrophage Origin and Development 
In adults, tissue macrophage populations are maintained by self-renewal of local 
precursor cells, which initially arise from the yolk sac and/or fetal liver progenitors in 
development, and recruitment of circulating monocytes, which are originated from 
common myeloid progenitors in the bone marrow [9, 11, 12]. In the bone marrow, 
hematopoietic stem cells (HSCs) give rise to the multipotent common myeloid 
progenitor cells (CMPs; defined by surface marker expression: cluster of 
differentiation (CD) 34+ and stem cell antigen-1- (SCA-1-)) [13, 14], granulocyte-
macrophage precursors (GMPs; CD34+, CD16+ and CD32+) [13], and 
macrophage/DC progenitors (MDPs; CD115+, CX3C chemokine receptor 1 
	  4	  
(CX3CR1)+ and CD135+). MDPs further develop to monocytes/macrophages, 
conventional/monocyte-derived DCs or plasmacytoid DCs without monocytic 
intermediates [15]. Recent studies also showed that MDPs give rise to a new subset of 
cells known as common monocyte progenitors (cMoPs; CD115+, CX3CR1+ and 
Ly6C+), which differentiate to Ly6Chigh monocytes (CD115+, CX3CR1low, C-C 
chemokine receptor type 2 (CCR2)high and CD62Lhigh) upon leaving bone marrow and 
then to Ly6Clow monocytes (CD115+, CX3CR1high, and CCR2low and CD62Llow) after 
arriving local tissues or organs and differentiating to macrophages [16].  
Macrophage lineage survives, proliferates and differentiates under the influence of 
CSFs, mainly macrophage-CSF (M-CSF) and granulocyte-macrophage-CSF (GM-
CSF), which regulate expression of transcription factors that are important in 
monopoiesis.  
Purine-rich nucleic acid binding protein 1 (PU.1) transcription factor belongs to the 
E26 transformation-specific (ETS) transcription factor family and is involved in the 
development of myeloid lineages [17]. Different expression levels of PU.1 in 
progenitor cells were shown to direct such development; where high levels of PU.1 
expression favor DC development and moderate levels of PU.1 expression promote 
macrophage over neutrophil development [18, 19]. One of the mechanisms 
underlying such a graded response to PU.1 expression levels is its competitive 
interaction with other transcription factors such as CCAAT/enhancer binding protein 
(C/EBP) α. C/EBPα is crucial for neutrophil development and competes with the 
PU.1 macrophage promoting activity. Indeed, the ratio of PU.1 to C/EBPα expression 
levels directs macrophage or neutrophil development [19-21]. M-CSF and GM-CSF 
both have been shown to induce PU.1 and therefore macrophage development [22, 
23]. M-CSF also induces other transcription factors such as interferon regulatory 
factor (IRF) 8, which is also important in the development of 
monocytes/macrophages [24, 25]. In contrast, granulocyte-CSF (G-CSF) has been 
shown to induce the expression of C/EBPα and growth factor independent (GFi) 1 
transcription factors, favoring neutrophil development [19, 26]. Overall, these 
observations demonstrated that CSFs induce interaction of a pool of transcription 
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factors, where expression levels dictate lineage commitment and subset specification.      
1.2.2 Macrophage Cell-Surface Markers 
Monocytes/macrophages express several specialized cell-surface molecules at 
different stages of development and activation states. These molecules, including 
CD11b, F4/80, CD11c, Ly6G, and Ly6C are often used as markers to distinguish 
monocytes/macrophages from other cell types [10]. Of note, the expression levels of 
these macrophage markers may differ among various tissues. Therefore, combinations 
of these markers should be used to identify macrophages in different stages of 
development and activation, and in different tissues. 
F4/80 
F4/80 glycoprotein, a member of the epidermal growth factor (EGF)-seven 
transmembrane (EGF-TM7) family, is a well-known specific cell-surface marker for 
murine macrophages [27, 28]. The human homologue is known as EGF-like module-
containing mucin-like hormone receptor-like 1 (EMR1). F4/80 is less expressed in 
monocytes than most tissue macrophages, including intestinal macrophages, Kupffer 
cells, red pulp macrophages of the spleen, epithelial macrophages, endothelial 
macrophages, microglia cells and Langerhans cells [29, 30]. However, expression of 
F4/80 in alveolar macrophages and myeloid DC is low, and absent in osteoclasts [29]. 
Expression of F4/80 was also observed on eosinophils [31], but not in neutrophils. 
Therefore, the presence of F4/80 has been used to distinguish macrophages from 
neutrophils. Interferon (IFN)-γ has been shown to down-regulate F4/80 expression 
[32]. GM-CSF driven macrophages, in contrast to their M-CSF driven counterparts, 
also showed reduced F4/80 expression [33, 34].  
Studies with F4/80 deficient mice have shown that F4/80 plays an important role in 
peripheral immune tolerance [35, 36]. These studies demonstrated that F4/80 
deficient mice fail to induce antigen-specific efferent regulatory T cells and result in 
Anterior Chamber Associated Immune Deviation (ACAID). To date, functions of 
F4/80 are not yet fully understood and await further characterization. 
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CD11b and CD11c 
CD11b, also termed macrophage-1 antigen (Mac-1) or complement receptor type 3 
(CR3), is a heterodimeric integrin comprised of an integrin αM (CD11b) subunit and 
a common integrin β2 (CD18) subunit. CD11b is found on leukocytes, including 
monocytes/macrophages, granulocytes such as neutrophils and natural killer cells 
(NKs) [37, 38]. CD11b binds to endogenous ligands, such as extra cellular matrix 
(ECM) proteins [39], intercellular adhesion molecule (ICAM)-l receptor [40] and 
complement C3bi factor deposited on the microbial surface [41]. It also binds to 
exogenous microbial and fungal ligands, such as lipopolysaccharide (LPS), mannose 
and zymosan [42, 43]. CD11b mediates adhesion, migration, chemotaxis, cellular 
activation in coordination with other receptors such as CD14, and phagocytosis 
during immune responses [38, 40].  
Similarly, CD11c, also known as CR4, consists of a CD11c subunit and a CD18 
subunit [44]. Different cell types express CD11c, including DCs, 
monocytes/macrophages, granulocytes (at lower level) and some lymphocytes [45]. 
Similar to CD11b, CD11c is involved in phagocytosis [46], adhesion and migration of 
cells [46, 47] as well as binding of cells to C3bi factor [48] and fibrinogen [49]. 
Ly6C and Ly6G 
The lymphocyte antigen 6 (Ly6) family of murine proteins are tethered to the cell 
membrane via a C-terminal Glycophosphatidylinositol (GPI) anchor [50]. Ly6C is 
expressed in monocytes/macrophages, neutrophils, subsets of CD4+ and CD8+ 
lymphocytes, and endothelial cells [51]. Ly6C is involved in co-stimulatory activation 
of T cells [52] and endothelial adhesion of leukocytes [53]. Recently, it was observed 
that monocytes released from mice bone marrow into peripheral blood express high 
levels of Ly6C, which gradually decrease [54, 55]. In a steady state, Ly6C- monocytes 
migrate to different tissues and give rise to tissue-resident macrophages or DCs with 
anti-inflammatory characteristics [55]. However, under inflammatory conditions, 
Ly6C+ monocytes are recruited to inflammatory sites and differentiate into 
macrophages or DCs [55-57]. The murine blood ratio of Ly6C- to Ly6C+ monocytes 
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in a steady state is 4:6; however, inflammatory conditions favor Ly6C+ monocytes 
[55, 58, 59]. In human, CD14+/CD16+ monocytes correspond to mouse Ly6C- 
monocytes and CD14high/CD16- monocytes correspond to mouse Ly6C+ monocytes 
[60].  
Ly6G, also known as granulocyte receptor 1 (Gr-1), is another member of Ly6 family 
expressed on granulocytes, mainly neutrophils [61, 62]. Gr-1 is a specific marker for 
distinguishing neutrophils from other leukocytes; however, its function is poorly 
understood. It has been speculated that Gr-1 is involved in myeloid expansion [63] 
and neutrophil migration [64]. Gr-1 associates with CD11a and CD11b and involves 
in adhesion and crawling of neutrophils, respectively [64, 65], leading to  optimal 
emigration of neutrophils out of the vasculature [65]. However, migratory effects of 
Gr-1 are controversial, as others have shown no migratory effect of Gr-1 on 
neutrophils [66].  
1.2.3 Macrophage Activation States 
Signals from cytokines, microbial components and damaged tissues can affect 
polarization of monocytes/macrophages towards one of the two distinct macrophage 
activation states: classically activated macrophages (M1) and alternatively activated 
macrophages (M2) [67]. This classification of macrophages mirrors the T helper 1 
(Th1) (cell-mediated immunity) and Th2 (humoral immunity) polarization; where 
Th1 cells induce bactericidal activity of macrophages by producing IFN-γ and Th2 
cells induce alternative states of activation through producing cytokines such as IL-4 
[60, 68]. 
M1 macrophages are mainly induced by the Th1 cytokine IFN-γ with or without 
microbial stimuli, such as LPS [67, 69]. Other cytokines such as tumor necrosis factor 
(TNF)-α and GM-CSF can also polarize macrophages towards the M1 phenotype [70-
72]. These macrophages are characterized by high production of IL-12, IL-23, IL-1β, 
TNF-α, IL-6, CXCL9 and CXCL10, and low production of IL-10. M1 macrophages 
also efficiently produce toxic intermediates, such as nitric oxide (NO) and reactive 
oxygen intermediates (ROI), and have high capacity of antigen presentation by the 
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expression of co-stimulatory molecules, such as CD80 and CD86 (Table 1.1) [69, 72, 
73]. M2 macrophages are further divided into three subsets, M2a, M2b and M2c, 
based on their stimuli and subsequent gene expression profiles. The M2a subset is 
induced by IL-4 or IL-13; however, the M2b subset is induced by immune complexes 
in combination with TLR/IL-1R ligands, such as LPS. The M2c subset is induced by 
IL-10, transforming growth factor (TGF)-β or glucocorticoid hormones [72, 74]. 
Cytokines such as M-CSF and chemokines such as C-C chemokine ligand (CCL) 2 
can also polarize macrophages towards the M2 phenotype [70, 71, 75]. M2 
macrophages are generally characterized by high production of IL-10, low production 
of IL-12 and IL-23, less efficient in production of TNF-α, and high expression levels 
of scavenger receptors (CD163), transferrin receptor (CD71), mannose receptors 
(CD206), and programmed cell death 1 ligand 2 (PDL2), Chitinase-3-like protein 3 
(Ym1), found in inflammatory zone 1 (FIZZ1), TGF-β, chemokines such as CCL17, 
CCL22, CCL24, and shifted arginine metabolism to ornithine and polyamines (Table 
1.1) [69]. M2 macrophages are mainly involved in immune suppression and tissue 
remodeling [72].  
1.2.4 Macrophage Pattern Recognition Receptors 
Macrophages express pattern recognition receptors (PRRs): a group of innate immune 
receptors involved in sensing unique microbial molecules, termed microbial-
associated molecular patterns (MAMPs) and host-derived signals from damaged cells, 
known as danger-associated molecular patterns (DAMPs). Receptors in this family 
include membrane-associated receptors such as toll-like receptors (TLRs) and 
cytoplasmic receptors such as the nucleotide-binding oligomerization domain (NOD)-
like receptors (NLRs) [76].  
To date, more than 10 TLRs (13 in mice) and 23 NLRs have been identified in 
humans. All TLRs are plasma membrane-associated receptors, except TLR3, TLR7, 
TLR8 and TLR9 which are endosomal membrane-associated. In addition, all TLRs 
except TLR10 have at least one known MAMP ligand, including double-strand RNA 
(TLR3), LPS (TLR4), flagellin (TLR5), single-stranded RNA (TLR7 and TLR8), and 
bacterial/viral unmethylated CpG DNA (TLR9). All TLRs homodimerize or  
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Table 1.1. Characteristics for M1 and M2 macrophage populations 
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Table 1.1 
Macrophage  M1 M2a M2b M2c 
Stimulation IFNγ/LPS  TNF-α  IL-4/IL-13 
ICs/TLR or IL-
1R ligands 
IL-10 
TGF-β 
GHs 
Expression 
CD80 
CD86 
MHCII 
iNOS 
CCR7 
CD23 
CD71 
CD163 
CD206 
YM1 
FIZZ1 
Arginase I 
PDL2 
CXCR1 
CXCR2 
MHCII 
Decoy IL-
1RII 
IL-1RA 
CD80 
CD86 
Arginase I 
MHCII 
 
CD163 
CD206 
Arginase I 
CCR2 
CD150 
 
Cytokines 
TNF-α 
IL-1β 
IL-12 high 
IL-23 
IL-6 
IL-10 low 
IL-10 
TGF-β 
IL-1 
IL-6 
IL-10 high 
TNF-α 
IL-12 low 
IL-10 
TGF-β 
Chemokines 
CCL2 
CCL5 
CCL3 
CCL9 
CCL10 
CXCL8 
CXCL9 
CXCL10 
CXCL11 
CXCL16 
CCL17 
CCL18 
CCL22 
CCL24 
CCL1 
CCL16 
CCL18 
CXCL13 
IFNγ, interferon γ; LPS, lipopolysaccharide; IL, interleukin; IL-1R, IL-1 receptor; 
ICs, immune complexes; TGF-β transforming growth factor β; TLR, Toll-like 
receptor; GHs, glucocorticoid hormones; CD, cluster of differentiation; YM1, 
Chitinase-3-like protein 3; FIZZ1, found in inflammatory zone 1; PDL2, programmed 
cell death 1 ligand 2;CCR, C-C chemokine receptor; CXCR, C-X-C chemokine 
receptor; MHCII, major histocompatibility complex class II; iNOS, inducible nitric 
oxide synthase; Decoy IL-1RII, type II decoy receptor of IL-1; IL-1RA, IL-1 receptor 
antagonist; TNF-α, tumor necrosis factor α; CCL, chemokine (C-C motif) ligand; 
CXCL, C-X-C motif ligand  
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heterodimerize upon binding to their ligands. TLR2 heterodimerizes with TLR6 by 
diacylated lipopeptides (Pam2CSK4), zymosan and lipoteichoic acid (LTA) and with 
TLR1 by triacylated lipopeptides (Pam3CSK4) and lipoarabinomannan [77-81]. 
Among NLRs, NOD1 and 2 recognize the units of peptidoglycan cell wall 
components, diaminopimelic acids and muramyl dipeptide, respectively [82, 83].  
1.2.4.1 Signaling Pathways of TLRs 
TLRs, as type I transmembrane proteins, contain an ectodomain with leucin-rich 
repeats, a transmembrane domain, and an intracellular Toll-interleukin 1 receptor 
(TIR) domain [84]. Ligation of TLRs by their respective ligands leads to the 
activation of downstream signaling pathways that have been divided into two major 
distinct pathways depending on the TIR-domain-containing cytoplasmic adaptor 
proteins: myeloid differentiation primary response gene 88 (MyD88)-dependent and 
TIR-domain containing adaptor-inducing interferon-β (TRIF)-dependent pathways. 
[85]. MyD88 is the main adaptor molecule for all TLRs with the exception of TLR3, 
which exclusively utilizes TRIF, and TLR4, which uses both MyD88 and TRIF [85, 
86]. Triggering TLRs by MAMPs induces an engagement of TIR domains of TLRs 
with TIR domain of MyD88 or MyD88-adaptor-like protein (MAL), resulting in the 
recruitment of interleukin (IL)-1 receptor-associated kinases (IRAKs) and subsequent 
interaction with tumor necrosis factor receptor (TNFR)-associated factor (TRAF) 6. 
This leads to the activation of the transforming growth factor β-activated kinase 1 
(TAK1). TAK1 activation in turn couples to the nuclear factor kappa-light-chain-
enhancer of B cells (NF-κB) and mitogen-activated protein kinases (MAPKs) 
pathways. The other pathway that is activated upon the activation of TLRs is the 
phosphoinositide 3-Kinases (PI3Ks) pathway [85, 87]. 
The NF-κB signaling pathway is an important signaling cascade for cell proliferation, 
differentiation and survival, as well as expression of pro-inflammatory cytokines such 
as TNF-α, IL-1β, IL-6, and IL-12 p40 [88-90]. The NF-κB family includes RelA 
(p65), RelB, c-Rel, P50, and P52 members that are capable of binding to DNA as well 
as inhibitor of NF-κB (IκB) [91]. Upon activation, TAK1 phosphorylates and 
activates the inhibitor kappa B kinase (IKK) complex that comprise IKKα, IKKβ and 
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IKKγ (also known as NEMO). Activated IKK phosphorylates IκB, resulting in 
proteasome-mediated degradation and translocation of NF-κB complexes, 
predominantly the P50/RelA dimer, to the nucleus [85, 87]. 
The MAPKs are a family of protein kinases involve in diverse cellular functions, such 
as cytokine production and cell survival. The MAPK family comprises p38 MAPK, 
extracellular signal regulated protein kinases (ERKs), and c-Jun N-terminal kinases 
(JNKs). Activation of MAPKs is mediated by two families of upstream protein 
kinases: the MAP kinase kinase kinase (MKKK) and MAP kinase kinase (MKK). 
Each MAPK is activated by a specific MKK: MKK 3/6 activates p38 MAPK, MKK 
1/2 activates ERKs and MKK4/7 activates JNKs. Phosphorylation of MAPKs leads to 
activation of transcription of their effector genes [92]. 
The p38 MAPK is strongly activated by environmental stressors, cytokines and other 
receptors [93-96]. There are four members of p38 MAPK family: α, β, γ, and δ. p38α 
is ubiquitously expressed in most cells including macrophages, whereas p38β, p38γ 
and p38δ are expressed in brain, skeletal muscle and endocrine glands, respectively 
[97]. TAK1 and apoptosis signal-regulating kinase 1 (ASK1) phosphorylate MKK3 
and MKK6 which are upstream kinases for p38 MAPK. Activation of p38 MAPKs 
then leads to the activation of downstream protein kinases such as MAPK-activated 
protein kinase (MAPKAP) 2/3, mitogen- and stress-activated kinase (MSK) 1/2, as 
well as transcription factors such as activating transcription factor (ATF) 1/2/6, 
C/EBPβ, and P53 [93, 97]. In macrophages, the activation of p38α MAPK has been 
associated with expression of key inflammatory cytokines such as TNF-α, IL-6 and 
IL-1β [98, 99], and inflammatory mediators such as inducible nitric oxide synthase 
(iNOS) and cyclooxygenase (COX) 2 [100]. p38α MAPK also plays a central role in 
cell survival [101] of osteoclasts [102] and chemotactic-induced macrophage 
migration [103]. Altogether, these findings suggest that p38 MAPK is essential for 
inflammatory cytokine production and many other cellular processes.	  	  	  	  	  	  
The ERKs, comprising ERK1, ERK2, ERK3/4, ERK5 and ERK7, are expressed 
ubiquitously and activated by a variety of extracellular agents. Following TLRs 
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activation, the tumor progression locus 2 (Tpl2) complex, containing NF-κB subunit 
precursor protein p105, A20-binding inhibitor of NF-κB activation (ABIN) 2 and 
Tpl2, becomes activated through phosphorylation of the p105 inhibitory subunit by 
TAK1-dependent activation of IKKβ of IKK complex [104, 105]. Consequently, the 
Tpl2 is released from the complex and activates MKK1/2 leading to activation of 
ERKs [86, 106]. Following ERKs activation, MSKs, subfamilies of ribosomal protein 
S6 kinases (RSKs), MAPK-interacting kinases (MNKs) and other cytoplasmic and 
nuclear substrates are activated [86]. Activation of MSKs induces expression of anti-
inflammatory cytokines, such as IL-10 and IL-1 receptor antagonist (IL-1RA) protein 
[107-109] and expression of the dual-specificity protein phosphatase (DUSP) 1/2/4, 
which in turn, limits MAPKs activation [86]. Overall, ERKs are involved in anti-
inflammatory cytokine production and limiting inflammation. ERKs activity have 
also been implicated as a crucial mediator of cell proliferation [110] and myeloid cell 
differentiation [111].	  
The JNK family comprises JNK1, JNK2 and JNK3. Of these, JNK1 and JNK2 are 
ubiquitously expressed while JNK3 is largely restricted to the brain, heart and testis 
[112, 113]. JNKs are activated in response to a wide variety of stimuli including 
cytokines, ultra violet irradiation, growth factors, DNA-damaging chemicals and 
other receptors such as TLRs [114-118]. JNKs activate a large number of 
transcription factors including ETS domain-containing protein Elk-1/3 (Elk1/3) and 
AP-1 complex (composed of c-Fos, c-Jun, ATF and Jun dimerization partner), and 
involved in the expression of various pro-inflammatory cytokines [119]. JNKs are 
also implicated in apoptosis of macrophages and inhibition of M-CSF-dependent 
differentiation of bone marrow cells (BMCs) into macrophages [120]. Other studies 
have also shown that JNK2 is required for TNF-α production [121] and phagocytosis 
[122] in macrophages. 
The PI3Ks are lipid kinases that mediate conversion of phosphatidylinositol 4,5-
biphosphate (PIP2), which is normally located in the inner leaflet of the plasma 
membrane, to phosphatidylinositol 3,4,5-triphosphate (PIP3) [123]. The 
dephosphorylation of PIP3 is mediated by the lipid phosphatase activity of 
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phosphatase and tensin homolog (PTEN), which is a negative regulator of PI3K 
signaling [124]. PI3Ks are divided into three subclasses: I (A and B), II, and III. Class 
IA subtypes consist of a catalytic subunit (p110α, p110β, or p110δ) and a regulatory 
subunit (p85α or p85β). Class IB consists of p110γ, which associates with either p87 
or p101 regulatory subunit [85]. Although p110α and p110β are expressed 
ubiquitously, p110δ and p110γ are primarily expressed in leukocytes [125, 126]. 
However, p110δ is found as the major enzyme involved in the production of PIP3 in 
myeloid cells [127].  
The signaling mechanism involved in PI3K activation by TLRs is not well 
understood. Several studies indicate that MyD88 [128], MAL [129], TRIF [130, 131] 
and scaffold protein B-cell adaptor for PI3K (BCAP) [132] can induce PI3K. Once 
PI3K is activated, it mediates conversion of PIP2 to PIP3. PI3K production of PIP3 
leads to the activation of downstream signaling molecules such as protein kinase B 
(PKB), also known as Akt through the phosphatidylinositol-dependent kinases (PDK) 
1/2 [133]. Akt1 is mainly involved in suppressing the production of inflammatory 
cytokines, while Akt2 has been reported to increase inflammatory functions in 
macrophages [134]. Activated Akt1 phosphorylates substrates including the forkhead 
box protein O 1 (FOXO1) [135] and glycogen synthase kinase 3 (GSK3α/β) [136], 
which result in inactivation of these molecules. Production of inflammatory cytokines 
is suppressed due to the inhibition of FOXO1 activity, while the production of anti-
inflammatory cytokines, such as IL-10, is increased by enhanced cAMP response 
element-binding protein (CREB) function as a result of GSK3α/β inhibition [135, 
136]. 
1.3 GUT IMMUNITY 
The gastrointestinal (GI) tract, which is the largest organ in the body, has a dual 
function: nutrition uptake and maintaining immune homeostasis. The GI tract is 
constantly in contact with microorganisms and food antigens, and the presence of 
food, moisture and appropriate temperature makes the GI tract a favorable habitat for 
a diverse array of microorganisms. Therefore, mounting proper immune responses 
that prevent microbial invasion and maintain immune tolerance is crucial. Both the 
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innate and adaptive immune systems contribute to the development of a balanced and 
regulated host immune system, and any disturbance to this balance may negatively 
impact on the host’s health [137]. 
The GI tract microbiota, itself, plays also a central role in the host’s protection. They 
out-compete pathogenic bacteria via competition for binding sites, and production of 
antimicrobial compounds and volatile fatty acids [138, 139]. Also, their effects on 
intestinal structure and contributions to the development of a balanced and regulated 
host immune system have been reported [140, 141]. In addition, they provide the host 
with essential nutrients, including short chain fatty acids, amino acids. and vitamins 
[138]. 
1.3.1 The Structure of the Gut Immune System 
The GI tract is a dynamic ecosystem that is a habitat for approximately 1014 microbes, 
which outnumber the total number of body tissue cells by a factor of ten [142]. The 
GI tract microbiota is separated from the host’s gut associated lymphoid tissue 
(GALT), the primary tissue involved in GI tract immunity, by intestinal epithelial 
cells (IECs). IECs consist of absorptive columnar epithelial cells with physical barrier 
function and microfold cells (M cells; possessing a unique antigen uptake function), 
as well as secretory cells, such as goblet cells (producing mucin, trefoil etc.), Paneth 
cells (producing antimicrobial factors such as α-defensin) and enteroendocrine cells 
(producing hormones and neuropeptides such as serotonin and secretin). The IECs act 
as a highly selective barrier, providing a degree of permeability for optimal nutrient 
and fluid uptake, while preventing translocation of microorganisms from the gut 
lumen [137]. The mucus layer above the IECs provides a higher degree of protection 
by inhibiting overgrowth of microbiota and potential pathogens using acidic pH, 
enzymes, such as lysozyme, secretory anti-microbial peptides, such as mucins and 
trefoil and immunoglobulins, such as IgA and IgM [137, 143, 144].  
The lamina propria is a layer of connective tissue that lies beneath the epithelial 
monolayer, and contains diffused mucosa-associated lymphoid tissue (MALT) that is 
densely populated by macrophages, DCs, granulocytes such as neutrophils, mast cells 
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and lymphocytes. This layer also contains organized GALT and mucosal lymphoid 
follicles, including the Payer’s Patches (PPs) and the mesenteric lymph nodes 
(MLNs), which are very rich in immune cells including B cells, T cells, DCs and 
macrophages [137, 145]. 
1.3.2 Gut Macrophages 
The gut is the largest reservoir of macrophages in the body [30]. Gut macrophages are 
mainly populated in the lamina propria and other parts of the gut such as mucosa, 
submucosa and muscularis mucosa [146]. Gut resident macrophages exhibit granular 
cytoplasm and active phagocytic behavior [146] and are identified by different cell 
surface markers such as CD11b, CD11c, F4/80, Fc-gamma receptor 1 (FcγRI; CD64), 
macrosialin (CD68), CD115, MHCII, CD206, hemoglobin scavenger receptor 
(CD163), Siglec F and αEβ7 receptor (CD103) [147]. In fact, distinguishing gut 
macrophages from other cells has to be performed by a combination of these markers, 
as CD11b+ and F4/80+ eosinophils [146] or CD11b+, CD11c+ and MHCII+ DCs  [148] 
have been previously reported. Recently, CX3CR1+ or the fractalkine receptor has 
been shown to be associated with gut macrophages rather than gut DCs [148, 149]. 
On these grounds, gut macrophages in a steady state can be characterized by CD11b+, 
CD11c+, F4/80+, CX3CR1+, MHCII+, Siglec F-, and CD103-. 
Studies have demonstrated that gut resident macrophages mainly originate from bone 
marrow-derived Ly6Chigh monocytes [150, 151]. It was further shown that these 
recruited Ly6Chigh monocytes differentiate to F4/80+ CD64+ CX3CR1high Ly6C- 
resident macrophages at least in part in a CCR2/CCL2-dependent manner [147]. 
Other chemokines such as TGF-β and IL-8, which are constantly produced by 
mucosal IECs and mast cells, have also been shown to be involved in the recruitment 
of blood monocytes [152, 153].  
1.3.2.1 Gut Macrophage Roles 
Gut macrophages are key players in maintaining gut immunity and homeostasis. In 
normal conditions, gut macrophages are tolerant to microbial products [147]. 
However, they retain their housekeeping functions, such as clearance of apoptotic 
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cells [154], as well as tissue remodeling [155]. Additionally, gut macrophages are 
highly phagocytic and bactericidal [156]. They lack respiratory burst activity [157] 
and do not produce NO [158] or inflammatory cytokines such as IL-1 and IL-6 [147, 
156]. They, however, produce high levels of the anti-inflammatory cytokine IL-10 
[147]. IL-10 plays a pivotal role in gut homeostasis. It induces production of the 
scavenger receptors such as CD206 and CD163. Additionally, IL-10 suppresses 
activation of gut macrophages to inflammatory stimuli [156]. Gut microbiota plays an 
important role in the production of IL-10 by gut macrophages. In fact, gut 
macrophages from germ free mice produce less IL-10 [159, 160]. Gut macrophages, 
however, produce low levels of TNF-α. Such effects have also been shown to be 
beneficial in regulating enterocyte growth, altering the permeability of the IEC barrier 
and inducing of matrix metalloproteinases and other tissue remodeling enzymes [161, 
162]. Furthermore, gut macrophages produce prostaglandin E2 that stimulates 
proliferation of epithelial progenitors [163]. Overall, in the gut it appears that 
macrophages display a partial activation state with inflammatory anergy [156]. 
Gut macrophages also serve as APCs as they express high levels of MHCII [149]. It 
has been speculated that gut macrophages can differentiate naïve CD4+ T cells to 
forkhead box P3 (FoxP3+) T regulatory cells in the gut [164]. Such effects of gut 
macrophages are still debatable, as gut macrophages cannot migrate to MLNs in a 
steady state [148]. In addition, it has been shown that gut macrophages do not 
efficiently activate naïve CD4+ T cells in vitro [148]. Thus, other mediators may also 
be involved indirectly in this process. For instance, IL-10 is a substantial cytokine 
produced by gut macrophages and has been shown to regulate T regulatory cells that 
have migrated to the gut after initial priming in the MLNs [165, 166]. Gut 
macrophages may also facilitate the maintenance of other T cell populations. Indeed, 
microbiota-dependent IL-1β production in gut macrophages have been shown to 
contribute to the development of IL-17 producing T (Th17) cells in non-inflamed 
conditions [167].  
1.3.2.2 Gut Macrophage Roles in IBD 
The GI tract is one of the sites in the body that the immune system establishes a 
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profound presence due to heavily localized bacteria. Any disturbance to this balance 
may result in gut disorders, such as IBD [168]. IBD mainly comprises Crohn’s 
disease (CD) and ulcerative colitis (UC). CD is characterized by transmural 
inflammation in any part of the GI tract, mostly in the ileocecal region and terminal 
ileum, bowel obstruction, the presence of granulomas and the development of skip 
lesions. In contrast, UC inflammation is limited to the mucosa of the colon and 
rectum, and is characterized by bloody stool and severe diarrhea [169, 170]. Both CD 
and UC are caused by abnormal immune activation in the intestine [171]. It is 
postulated that the loss of immune tolerance to endogenous flora is responsible for 
initiating abnormal immune responses in genetically defective hosts [169]. In 
addition, the microbiome has also been found as a source of inflammation in IBD, as 
transferring the microbiome from IBD established T-bet-deficient mice (lacking Th1 
immune response) to a wild-type mice caused intestinal inflammation [172]. Other 
theories such as genetic background and environmental factors have also been 
suggested to play a role in IBD [169, 173-176]. To date no cure has been found for 
IBD and most patients receive only antibiotics or anti-inflammatory drugs with 
negative consequences to reduce the symptoms and complications of the disease, 
which leads to less hospitalization and surgery. Therefore, new therapeutic treatments 
are needed to overcome these diseases [170, 177]. 
Macrophages are an abundant immune cells in the gut and are of major importance in 
the regulation of the immunological and inflammatory responses [30]. Dysregulation 
of cytokine production in macrophages has also been reported to associate with IBD. 
Macrophages from CD patients secrete high levels of pro-inflammatory IL-23 but low 
levels of anti-inflammatory IL-10. However, macrophages from UC patients mainly 
secrete high levels of pro-inflammatory IL-12 [178]. Macrophage polarization has 
also been shown to affect outcome of colitis. M1 macrophages contribute to 
pathogenesis of colitis; where M2 macrophages reduced the severity of the disease 
[134, 179, 180]. G-CSF was also produced less in IBD patients [181]. Less efficient 
bacterial clearance resulting from decreased ROS production [182] and phagocytosis 
[183] in macrophages have also been linked to IBD. Taken together, these findings 
indicate that an imbalance in any of the physiological functions of gut macrophages, 
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including inadequate response to GI tract flora, inappropriate clearing of microbes 
and ineffective switch from pro-inflammatory response to anti-inflammatory 
response, may tip the balance between GI bacteria and host’s immune system toward 
gut disorders such as IBD [171]. Indeed, recent genome-wide association studies 
revealed several single-nucleotide polymorphisms that contribute to the development 
of IBD: genes for microbial sensing (NOD2, IRF5, NFKB1, RELA, REL, RIPK2, 
CARD9 and PTPN22), clearance (ATG16L1, IRGM and NCF4) and integrating 
antimicrobial adaptive immune responses (IL-23R, IL-10, IL-12, IL-18RAP/IL-1R1, 
IFNGR/IFNAR1, JAK2, STAT3 and TYK2) [171, 184]. These analyses again 
suggest that defects in macrophage and DC function may contribute to the 
pathogenesis of IBD.  
1.3.2.3 Mouse models of IBD 
Animal models have been extensively used to increase our understanding of IBD. 
Mice can be used as an IBD model due to their inexpensive cost and small size 
compared to their counterparts such as monkeys. However, no ideal model that 
mimics all aspects of human IBD currently exists. To date, there are different models 
of IBD that can be grouped in three major categories based on the nature of 
inflammation and method of generation; the erosive self-limiting models of acute 
colitis, spontaneous models induced by targeted gene deletion and models induced by 
disruption of T-cell homeostasis [185]. As each animal model serves for different 
purposes, finding an appropriate model to study role of gut macrophages in colitis is 
an asset.  
The erosive, self-limiting model of colitis can be used to resemble acute colitis with 
similar histopathological characteristics of UC such as neutrophil infiltration, mucosal 
erosions and ulcerations. This model can be produced by administration of dextran 
sulfate sodium (DSS) [186, 187]. DSS is a water-soluble heparin-like sulfated 
polysaccharide that is widely used to investigate the pathogenesis of UC [188]. 
Supplementing the drinking water of mice with DSS induces colonic mucosal 
inflammation with ulceration, body weight loss, bloody stools and diarrhea for several 
days [189]. Its mechanism of action is thought to be mediated by intestinal epithelium 
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damage through killing IECs and does not induce T cell responses, at least in the 
acute model [190, 191]. To investigate chronic inflammation, DSS can be 
administrated in low dose for several cycles [192]. Indeed, DSS-treatment of C.B17 
SCID (sever combined immunodeficiency) mice resulted in colitis in these mice 
[189], indicating that innate immune cells such as macrophages and DCs are 
responsible for pathogenesis in this model. 
In contrast to the DSS model, the trinitrobenzene sulfonic acid (TNBS) model induces 
colonic inflammation when administrated intrarectally in only susceptible strains of 
mice (but not C57BL/6j mice) and depends on the gut microbiota [186, 187, 193, 
194]. This model closely resembles CD and has been shown to induce a CD4+ T cell-
mediated-Th1 response [193, 194]. In addition, depletion of phagocytes in a TNBS 
model also showed to be effective in reducing colitis conditions in this model, 
confirming the role of macrophages and DCs in pathogenesis of IBD [195]. 
Spontaneous models induced by targeted gene deletion such as IL-10-deficient mice 
(IL-10-/-), resembling CD, have also been used [196]. The IL-10-/- mice produce Th1-
mediated immune responses, mucosal hyperplasia, a transmural mononuclear cell 
infiltration, occasional crypt abscesses and focal erosions [185]. This model has been 
used for studies of various immunologic agents (anti-TNF-α and anti-IFN-γ 
antibodies), antibiotics and probiotics. Similar to TNBS model, elimination of 
phagocytes in IL-10-/- mice also ameliorates the disease conditions in these mice, 
again indicating the importance of innate immune cells in this model [197].    
 Models induced by disruption of T-cell homeostasis have also been shown to be 
effective in resembling of IBD. This model is produced by adoptive transfer of CD4+ 
CD45RBhigh T cells (naive T-cells) from healthy wild-type mice into syngeneic 
recipients that lack T and B cells (such as SCID or RAG-deficient mice). This model 
produces transmural inflammation, epithelial cell hyperplasia, polymorphonuclear 
neutrophil and mononuclear leukocyte infiltration, crypt abscesses and epithelial cell 
erosions [185]. 
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1.4 COLONY STIMULATING FACTORS 
The colony stimulating factors (CSFs) are glycoproteins that include M-CSF, GM-
CSF and G-CSF, each with differing colony stimulatory activity [198]. CSFs were 
initially considered as in vitro hematopoietic growth factors involved in the 
generation of myeloid cell populations from bone marrow precursor cells [199]. 
Additional studies, however, have identified other functions of CSFs, including 
differentiation and immunomodulatory effects [200, 201].  
1.4.1 M-CSF 
M-CSF, also known as CSF-1, is a hematopoietic growth factor required for the 
generation of the major macrophage populations [198, 201-203]. M-CSF also serves 
other functions, such as bone metabolism and macrophage chemotaxis [204, 205]. In 
addition, M-CSF has immune-related functions, including promoting resistance to 
inflammatory signals [206], modulating cytokine production and phagocytic activity 
of macrophages [207-209]. M-CSF is a steady state growth factor [201, 210] 
produced by variety of cells, including bone marrow stromal cells [211], activated 
monocytes/macrophages [212], activated granulocytes [213], endothelial cells [214] 
and fibroblasts [215]. Since M-CSF alone supports the survival and generation of 
macrophage-like cells, it is commonly used in vitro to prepare BMCs [216]. 
M-CSF deficient mice (M-CSF-/-; Csf1op/Csf1op) display deficiency in major 
macrophage populations [217, 218], demonstrating an important role of M-CSF in 
macrophage generation.  In contrast to M-CSF-/- mice, M-CSF receptor deficient mice 
(M-CSFR-/-, CSF1R-/- or CD115-/-) have more severe defects in macrophage 
populations, as well as a more severe osteoporosis, than M-CSF-/-, [219]. Differences 
in phenotypes between M-CSF-/- and M-CSFR-/- can be explained by the identification 
of IL-34 as another ligand for M-CSFR [220]. Interestingly, IL-34 deficient mice (IL-
34-/-) showed loss of microglia and Langerhans cells with minimal impact on other 
tissue macrophages [221].   
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1.4.1.1 M-CSFR Structure and Signal Transduction 
M-CSFR is a tyrosine kinase transmembrane receptor which is encoded by the proto-
oncogene c-fms [222]. M-CSFR is mainly expressed on progenitor and mature 
monocyte/macrophage cells [223]; however, its expression is also detected on 
deciduas and placental trophoblast cells, indicating its additional role outside the 
hematopoietic system [224].  
M-CSFR contains an extracellular ligand binding domain with five immunoglobulin-
like loops, a single membrane-spanning helix and an intracellular protein tyrosine 
kinase domain [202, 206]. Ligand binding to M-CSFR results in the dimerization of 
receptor and subsequent phosphorylations at tyrosine residues of M-CSFR initiating 
several downstream signaling pathways, including Ras/ERKs and PI3K/Akt [225]. 
These signaling events lead to the activation and nuclear translocation of transcription 
factors, such as PU.1, and expression of many genes involved in cell survival (e.g. 
Bcl-2-related protein A1 and Myeloid cell leukemia 1), proliferation (e.g. cyclins A2, 
B1/2, D1/3, and E2) and differentiation (e.g. COX 1/2) [23, 71, 226, 227].   
1.4.2 GM-CSF 
GM-CSF, also known as CSF-2, is another hematopoietic growth factor which is able 
to promote development of granulocytes including neutrophils and eosinophils [228], 
monocytes/macrophages [216] and DCs [229]. GM-CSF, in contrast to M-CSF, is 
normally present in very low concentrations in the serum, but its production is rapidly 
elevated in response to inflammation and infections [198]. GM-CSF is produced by 
different cell types, including stromal cells [230], activated monocytes/macrophages 
[231], natural killer cells [232], endothelial cells [233], epithelial cells [234], CD4+ T 
cells [235] and Paneth cells, [236]. In vitro, GM-CSF is used to differentiate certain 
types of macrophages from BMCs [208, 237]. GM-CSF alone or in combination with 
IL-4 has also been used to induce the in vitro generation of DCs [238]; however, 
these DCs display a transcriptome pattern more closer to macrophages rather than 
DCs [239] and also express macrophage markers [70, 240].  
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GM-CSF deficient (GM-CSF-/-) or GM-CSF receptor (GM-CSFR or CSF2R) 
deficient (GM-CSFR-/-) mice generally display normal myelopoiesis except for 
abnormalities of alveolar proteinosis in the lung, indicating a role of GM-CSF in the 
maintenance of alveolar macrophages responsible for phagocytosis of surfactant 
protein [241-245]. Other studies have also shown that these mice are more susceptible 
to pulmonary infections, including Mycobacterium tuberculosis [246], Pseudomonas 
aeruginosa [247] and pulmonary group B streptococcal [248] infections. GM-CSF-/- 
mice also showed an increased neutrophilic infiltration in lungs upon bacterial 
infections, suggesting a defect in macrophage clearance of bacteria in the absence of 
GM-CSF [248]. Mice lacking both M-CSF and GM-CSF are still viable with similar 
characteristics related to M-CSF-/- and GM-CSF-/- mice. These double knockout mice 
still have a similar number of circulating monocytes to that of M-CSF-/- mice and 
functional phagocytic macrophages in the diseased lung. This suggests involvement 
of other compensatory mechanisms for macrophage production and function in vivo 
[249]. 
1.4.2.1 GM-CSFR Structure and Signal Transduction 
GM-CSFR is a heterodimer of type I transmembrane glycoproteins comprised of a 
ligand-binding α subunit (CSF2Rα) and a signal-transduction β subunit (CSF2Rβ). 
GM-CSFR is expressed in myeloid cells but not B and T cells [250]. Other studies 
have also shown that GM-CSF is also active on non-hematopoietic cells such as 
fibroblasts [251] and endothelial cells [252]. Activation of GM-CSFR induces 
activation of several signaling cascades, including the Janus Kinase 2 (JAK2)/STATs 
(1/3/5), PI3K/AKT, Ras/MAPK and NF-κB pathways [253-256]. These events induce 
expression of specific genes related to cell survival, proliferation, differentiation and 
activation in monocytes and granulocytes. 
1.4.3 G-CSF 
G-CSF, also known as CSF3, is a 25 kDa-secreted glycoprotein and has a wide range 
of actions. G-CSF, as a hematopoietic factor, plays an important role in the survival, 
proliferation, differentiation and function of neutrophil progenitor cells and mature 
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neutrophils [257-259]. G-CSF is produced in response to inflammatory stimuli such 
as LPS, TNF-α, IL-17 and IL-1β by a variety of cell types, including 
monocytes/macrophages [260, 261], bone marrow stromal cells [262] and endothelial 
cells [263]. Similar to GM-CSF, serum concentrations of G-CSF remain low in the 
steady state; however, its production markedly increases upon inflammation or 
infection [264, 265]. Administration of G-CSF into non-human primates resulted in 
an increase in neutrophil numbers in the peripheral blood [266]. A study in mice has 
demonstrated that G-CSF significantly reduces the transit time through bone marrow 
stem cells to circulating neutrophils [267]. Likewise, G-CSF has been shown to 
increase mobilization of neutrophils into tissue from vascular compartments in 
humans [268]. A series of studies have also demonstrated that administration of G-
CSF increases the levels of HSCs and progenitor cells in the peripheral blood, 
indicating a role of G-CSF in mobilization of multipotential hematopoietic progenitor 
cells from bone marrow to circulation [269, 270]. Overall, G-CSF is required for 
myeloid progenitor cells mobilization and increases survival and maturation of 
neutrophils. These effects make G-CSF a good candidate to compensate neutropenia 
in patients undergoing chemotherapy. Several clinical studies have proven the 
beneficial effects of G-CSF in this context, showing that administration of 
recombinant human G-CSF in febrile neutropenia and small-cell lung cancer patients 
reduces periods of neutropenia, infection episode and mortality [271-273].   
Mice lacking G-CSF (G-CSF-/-) remain healthy, fertile and display normal long-term 
survival rates. However, these mice have a 70-80% reduction in peripheral neutrophil 
counts compared to wild-type mice, and a 50% reduction in bone marrow 
granulocyte/macrophage progenitor cells (indicated by frequency of colony-forming 
cells in response to different hematopoietic stimuli) [259]. Surprisingly, G-CSF-/- 
mice infected with Candida albicans had a normal neutrophilic response [274]. 
Likewise, Mycobacterium avium infection in these mice showed no depletion in 
myeloid precursor cells in the bone marrow without exacerbation of infection. 
However, subjecting these mice to Listeria monocytogenes infection resulted in a 
decrease and a delay in the production of peripheral neutrophils [259]. These finding 
suggest that emergency granulopoiesis in response to infections can still occur in the 
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absence of G-CSF with yet unknown compensatory mechanism.  
G-CSF receptor (G-CSFR or CSF3R) deficient mice (G-CSFR-/-) are also viable and 
fertile, but they develop more severe neutropenia than G-CSF-/- mice, harboring 88% 
reduction in peripheral neutrophil counts compared to wild-type mice. However, G-
CSFR+/- mice are not neutropenic. Additionally, these mice display decreased 
hematopoietic progenitors in the bone marrow and deficiency in differentiation of the 
progenitor cells into granulocytes. Interestingly, these mice had normal neutrophil 
migration to the thioglycollate-inflamed peritoneum with normal myeloperoxidase 
activity, showing that G-CSF signaling is necessary for increasing the production of 
neutrophils in inflammatory conditions, but it is not an absolute necessity for 
granulocytopoiesis. This group also demonstrated that an addition of G-CSF to IL-6-
stimulated cultures of G-CSFR-/- progenitor cells promotes macrophage populations, 
indicating that G-CSF may also have a role in monocyte/macrophage production in a 
G-CSFR-independent manner [257].  
1.4.3.1 G-CSFR Structure and Signal Transduction 
G-CSFR is a type 1 transmembrane protein expressed mainly in neutrophils, 
monocytes/macrophages [260], lymphocytes [275], and hematopoietic stem cells and 
progenitor cells [257, 259]. It is also expressed in endothelial cells [276], placenta 
[277] and non-hematopoietic tumor cell lines [278]. Extracellular domain of G-CSFR 
contains an immunoglobulin-like domain, a cytokine recognition domain with four 
cysteine residues and a WSXWS motif required for ligand binding, and three 
fibronectin type III domains (Fig. 1.1). The cytoplasmic portion consists of three 
conserved regions with sequence homology to other cytokine receptors; Box1, Box2, 
and Box3 [279]. Box1 and Box2 have been linked in the transduction of proliferation 
signals, while Box3 has been shown to be involved in the differentiation process 
[280].  
Upon binding to G-CSF, G-CSFR forms homodimers and activates multiple signaling 
pathways. G-CSFR lacks intrinsic kinase activity; therefore, it mainly relies on 
various non-receptor kinases such as the JAK family (JAKs), mainly JAK1, JAK2, 
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Figure 1.1. G-CSFR signaling pathways. Ligand binding to G-CSFR induces 
phosphorylation of JAKs and subsequent phosphorylation of four tyrosine residues 
located on the cytoplasmic portion of the G-CSFR. These phosphorylated tyrosine 
residues serve as docking sites for different proteins characterized by src homology 2 
domains leading to activation of different signaling pathways that regulate various 
cell processes. 
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Figure 1.1 
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and tyrosine kinase 2 (TYK2). Upon activation, the G-CSFR dimerizes and JAKs, 
which bind to a tryptophan residue localized between Box1 and Box2, are readily 
phosphorylated, leading to phosphorylation of four tyrosine (Y) residues (Y703, 
Y728, Y743, and Y763) in the murine receptor. Phosphorylation of Y703 and Y743 
occurs at low levels of G-CSF, resulting in activation of STAT3 and subsequent 
proliferation and differentiation of neutrophils. At high levels of G-CSF, however, 
STAT3 activation is largely tyrosine-independent. It is also apparent that G-CSFR 
activation induces tyrosine-independent STAT1 and 5 activation, resulting in cell 
proliferation. Likewise, phosphorylation of Y763 mediates activation of Ras/ERK1/2 
pathway through several adaptor proteins, leading to cell proliferation. 
Phosphorylation of Y728, however, involves in suppression of G-CSFR signaling 
through suppressor of cytokine signaling (SOCS) 3. Other pathways that are activated 
by G-CSFR, include PI3K/Akt and Src-like kinases Lyn and Hck pathways that are 
tyrosine-independent and crucial for cell survival, proliferation and differentiation 
[279]. 
1.4.3.2 Immunomodulatory Roles of G-CSF 
Besides being a hematopoietic growth factor, G-CSF also exerts profound 
immunoregulatory effects in both innate and adaptive immunity [260, 281, 282]. In 
vitro studies revealed that G-CSF is able to down-regulate the production of 
inflammatory cytokines such as TNF-α and IL-12 in monocytes/macrophages, DCs 
and neutrophils induced by TLR agonists [260, 283]. Administration of anti-G-CSF 
antibody in pneumococcal pneumonia-infected mice showed elevated production of 
TNF-α, IL-1β and cytokine-induced neutrophil chemoattractant, indicating a role of 
G-CSF in host defense [284]. The mechanism underlying the inhibitory effect of G-
CSF was shown to be mediated by G-CSF-dependent activation of JAK2/STAT3 
pathway [285, 286]. JAK2/STAT3 activation inhibits activation of JNKs, known to 
be involved in pro-inflammatory cytokine production, and subsequent suppression of 
TNF-α production in LPS- or Escherichia coli-activated macrophages [285].  
G-CSF may also directly or indirectly modulate adaptive immune effector cells, 
through promoting tolerogenic DCs in the peripheral blood [287, 288]. Follow up 
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studies have shown that those regulatory DCs are CD14+ monocyte derivatives and 
are capable of generating regulatory T cells with the ability to produce 
immunosuppressive cytokines such as TGF-β and IL-10 [289]. Rossetti et al., 
reported that CD14+ monocyte-derived DCs spontaneously secreted IL-10, but very 
little IL-12 in response to LPS and induced anergy in T cells. They also reported that 
G-CSF-treated DCs expressed higher co-stimulatory molecules, such as CD80 and 
CD86 [290]. Interestingly, in vivo administration of G-CSF reduced the expression of 
these co-stimulatory molecules on monocytes, B cells, and T cells [291]. 
Furthermore, monocytes collected from peripheral blood stem cells of G-CSF-treated 
breast cancer patients induced apoptosis in CD4+ T cells through Fas–Fas ligand 
interaction [292]. Other studies also reported that G-CSF-mobilized human donor 
monocytes suppressed T cell alloreactivity by different mechanisms, including 
production of IL-10, and inhibition of IL-12 and TNF-α secretions [291, 293, 294]. 
The other biological effects of G-CSF in relation to T cells is associated with the 
ability of G-CSF to promote the generation of IL-10 producing regulatory T cells 
[281, 295]. Indeed, G-CSF pretreatment of mice treated with LPS reduced IFN-γ (Th1 
cytokine) production [296]. G-CSF may also directly modulate adaptive immune 
cells. A recent in vitro study has shown that G-CSF suppressed the production of 
IFN-γ and increased secretion of IL-4 in activated CD4+ T cells, suggesting the G-
CSF immunomodulatory role on T cell polarization [297]. Overall, G-CSF seems to 
play an important role in shaping innate and adaptive immunity by inducing 
regulatory monocytes/macrophages and DCs, as well as changing the function of T 
cells, such as Th2 polarization, reflected by higher production of IL-10 and IL-4 
rather than IFN-γ.   
A growing body of experimental evidence suggests that G-CSF has also other 
functions in non-hematopoietic cells. G-CSF has been found to promote cardiac cell 
generation and repair after myocardial infarction in animal models through 
JAK/STAT pathway [298]. G-CSF has also been shown to have a neuroprotective 
role in a cerebral ischemia mouse model [299]. Overall, these finding suggest that G-
CSF effects are not only restricted to myeloid lineage but also extend to other non-
hematopoietic cells. 
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1.4.3.3 G-CSF Roles in the Gut 
Several studies have previously highlighted the importance of G-CSF in gut immune 
regulation. Previously published work from our laboratory has documented that colon 
tissue explants from G-CSFR-/-, but not wild-type, mice had high levels of 
spontaneous inflammatory cytokine production such as TNF-α, IL-12 and IL-23, 
which have been shown to play important roles in the pathogenesis of IBD [181]. 
However, no apparent features of spontaneous colitis were detected in G-CSF-/- or G-
CSFR-/- mice. Indeed, these observations were in agreement with the ability of G-CSF 
in down-regulating inflammatory cytokines in macrophages, DCs and neutrophils 
[283, 285, 300], promoting maturation of tolerogenic DCs [289] and differentiation of 
T lymphocytes to regulatory T cells [301]. In addition, it was demonstrated that 
exogenously applied recombinant G-CSF is beneficial in both murine DSS- and 
hapten-induced colitis models [302, 303], as well as in CD patients [304-306]. 
Interestingly, cells isolated from non-inflamed sections of IBD patients undergoing 
gut surgery for colon cancer showed significant reduction in the G-CSF production 
[181]. In contrast, inflamed sections of the gut from those patients have been shown 
to express substantial levels of G-CSF [307]. Differences in G-CSF production in the 
inflamed and non-inflamed sections could be due to the massive ongoing 
inflammation in the inflamed region of the gut that has been shown to be associated 
with production of both inflammatory (TNF-α and IL-1) and non-inflammatory (IL-
10) cytokines, which implies that the balance of cytokines is more crucial rather than 
the presence or absence of a particular cytokine [308]. Moreover, G-CSF has been 
shown to have protective effects on IECs. Administration of G-CSF to rats treated 
with the chemotherapeutic agent reduced villus atrophy, enterocyte apoptosis, and gut 
bacterial translocation [309]. Overall, it appears that G-CSF plays a crucial role in gut 
immune regulation, where both avid immune surveillance and tolerance against 
infiltrating commensal microbes are required.  
1.5 PROBIOTICS 
Probiotics are defined as “living microorganisms, which, when administered in 
adequate amounts, confer a health benefit to the host” [310]. Although people have 
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consumed probiotics for many years, their health effects have only recently been 
addressed scientifically. To date, microorganisms with probiotic properties mainly 
include members of the genera Lactobacillus, Bifidobacterium, Streptococcus, and 
Bacillus. Other bacteria such as avirulent E. coli, Enterococcus faecium and yeasts 
have also been used infrequently as probiotics [311, 312].  
Probiotic microorganisms are believed to out-compete pathogens for nutrients or 
binding sites in the gastrointestinal tract, while some secrete antimicrobial substances, 
such as short chain fatty acids (SCFA), hydrogen peroxide and bacteriocins to 
adjacent microorganisms [139, 313]. Probiotics also enhance the host intestinal 
barrier functions by increasing the production of mucins, antibacterial peptides such 
as defensins, and maintaining or restoring tight junctions [314, 315]. Another 
strategies by which probiotics elicit their effect is by increasing anti-inflammatory 
cytokines such as IL-10 and G-CSF, while decreasing pro-inflammatory cytokines 
such as TNF-α [285, 300]. In addition, probiotics elicit immunomodulatory effects on 
the host T cells through modulation of DCs [316]. Furthermore, the 
immunomodulating effects are not limited to the level of intestinal mucosa, but also 
reach distant sites [317].  
Several strains of probiotic bacteria have been implicated as therapeutic reagents for 
preventing and/or treating various gastrointestinal diseases such as traveler’s diarrhea 
and IBD, as well as atopic diseases such as arthritis and allergies [318-320]. 
However, these generalized probiotic effects are required to be itemized for specific 
strains, and in-depth understanding of the mechanisms of probiotics effects should be 
sought for their efficient and effective use [321]. For instance, L. casei subsp. alactus 
alone induces pro-inflammatory cytokines in murine DCs; however, the stimulatory 
effect is diminished when it is used in combination with L. reuteri [322]. It was also 
observed that the administration of mixtures of L. casei, L. delbrueckii subsp. 
bulgaricus and L. acidophilus increases the production of IgG1 (a Th2 response) in a 
mouse model, but L. acidophilus alone results in the production of IgG2a (a Th1 
response) [323]. Further studies will greatly increase our understanding on specific 
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biological features of each probiotic strain and their modes of action, leading to 
proper applications of probiotics. 
1.5.1 Probiotics and Immune Sensing Mechanisms 
All microbes harbor MAMPs and induce inflammatory responses through activating 
PRRs. Although probiotics harbor MAMPs, they rarely induce inflammatory 
diseases, but instead effectively modulate host immune responses [324, 325]. During 
the last 10 years, several mechanisms modulating the host cell signaling pathways by 
bacterial probiotics have been unraveled, which includes modulation of NF-κB [326], 
MAPKs [285, 327] and Akt [314] pathways.  
In macrophages, probiotics were shown to affect signaling pathways altering cytokine 
production profiles. For instance, NF-κB, as an important signaling molecule in pro-
inflammatory cytokine production, was shown to be inhibited by E. coli M17, 
resulting in decreased production of pro-inflammatory TNF-α, IL-1β and IL-6 [328]. 
LTA from L. plantarum was found to inhibit LPS-induced TNF-α in macrophages 
through NF-κB and MAPKs signaling pathways [329]. Supernatant of L. casei strain 
Shirota was also shown to have TNF-α-inhibitor activity in LPS-treated macrophages 
through suppression of NF-κB signaling pathway [327]. Similar findings were also 
observed in secreted factors from B. bifidum B536 and Ruminococcus gnavus FRE1 
[330]. However, the probiotic factors responsible for the signaling modulation are still 
unknown.  
1.5.2 Probiotic Characteristics of L. rhamnosus 
Lactobacillus, a Gram-positive aerotolerant anaerobic bacteria, is a common 
constituent of the indigenous microbiota in the human intestinal [331] and urogenital 
[332, 333] tracts. Several strains of this genus have been used as probiotics and their 
effects on inflammatory diseases, such as IBD, in human and animal disease models 
have been well documented [324, 334, 335].  
L. rhamnosus GG (LGG) is a well-studied strain of this species and has been shown 
to have disease-ameliorating effects on various animal inflammatory disease models 
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and human patients [324, 336, 337]. LGG produces soluble proteins that inhibit TNF-
α production in LPS- or LTA-activated murine macrophages with no effect on IL-10 
production [325]. LGG also produces p75 (75 kDa) and p40 (40 kDa) proteins that 
have a cytoprotective effect on IECs through activation of the epidermal growth 
factor receptor (EGFR) and its down-stream signaling molecule Akt [314, 338, 339]. 
Activation of EGFR by p40 is mediated by the release of the heparin binding (HB)-
EGF which is released by activated ADAM17 (a disintegrin and metalloproteinase 
domain-containing protein 17) [340]. Delivery of p40 to DSS-treated mouse colon 
reduced intestinal epithelial apoptosis and disruption of barrier function [341]. Also, a 
recent study has indicated that LGG-fermented milk, containing p40 and p75, 
significantly reduced severity of the DSS-induced murine model of colitis [342].  
L. rhamnosus GR-1 (GR-1) is closely related to LGG and renders a number of 
properties considered important for probiotics [285, 320, 343]. Both LGG and GR-1 
induce miniscule amounts of pro-inflammatory cytokines such as TNF-α, but potently 
induces anti-inflammatory cytokines such as G-CSF and IL-10. G-CSF produced by 
LGG- or GR-1-exposed macrophages inhibits production of pro-inflammatory 
cytokines in E. coli- or LPS-activated macrophages [285]. Administration of yogurt 
supplemented with probiotic strains including GR-1 has also been shown to increase 
T regulatory cells in the peripheral blood of IBD patients. In addition, the treatment 
resulted in a decreased percentage of TNF-α and IL-12-producing monocytes and 
DCs [320]. Overall, these findings indicate that LGG and GR-1 induce anti-
inflammatory effects by directly releasing a soluble factor(s) or indirectly by inducing 
production of immunomodulatory cytokines, such as G-CSF and IL-10. To date, the 
signaling mechanisms and GR-1 factor(s) responsible for the G-CSF preferential 
production in macrophages are unknown.   
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2.1 RATIONALE AND HYPOTHESIS 
Granulocyte-colony stimulating factor (G-CSF) is a pleiotropic cytokine with various 
functions in the immune system. It is primarily involved in neutrophil generation [1], 
but its role in macrophage generation has also been documented [2, 3]. An anti-
inflammatory role of G-CSF in down-regulating inflammatory cytokine production 
has also been reported in immune cells, including macrophages and DCs [4-8]. It is 
also apparent that G-CSF has potential therapeutic properties in gut inflammatory 
diseases such as inflammatory bowel diseases (IBD) [9-13]. To date, little is known 
about the role of G-CSF in macrophage generation and gut immunity. Additionally, 
LGG and GR-1 have been shown to render immunomodulatory effects through 
preferentially and potently inducing G-CSF in macrophages. However, how GR-1 
preferentially induces G-CSF in macrophages still remain to be unraveled. This thesis 
aims to elucidate the effects of G-CSF on macrophages and gut immunity, and 
examine the signaling mechanisms involved in the preferential production of G-CSF 
in macrophages. According to previous findings, I hypothesize that G-CSF plays an 
important role in the generation of gut-homing immune regulatory macrophages 
and in the maintenance of gut immune homeostasis.  
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2.2 SPECIFIC AIMS 
2.2.1 Aim 1: Examine the role of G-CSF in the generation 
and characteristics of macrophages. 
Macrophages represent the most abundant mononuclear phagocytes in the gut lamina 
propria and play a critical role in immune responses, inflammation and tissue 
homeostasis [14-17]. Gut macrophages originate from bone marrow under the 
influence of IL-3, and growth factors such as macrophage (M)-CSF and 
granulocyte/macrophage (GM)-CSF [18-21]. G-CSF primarily influences the 
generation and differentiation of granulocytes, mainly neutrophils [1]. However, 
studies on G-CSF-/- or G-CSFR-/- mice indicated that G-CSF is also involved in 
macrophage generation [2, 3]. To date, the influence of G-CSF on macrophage 
development is poorly understood. In Chapter 3, I will be evaluating effects of G-CSF 
on the generation of macrophages using in vitro bone marrow cell culture models. 
Then, I will be addressing the characteristics of G-CSF-responsive macrophages in 
regards to morphology, cytokine secretion and cell-surface marker profiles. Finally, I 
will be examining the in vivo localization of adoptively transferred in vitro G-CSF-
treated bone marrow derived macrophages (G-BMDM) in mice. Collectively, this 
study demonstrates that G-CSF plays an important role in the generation of gut-
homing, M2-like macrophages. 
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2.2.2 Aim 2: Examine the role of endogenous G-CSF in 
DSS-induced acute colitis. 
Several studies have shown that exogenous administration of G-CSF is effective in 
ameliorating disease severity in murine colitis models and IBD patients [9-13]. 
However, the role and mechanism of endogenous G-CSF in gut immunity is still 
unknown. As illustrated in Aim 1, G-CSF involves in the generation of gut-homing 
M2-like macrophages [22]. Therefore, I will be using oral administration of dextran 
sulfate sodium (DSS) to induce self-limiting acute colitis in mice and further 
characterize macrophages using hallmarks of M1 and M2 macrophages, and 
determine if adoptive transfer of G-CSF-treated macrophages reduce severity of 
colitis in DSS-treated G-CSFR-/- mice. Taken together, this study indicates that G-
CSF plays a protective role in DSS-induced acute colitis through generating gut-
homing macrophages. 
	  	  
65	  
2.2.3 Aim 3: Examine the signaling mechanisms involved in 
the preferential G-CSF production in macrophages by 
GR-1. 
Previously, our laboratory showed that G-CSF plays a key role in suppressing 
production of TNF-α or IL-12/23 p40 in macrophages and DCs, respectively [6, 23]. 
G-CSF is potently and preferentially produced by LGG- or GR-1-exposed 
macrophages; however, the microbial factor(s) and its mechanism by which L. 
rhamnosus elicits such effects on macrophages are largely unknown. In Chapter 5, I 
will be evaluating the cytokine profile of GR-1-treated macrophages and will be 
comparing it to the profile of macrophages stimulated with other stimuli. 
Additionally, I will be determining the responsible receptor for GR-1 recognition in 
macrophages and subsequent downstream signaling pathways initiated by GR-1 in 
these cells. Moreover, I will be addressing the signaling pathway responsible for 
preferential G-CSF production in GR-1-exposed macrophages and will be partially 
characterizing the GR-1 factor(s) responsible for such preferential G-CSF production 
in macrophages. Collectively, this study demonstrates that a protein-like factor(s) 
secreted from GR-1 preferentially induces G-CSF production in macrophages through 
selectively activating ERKs, NF-κB and Akt in a TLR2-dependent manner. 
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3.1 INTRODUCTION 
Macrophages are distributed throughout the body and play key roles in metabolic, 
immunological and inflammatory processes [1]. In adults, tissue macrophage 
populations are maintained by self-renewal of local macrophages, which initially arise 
from the yolk sac in development, and recruitment of circulating monocytes, which 
originate from common myeloid progenitors in the bone marrow [2-4].  Macrophages 
also show remarkable plasticity and functional diversity determined by environmental 
cues. In general, macrophages are classified into two different types: interferon-γ 
(IFN-γ)- and tumor necrosis factor (TNF)-α-exposed ‘classically activated’ or ‘M1’ 
macrophages, which release high amounts of pro-inflammatory cytokines, such as 
interleukin (IL)-1β, -6, -12 and -23, in response to microbial infections, and IL-4-, -
10- and -13-exposed ‘alternatively activated’ or ‘M2’ macrophages, which are 
involved in anti-inflammatory responses [5]. The repertoire of M2 macrophages has 
expanded and now encompasses at least two main subtypes, namely wound-healing 
and regulatory macrophages, based on their function and cytokine release profiles [6, 
7].  Of the more than 20 soluble hematopoietic factors, the colony-stimulating factors 
(CSFs), including macrophage (M)-CSF and granulocyte/macrophage-CSF (GM-
CSF), are crucial for the generation of myeloid cells in the bone marrow and 
differentially affect the type of macrophages that can be produced from hematopoetic 
bone marrow precursors and monocytes [8, 9]. In general, GM-CSF is known to 
generate dendritic cells (DCs), granulocytes, alveolar macrophages and invariant 
natural killer T cells, whereas M-CSF is involved in the generation and maintenance 
of monocytes/macrophages [10]. Therefore, M-CSF-treated bone marrow cells (M-
BMCs) have frequently been used as a source for primary macrophages in vitro and 
were shown to have anti-inflammatory/regulatory macrophage “M2-
like”characteristics in cytokine production upon activation [11]. Unlike M-CSF, GM-
CSF-BMCs (GM-BMCs) give rise to inflammatory DCs and have often been used as 
a model for generating DCs. However, further studies demonstrated that GM-BMCs 
resemble macrophages rather than DCs, based on transcriptomic analysis [12] and 
cytokine profiles [11]. In line with these notions, GM-CSF, which is rapidly induced 
during infections, is particularly implicated in inflammatory processes and generation 
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of inflammatory “M1-like” macrophages [11]. M-CSF, which is constitutively and 
ubiquitously expressed, is involved in generating the steady state tissue macrophages, 
counteracting GM-CSF effects, suppressing pro-inflammatory stimuli and restoring 
tissue homeostasis from inflammatory damage [11, 13-17].  
Distinct from M-CSF and GM-CSF, granulocyte-CSF (G-CSF) is intimately involved 
in the generation, mobilization and activation of granulocytes, namely neutrophils 
[18-22]. However, recent studies have revealed that G-CSF also plays a role in 
immunomodulation and maintenance of gut homeostasis [10, 23-25]. In the bone 
marrow, G-CSF is produced by stromal cells, which supports proliferation and 
survival of G-CSF-dependent myeloid precursor cells. G-CSF is also produced by 
fibroblasts, endothelial cells and macrophages in response to various inflammatory 
cytokines, including IL-1, IL-17 and TNF-α, as well as pathogen-associated or 
danger-associated molecular pattern molecules such as lipopolysaccharide (LPS) and 
the acute-phase protein serum amyloid A, respectively [22, 26, 27]. Normal serum 
levels of G-CSF are low, but the levels greatly increase during infection or chronic 
inflammatory diseases such as rheumatoid arthritis. Peak levels of G-CSF in the 
serum or tissues are expected to recruit and activate neutrophils, which is key for 
restricting infection and inducing local inflammation. Consistent with these effects, 
administration of G-CSF can exacerbate pathophysiology in animal models of 
arthritis and graft-versus-host disease [28], whereas G-CSF deficiency or neutralizing 
antibodies can alleviate symptoms. In contrast, a high constitutive level of G-CSF is 
detected in the colon [29], and administration of G-CSF confers protective effects on 
colitis, pulmonary inflammation [30], neuronal inflammation, cell death [31, 32], and 
cardiac ischemia/reperfusion injury [33]. Furthermore, G-CSF reduces TNF-α and 
IL-12 production in myeloid cells [29, 34], and promotes the generation of 
tolerogenic DCs and T lymphocytes [23, 35-37]. These seemingly opposing effects 
suggest that G-CSF has tissue- and disease-specific roles.  
In early in vitro studies, G-CSF was shown to support the survival of both M-CSF- 
and GM-CSF-responsive progenitor cells in bone marrow, suggesting a role in 
macrophage development [38]. Consistent with these observations, mice deficient in 
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G-CSF or G-CSFR harbour ~85-90 % and ~50% reduced circulating neutrophils and 
monocytes, respectively, compared to wild-type mice [20]. G-CSFR-/- mononuclear 
cells also showed higher levels of apoptosis in bone marrow cell cultures [20], 
suggesting a role of G-CSFR in supporting the survival of monocytes/macrophages. 
Therefore, lower numbers of circulating monocytes in G-CSFR-/- mice could be due 
to their defects in maintaining myeloid precursor cells necessary to sustain continual 
differentiation of monocytes/macrophages in different tissue compartments. To date, 
the role of G-CSF in the development of tissue-specific macrophages has not yet been 
explored. Here, using in vitro bone marrow cell culture models, we found that G-CSF 
plays an important role in the generation of Gr-1high/F4/80+ “M2-like” macrophages, 
which are localized mainly in the intestine after adoptive transfer.  
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3.2 MATERIALS AND METHODS 
3.2.1 Mice 
C57BL/6j wild-type mice were obtained from Jackson Laboratories (Bar Harbour, 
ME, USA). Homozygote G-CSFR-/- mice (C57BL/6 background) were originally 
obtained from Dr. D.C. Link (Washington University Medical School, St Louis, MO, 
USA) and maintained in the animal care and veterinary facility at Western University 
under conventional conditions. C57BL/6 mice were crossed to G-CSFR-/- mice, and 
G-CSFR+/- offspring were then crossed with each other to generate G-CSFR+/+ and -/- 
genotypes. Mice were genotyped for G-CSFR+/+ by PCR using the following primers; 
forward: AGCCCTCTCCATCGGAAAGTTTGA, reverse: 
AGCGAAGTTCACACTCCTGTTCCA. Mice were genotyped for G-CSFR-/- by 
PCR using the following primers; forward: AGAGGCTATTCGGCTATGACTG, 
reverse: CCTGATCGACAAGACCGGCTTC. Matched pairs of littermates were used 
whenever possible. Male and female mice, aged 4-12 weeks, were used in all 
experimental procedures. The lys-EGFP-ki mice were originally obtained from Dr. 
Thomas Graf (Albert Einstein University, NY, USA) and have been maintained in a 
barrier facility as homozygous mice on a C57BL/6 background. These transgenic 
mice express EGFP under the control of the lysozyme M promoter in mature myeloid 
and granulocytic populations [39]. All experimental protocols were approved by the 
Western University Animal Use Subcommittee, which follows the regulation of the 
Animals for Research Act (Ontario, Canada) and the Canadian Council on Animal 
Care.  
3.2.2 Reagents 
The antimitotic agent nocodazole was purchased from Sigma-Aldrich (St. Louise, 
MO, USA). M-CSF, GM-CSF and G-CSF, FITC-anti-mouse F4/80, PE-anti-mouse 
Ly6C, PE-Cy5-anti-mouse CD11c, APC-anti-mouse CD11c, PE-Cy7-anti-mouse Gr-
1 (Ly6G), PE-anti-mouse CD11b, PE-anti-mouse CD71, PE-anti-mouse PDL2, APC-
anti-mouse CD206 antibodies, the Fixable Viability Dye eFluor® 660 (FVD eFluor® 
660), and the enzyme-linked immunosorbent assay (ELISA) kits of TNF-α, IL-10, 
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IL-23 and chemokine (C-C motif) ligand (CCL) 2 were purchased from eBioscience 
(San Diego, CA, USA). LPS from E. coli O111:B4 was obtained from List Biological 
Laboratories (Campbell, CA, USA). IL-4 and IL-13 cytokines were obtained from 
PeproTech (Rocky Hill, NJ, USA). CellTrace™ carboxyfluorescein diacetate 
succinimidyl ester (CFSE) cell proliferation kit was purchased from 
Invitrogen/Molecular Probes (Eugene, OR, USA). 
3.2.3 Generation of Bone Marrow-Derived Macrophages 
BMCs were flushed out from femurs and tibia of G-CSFR+/+ and/or -/- mice using a 
25.5 gauge needle and phosphate buffered saline (PBS). Isolated cells were cultured 
in complete RPMI 1640 (c-RPMI; Sigma-Aldrich, St. Louise, MO, USA) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, St. 
Louise, MO, USA), 100 U ml-1 of penicillin, 0.1 mg ml−1 of streptomycin (Sigma-
Aldrich, St. Louise, MO, USA), 5 mM sodium pyruvate (Sigma-Aldrich, St. Louise, 
MO, USA), 5 mM MEM non-essential amino acids (Sigma-Aldrich, St. Louise, MO, 
USA), and M-CSF or GM-CSF at 37°C in a humidified atmosphere with 5% CO2. 
The culture media was replaced with fresh media every 2 days. 
3.2.4 Cell Proliferation Assay 
BMCs were harvested from G-CSFR+/+ and -/- mice on the day of the experiment and 
cells were distributed evenly onto 24 well plates. Duplicate wells were created for M-
CSF (20 ng/ml) ± G-CSF (10 ng/ml), GM-CSF (20 ng/ml) ± G-CSF (10 ng/ml) and 
G-CSF (10 ng/ml). Cells were quantified using a haemocytometer every day for 5-7 
days.  
3.2.5 Flow Cytometry and Magnetic-Activated Cell Sorting 
For the analysis of F4/80, Gr-1, Ly6C, CD11c, CD11b, PDL2, CD206 and CD71 
expression, cells were harvested, washed twice, stained for cell surface markers and 
then read on the FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, 
NJ, USA). Flow cytometry analysis was done using the Flowjo software (version 
7.6.5; Treestar, Inc., OR, USA). Gr-1low/F4/80+ (P1), Gr-1high/F4/80+ (P2) and Gr-
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1+/F4/80-/ (P3), or F4/80+ cells were sorted using the FACSAria III cell sorter or the 
Magnetic-Activated Cell Sorting (MACS; Miltenyi Biotec, CA, USA), respectively, 
following the manufacturer’s protocol.  
3.2.6 CSFE Proliferation Assay 
Cell proliferation was analyzed by a CFSE dilution assay according to the 
manufacturer's instructions. Briefly, MACS-sorted P1 cells were counted, stained 
with 1 µL of 5 mM CFSE per mL and incubated at 37 °C for 15 min in the dark. Cells 
were then washed twice with 5 volumes of ice-cold FBS. Intracellular CFSE 
intensities were measured by flow cytometry immediately after washing or after 
culturing cells 2 days with M-CSF or M-CSF + G-CSF.  
3.2.7 Transmission Electron Microscopy 
Isolated BMCs from wild-type mice were cultured in the presence of M-CSF (20 
ng/ml) ± G-CSF (10 ng/ml). On day 5, cells were sorted for F4/80+, Gr-1low (P1) and 
F4/80+, Gr-1high (P2) cells using the FACSAria III cell sorter (BD Biosciences, CA, 
USA). The sorted cells were then washed with PBS twice and fixed with 2.5% 
glutaraldehyde in a 0.1 M sodium cacodylate buffer for 2 h at room temperature. 
Grids with specimens were prepared according to the Transmission Electron 
Microscope Facility Protocol at Western University (Canada), and micrographs were 
taken with a transmission electron microscope. Briefly, after fixing with 2.5% 
glutaraldehyde, cells were washed with 0.1 M cacodylate buffer three times, and cells 
were further fixed with 2% osmium tetroxide in 0.1 M cacodylate buffer for 1 h, and 
then rinsed with 0.1 M cacodylate buffer. Cells were enrobed in 5% Noble Agar and 
washed with distilled water 5 times, further fixing with 2% uranyl acetate for 2 h in 
the dark, followed by dehydration in 50% (15 min), 70% (16 h), 85% (15 min), 95% 
(15 min), and two changes of 100% ethanol (15 min each). They were then cleared by 
two changes of propylene oxide each 15 min and infiltrated with epon resin:propylene 
oxide (1:1) for 3 h, epon resin:propylene oxide (3:1) for 16 h at room temperature, 
and two changes with 100% epon resin for a total of 6 h. Following that, samples 
were baked for two days at 60°C. Thin sections were mounted on grids, and examined 
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under the electron microscope (Philips CM-10 80 Kv and AMT Digital Camera, OR, 
USA). 
3.2.8 Enzyme-Linked Immunosorbant Assays 
Isolated BMCs were cultured in the presence of M-CSF (20 ng/ml) + G-CSF (10 
ng/ml). On day 5, cells were sorted using FACSAria III cell sorter, washed with PBS 
twice and cultured in a 96-well plate for 2 h. Subsequently, cells were treated with 
100 ng/ml of LPS and cytokine levels were determined in cell culture supernatants 
using commercially available quantitative ELISA kits from eBioscience (San Diego, 
CA, USA). The same procedure was performed for unsorted bone marrow cells that 
were cultured in the presence of M-CSF (20 ng/ml) or GM-CSF (10 ng/ml) ± G-CSF 
(10 ng/ml) for 5 days. 
3.2.9 Cell Death Assay 
A 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay or 
FVD eFluor® 660 staining was used to assess cell death. For MTT assay, G-CSFR+/+ 
BMCs were cultured with c-RPMI supplemented with either M-CSF (20 ng/ml) or 
GM-CSF (10 ng/ml). On day three, the cultures were split into four 96-well plates for 
analysis on day 4, 5 and 6. Triplicate wells were created for M-CSF (5 and 10 ng/ml) 
or GM-CSF (1 and 5 ng/ml) ± G-CSF (10 ng/ml). Analysis on days 4 through 6 were 
done the same and conducted as follows. MTT was added at a final concentration of 
0.5 mg/ml and plates were then incubated for 2 h at 37°C. The plates were then 
centrifuged at 2900 rpm for 10 min to pellet cells and the media was carefully 
aspirated out. Dimethyl sulfoxide was then added to each well and the plates were 
incubated at room temperature in the dark while shaking gently to dissolve formed 
crystals. Optical densities of the wells were analyzed using an automatic ELISA plate 
reader (Bio-Rad Laboratories, Inc., CA, USA) at a wavelength of 590 nm. For FVD 
eFluor® 660 staining, cells were washed twice with PBS and re-suspended in PBS 
containing 1 µL/ml eFlour 660 dye at a density of 1-10 × 106 cells. After incubation 
on ice in the dark for 30 min, cells were washed twice, stained for surface markers as 
described above and analyzed by flow cytometry.   
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3.2.10 Splenocyte and Intestinal Lamina Propria Cell Isolation 
G-CSFR+/+ and -/- mice were euthanized by CO2 inhalation and were dissected 
immediately after sacrifice. Splenocyte Isolation: An incision was made along the 
right side of the mouse and the spleen was removed, mechanically disrupted and 
passed through a 70 µm filter. The suspension was centrifuged and re-suspended in 4 
ml Ammonium-Chloride-Potassium cell lysis buffer and left for 4 min at room 
temperature with gentle shaking. Then, 10 ml of c-RPMI was added to the suspension 
and was centrifuged at 1500 rpm for 5 min. The supernatant was discarded and cells 
were re-suspended in c-RPMI to 1 × 106 cells/ml and samples were prepared for flow 
cytometry analysis as described above. Intestinal Cell Isolation: Intestinal lamina 
propria cells were isolated as previously described [40] with some modifications. 
Briefly, intestines were flushed out with 1x PBS supplemented with 5% FBS and the 
Peyer's patches excised. The intestines were opened longitudinally, washed with ice-
cold 1x PBS twice and cut into 0.5-cm segments. These segments were incubated 
twice in Hank's balanced salt solution with 2  mM EDTA and 1mM dithiothreitol at 
37°C with shaking for 20 min. Remaining pieces of intestine were passed through a 
100 µm cell strainer and washed with 1x PBS. Intestinal tissues were then digested 
twice with 1x PBS including 0.13 wünsch units/ml of Liberase-TM (Roche Applied 
Science, CA, USA), 0.04 mg/ml of DNase I (Sigma-Aldrich, St. Louise, MO, USA) 
and 3 mg/ml of dispase II (Roche Applied Science, CA, USA) at 37°C with shaking 
for 30  min. Cells were then passed through a 40 µm cell strainer and washed twice 
with 1x PBS with 5% FBS. The cells were then re-suspended in 10 ml of the 40% 
percoll and the mixture was then overlaid on top of 5 ml of 80% percoll. Following 
the centrifugation at 1000 g for 20 min without breaking, lamina propria cells were 
collected from the interphase of two different percoll solutions and washed 
immediately with 1× PBS with 5% FBS. The cells were then stained for flow 
cytometry as described above. 
3.2.11 Adoptive Cell Transfer Experiment 
BMCs from lys-EGFP-ki transgenic mice [41] were harvested as described earlier and 
cultured in the presence of M-CSF (20 ng/ml) ± G-CSF (10 ng/ml). On day 5, F4/80+ 
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cells were sorted using MACS and the expression of EGFP was confirmed by flow 
cytometry (Appendix A.1). F4/80+ cells (1.0 × 106, unless otherwise indicated) were 
then intravenously injected to wild-type recipient mice and various tissues (intestine, 
spleen, liver, kidney, lung, heart and bone marrow) were obtained after 2, 5, 15 and 
30 days after adoptive transfer. These tissues were fixed in 10% neutral-buffered 
formalin for 48 h, paraffin-embedded and placed on poly-L-lysine coated slides after 
being sliced in 50 µm thickness. The tissue slides were then stained by hematoxylin 
and eosin, and EGFP+ cells were examined by the Olympus 1X51 fluorescent 
microscope (Olympus America Inc., NY, USA) attached to the QImaging Retiga 
2000R digital camera (QImaging Co., BC, Canada). Images were processed using the 
QCapture Pro image analyzing software (version 6.0; QImaging Co., BC, Canada).  
3.2.12 Statistical Analysis 
Statistical analysis was carried out using Prism 5.0c for Mac OS X (GraphPad 
Software, La Jolla, CA, USA). Student’s t tests and one-way ANOVA, followed by 
Tukey's multiple comparison post-hoc test, were performed as described in the figure 
legends.  
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3.3 RESULTS 
3.3.1 G-CSF preferentially increases numbers of M-BMCs. 
To examine the role of G-CSF in macrophage proliferation, BMCs from G-CSFR+/+ 
and -/- mice were cultured in the presence of M-CSF or GM-CSF, and viable cell 
numbers were counted each day for 7 days. In both M-CSF and GM-CSF treated cell 
cultures, G-CSFR-/- bone marrow cell numbers were growing significantly slower 
than G-CSFR+/+ cells (Fig. 3.1.A-B). These results are consistent with a previous 
study showing that G-CSF supports survival of both M-CSF and GM-CSF responsive 
progenitor cells in bone marrow [38]. However, when G-CSF was exogenously added 
to cell culture media, cell numbers of M-BMCs were significantly increased after 3 
days of cell culture, but not in GM-BMCs (Fig. 3.1C-D). G-CSF alone was not able to 
sustain continued survival/proliferation of BMCs. These results suggest that G-CSF 
had a growth promoting effect on M-BMCs, but not GM-BMCs. 
	  	  
79	  
Figure 3.1. G-CSF preferentially increases cell number of M-BMCs. (A-B) BMCs 
from wild-type and G-CSFR-/- mice were treated with either M-CSF (20 ng/ml) (A) or 
GM-CSF (20 ng/ml) (B), and cell numbers were counted each day for 7 days. (C-D) 
Similarly, BMCs from wild-type mice were treated with either M-CSF (20 ng/ml) ± 
G-CSF (10 ng/ml) (C) or GM-CSF (20 ng/ml) ± G-CSF (10 ng/ml) (D). Data shown 
as mean ± SEM (n ≥ 3; *, p < 0.05 by Student’s t-test). 	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Figure 3.1	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3.3.2 G-CSF induces proliferation of Gr-1high/Ly6C+ 
macrophage-like and neutrophil-like cells in M-BMCs. 
To further examine myeloid cell types that arise from G-CSF-, M-CSF- and GM-
CSF-treated BMCs, cells were stained with various macrophage surface markers 
including F4/80, Gr-1, Ly6C, CD11b and CD11c. As shown in Fig. 3.2A, M-BMCs 
showed 3 distinct cell populations, based on F4/80 and Gr-1 staining intensities: P1, 
Gr-1low/F4/80+; P2, Gr-1high/F4/80+; P3, Gr-1+/F4/80-. Further examination of other 
surface markers showed that both P1 and P2 were positive for CD11b and CD11c; 
however, levels of Ly6C staining were high in P2 but much lower in P1 (Fig. 3.2B, 
top lane). P3 was Ly6Chigh, CD11blow and CD11c-. These results suggest that P1 and 
P2 cells were macrophage-like and P3 were neutrophil-like cells. G-CSF alone 
generated a very small number of cells, which were mainly P3 (Fig. 3.2A left panel 
and 3.2C). M-CSF generated about 1.5 × 106 P1 cells (~38% in proportion), 0.3 × 106 
P2 (~7%) and 0.25 × 106 P3 (~5%) cells from 1 × 106 BMCs seeded. M-CSF together 
with G-CSF significantly increased cell numbers of all populations but much greater 
extents in P2 and P3 cells, which resulted in proportional increases of P2 and P3 with 
a slight, but non-significant decrease of P1 (Fig. 3.2C bottom panel). These results 
suggest that G-CSF support the generation of P2 and P3 cells, as well as survival of 
M-CSF responsive progenitor cells. Although G-CSF increased cell numbers, overall 
intensities for Ly6C and CD11c of these cells did not change (data not shown).  
GM-CSF induced generation of at least four distinct populations based on F4/80 and 
Gr-1 staining (Fig. 3.3A). Similar to M-BMCs, P3 of GM-BMCs were 
Ly6Chigh/CD11b+/CD11c-; P1 was Ly6Clow/CD11b+/CD11c+; P2 was 
Ly6Chigh/CD11b+/CD11c+; P4 was Ly6Clow/CD11b+/CD11c- (Fig. 3.3B). Unlike M-
BMCs, G-CSF had no effects on cell numbers and composition of populations in 
GM-BMCs (Fig. 3.3C). The differences in the cell populations between M-BMCs and 
GM-BMCs were not likely due to differences in granulocyte/macrophage progenitors, 
since BMCs from both wild-type and G-CSFR-/- mice generated the same cell 
population compositions in the presence of M-CSF or GM-CSF (Appendix A.2). 
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Collectively, these results suggest that G-CSF supported generation of P2 and P3 cells 
from M-BMCs. 
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Figure 3.2. G-CSF increases Gr-1high/F4/80+/Ly6C+/CD11b+/CD11c+ (P2) and Gr-
1+/F4/80-/Ly6C+/CD11b+/CD11c- (P3) cell populations in M-BMCs. BMCs from 
wild-type mice were treated with M-CSF (20 ng/ml), M-CSF + G-CSF (10 ng/ml) or 
G-CSF (10 ng/ml) alone for 5 days. (A) Based on the Gr-1 and F4/80 expression 
characteristics, cells were divided into 3 populations: P1, Gr-1low/F4/80+; P2, Gr-
1high/F4/80+; P3, Gr-1+/F4/80-. (B) Characteristics in expression of Ly6C, CD11c and 
CD11b markers were further examined in each cell population. (C) Number and 
percentage of each cell population was analyzed and plotted. Data shown as mean ± 
SEM (n ≥ 3; *, p < 0.05 by Student’s t-test or one-way ANOVA with Tukey's 
multiple comparison post-hoc test; columns accompanied by the same letter are not 
significantly different from each other). 	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Figure 3.2 	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Figure 3.3. G-CSF had no effect on cell numbers and surface marker expressions 
on GM-BMCs. BMCs from wild-type mice were treated with GM-CSF (10 ng/ml), 
GM-CSF + G-CSF (10 ng/ml) for 5 days. (A) Based on the Gr-1 and F4/80 
expression characteristics, cells were divided into 4 populations: P1, Gr-1low/F4/80+; 
P2, Gr-1high/F4/80+; P3, Gr-1+/F4/80-; P4, Gr-1-/F4/80-. (B) Characterization of Ly6C, 
CD11c and CD11b marker surface expression was examined on each of the four cell 
populations. (C) Number and percentage of each cell population was quantified and 
plotted. Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 by one-way ANOVA with 
Tukey's multiple comparison post-hoc test). 	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Figure 3.3 	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3.3.3 G-CSF supports cell survival/proliferation in M-CSF-
deprived cell culture conditions. 
Since G-CSF had a growth supporting effect on M-BMCs, we further examined 
whether G-CSF can support survival/proliferation of M-BMCs at low M-CSF 
concentrations. BMCs were cultured at a high dose of M-CSF (20 ng/ml) or GM-CSF 
(10 ng/ml) for 3 days, and then the doses of M-CSF and GM-CSF were lowered to 
suppress cell proliferation or induce cell death with or without G-CSF (10 ng/ml) 
supplements for an additional 3 days. With 10 ng/ml of M-CSF cell culture, cell 
survival/proliferation of M-CSF-derived cells, examined by MTT assays, remain 
stable (Fig. 3.4A, left panel); however, at 5 ng/ml of M-CSF, cell death was increased 
after 2 days (Fig. 3.4A, right panel). Adding G-CSF in these M-CSF culture 
conditions improved cell survival/proliferation. With 5 ng/ml of GM-CSF cell 
culture, overall cell survival/proliferation remained unchanged (Fig. 3.4B, left panel), 
but cell death started to increase after 2 days of 1 ng/ml GM-CSF cell culture (Fig. 
3.4B, right panel). Unlike M-BMCs, adding G-CSF in these GM-CSF culture 
conditions failed to support cell survival/proliferation. These results suggest that G-
CSF could specifically compensate the function of M-CSF but not GM-CSF in bone 
marrow cell culture. 
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Figure 3.4. G-CSF supports growth of M-BMCs but not GM-BMCs in CSF-
deprived cultures. Wild-type BMCs treated with M-CSF (20 ng/ml) or GM-CSF (10 
ng/ml) for 4 days. These cells were sub-cultured with 2 different doses of M-CSF (10 
ng/ml or 5 ng/ml; A) or GM-CSF (5 ng/ml or 1 ng/ml; B) with or without G-CSF (10 
ng/ml) for the next 3 days. Cell survival was measured by MTT assays each day. Data 
shown as mean ± SEM (n ≥ 3; *, p < 0.05 between samples with and without G-CSF 
by Student’s t-test). 
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Figure 3.4 
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3.3.4 G-CSF protects cell death of M-CSF-derived P2 and P3 
cells. 
G-CSF specifically promoted growth of P2 and P3 of M-BMCs (Fig. 3.2). We further 
examined whether G-CSF also specifically support continued growth or prevent cell 
death of these cells at low M-CSF concentrations. Culturing M-BMCs at a low dose 
of M-CSF (5 ng/ml) significantly reduced P1, but not P2 and P3, which were low 
even at optimal M-CSF concentrations. Adding G-CSF (10 ng/ml) in these culture 
conditions significantly increased P2 and P3 without affecting P1 (Fig. 3.5A and B). 
Further staining of these cells with the cell death dye FVD eFluor® 660 showed that 
basal cell death levels of P1 were relatively low (~22%), which became significantly 
increased (~80%) after 3 days of cell culture at the low M-CSF concentration (Fig. 
3.5C). Treatments of G-CSF had no effect on the extent of P1 cell death. Unlike P1, 
P2 cells showed high basal levels of cell death (~65%) at both concentrations of M-
CSF, which was significantly reduced by G-CSF (~45%). Similarly, P3 cells also 
showed ~22% of basal cell death levels at both M-CSF concentrations, which was 
reduced by G-CSF (Fig. 3.5C). These results, together with Fig. 3.4, suggest that G-
CSF selectively protected cell death of M-CSF-derived P2 and P3 BMCs cultured at 
sub-optimal and optimal doses of M-CSF. 
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Figure 3.5. G-CSF increases survival of P2 and P3 cells in M-BMCs. Wild-type 
BMCs were treated with M-CSF (20 ng/ml) for 4 days and then sub-cultured with 20 
ng/ml or 5 ng/ml of M-CSF, or M-CSF (5 ng/ml) + G-CSF (10 ng/ml) for an 
additional 2 days. (A) Based on the Gr-1 and F4/80 expression characteristics, cells 
were divided into 3 populations: P1, Gr-1low/F4/80+; P2, Gr-1high/F4/80+; P3, Gr-
1+/F4/80-. (B) Percentage of each cell population was quantified and plotted. (C) 
Percentage of dead cells (FVD eFluor® 660+ cells) from P1, P2 and P3 populations 
was quantified by flow cytometry and plotted. (B-C) Data shown as mean ± SEM (n 
≥ 3; *, p < 0.05 by one-way ANOVA with Tukey's multiple comparison post-hoc test; 
columns accompanied by the same letter are not significantly different from each 
other). 
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Figure 3.5 
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3.3.5 G-CSF enhanced the generation of P2 cells from P1 M-
BMCs. 
To examine whether P2 cells originated from P1 or bone marrow precursor cells, 
F4/80+ cells were isolated using the MACS column after culturing BMCs with M-
CSF for 4 and 7 days. Cells were further cultured for the next 2 days in the presence 
of M-CSF or M-CSF + G-CSF and expression of Gr-1 and F4/80 was examined. As 
expected, no P3 or residual BMCs were detected (Fig. 3.6A), suggesting complete 
removal of residual BMCs and P3 cells by the column. M-CSF alone was able to 
generate P2 cells, which was apparent after a total of 9 (7 + 2) days of cell culture 
(middle panel). G-CSF further enhanced P2 generation, resulting in corresponding 
decreases of P1, in both day 4 and day 7 M-BMCs (Fig. 3.6B, left panels). However, 
when cell proliferation was inhibited by the antimitotic agent nocodazole (10 µg/ml), 
an increase in the P2 ratio over P1 by G-CSF was not detected (Fig. 3.6B, right 
panel). We then examined whether P2 cells originated from P1 by culturing only P1 
cells. As shown in Fig. 3.6C, G-CSF enhanced the generation of P2 cells from 
isolated P1 M-BMCs. Also, both P1 and P2 cells completed one cell division after 2 
days (Fig. 3.6D). These results, together with nocodazole data, suggest that P2 cells 
were derived from P1 M-BMCs, which was enhanced by G-CSF. 
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Figure 3.6. Increase of Gr-1high/F4/80+ (P2) cells by G-CSF is due to proliferation 
of P1 M-BMCs. BMCs were treated with M-CSF (20 ng/ml) for 4 and 7 days, F4/80+ 
cells sorted by MACS columns, and then further cultured with M-CSF or M-CSF + 
G-CSF (10 ng/ml) in the presence or absence of the antimitotic agent nocodazole 
(Nocoda) for an additional 2 days. (A) Based on Gr-1 and F4/80 expression, 2 
populations of cells were detected: P1, Gr-1low/F4/80+; P2, Gr-1high/F4/80+. (B) 
Percentages of P1 and P2 populations (left panels) and the ratio of P2 to P1 with or 
without nocodazole in day 4 M-BMCs (right panel) were plotted. (C-D) P1 cells were 
isolated from M-BMCs and stained with CFSE. These cells were further cultured with 
M-CSF or M-CSF + G-CSF for an additional 2 days. G-CSF enhanced the generation 
of P2 cells from P1 (C), and both P1 and P2 cells went through cell cycle at a similar 
rate (D). (B-C) Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 and N.S., not 
significant by Student’s t-test). 
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Figure 3.6 
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3.3.6 P2 cells are “M2-like” macrophages as defined by 
cytokine and surface marker expression. 
GM-CSF and M-CSF induce inflammatory and regulatory macrophages, respectively, 
from BMCs. Consistent with previous studies, M-BMCs produced higher levels of 
IL-10 and CCL2 and lower levels of TNF-α than GM-BMCs, and undetectable levels 
of IL-23, whereas GM-BMCs produced high levels of TNF-α and IL-23, and lower 
levels of IL-10 and CCL2 than M-BMCs in response to LPS (Fig. 3.7A). G-CSF had 
no effects on overall production of TNF-α and IL-23 in M- and GM-BMCs; however, 
slightly reduced levels of IL-10 and CCL2 production in M-BMCs. G-CSF had no 
effects on cytokine production in GM-BMCs. These results suggest that G-CSF had 
only minor or no effects on overall “M1-” and “M2-like” phenotypes of GM- and M-
BMCs, respectively, in response to LPS. To further examine contributions of P1, P2 
and P3 cells in these cytokine productions, each subpopulation of M-BMCs treated 
with G-CSF were isolated by FACSAria III cell sorter and treated with LPS as before. 
P1 and P2 cells produced similar levels of TNF-α; however, the levels of IL-10 and 
CCL2 were slightly but not significantly reduced in P2 cells when compared to those 
of P1 cells (Fig. 3.7B). P3 cells also produced similar levels of IL-10 as P1 and P2 
cells, but the levels of TNF-α and CCL2 were low and unchanged by LPS. As 
expected, production of IL-23 was not detected in any of the cell populations. To 
examine responses to M2 stimuli, M-BMCs treated with G-CSF were treated with IL-
4 (20 ng/ml) and IL-13 (20 ng/ml) and expression of M2 surface markers PDL2 
(programmed cell death 1 ligand 2) [42], CD206 (mannose receptor, C type 1) and 
CD71 (transferrin receptor) [43] were examined. As shown in Fig. 3.7C, expression 
of PDL2, CD71 and CD206 were induced in all P1, P2 and P3 cells in response to IL-
4/IL-13, but the highest amounts of these markers were induced in P2 cells. LPS or 
LPS + IFN-γ did not induce these markers in any of the cell populations (data not 
shown). Wright-Giemsa staining of P1, P2 and P3 cells also suggested that P1 and P2 
cells were similar to each other in their overall characteristics including size, 
mononuclear morphology and adherence to culture dishes, whereas P3 cells were 
about half the size of P1 and P2 cells and non-adherent (data not shown). Ultra 
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structures of P1 and P2 cells, resolved by transmission electron microscopy, showed 
similar macrophage-like spherical morphologies [44] with limited membrane ruffles 
and developed vacuoles of about 12 microns in diameter (Fig. 3.7D). Collectively, 
these data suggest that both P1 and P2 cells are M2-like macrophages but P2 cells are 
more potent in expressing M2-specific surface markers in response to IL-4/IL-13, 
compared to P1 cells. 
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Figure 3.7. Gr-1high/F4/80+ (P2) cells are M2-like cells in cytokine production by 
LPS and cell surface marker expression by IL-4 and IL-13. (A) Wild-type BMCs 
were treated with either M-CSF (20 ng/ml) ± G-CSF (10 ng/ml) or GM-CSF (10 
ng/ml) ± G-CSF (10 ng/ml) for 5 days. Cells (1.0 x 105) were then plated on a 96-well 
plate and treated with LPS (100 ng/ml) for 6 h. Concentrations of cytokines in the cell 
culture media were measured by ELISA. (B) Wild-type BMCs were treated with M-
CSF (20 ng/ml) + G-CSF (10 ng/ml) for 5 days, and P1 (Gr-1low/F4/80+), P2 (Gr-
1high/F4/80+) and P3 (Gr-1+/F4/80-) cells were isolated using the FACSAria III cell 
sorter. Each sorted population of cells (1.0 × 105) was treated with LPS (100 ng/ml) 
for 6 h and cytokine concentrations in the cell culture media were measured by 
ELISA. (C) Mean fluorescent intensity (MFI) of PDL2, CD71 and CD206 markers 
were further examined in each cell population. (A-C) Data shown as mean ± SEM (n 
≥ 3; *, p < 0.05 by one-way ANOVA with Tukey's multiple comparison post-hoc test; 
columns accompanied by the same letter are not significantly different from each 
other). (D) Images shown are transmission electron micrographs of representative 
cells found in the sorted P1 and P2 populations. N.D, not detectable. 	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Figure 3.7 
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3.3.7 G-CSF enhanced gut-homing phenotype of M-BMCs. 
Since monocytes migrate to local compartments/tissues during normal homeostasis, 
we examined where M-BMCs treated with G-CSF migrated. To this end, BMCs from 
lys-EGFP knock-in mice [41] were treated with M-CSF or M-CSF + G-CSF for 5 
days and F4/80+ cells were injected into tail veins of recipient mice. Injected M-
BMCs were detected in the lamina propria of the small intestine after 2 days of 
injections, but not in other tissues including the spleen, liver, kidney, lung, heart and 
bone marrow (Fig. 3.8A, shown in arrows; Appendix A.3). Interestingly, G-CSF 
greatly enhanced the numbers of gut-homing M-BMCs in both small and large 
intestines (Fig. 3.8A-B). These transplanted cells could be detected in the intestine 
throughout the time frame examined (>30 days; Fig. 3.8C). 
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Figure 3.8. G-CSF enhances the localization of adoptively transferred F4/80+ M-
BMCs to the lamina propria of intestines. (A) BMCs from lys-EGFP-ki transgenic 
mice were treated with either M-CSF (20 ng/ml) or M-CSF (20 ng/ml) + G-CSF (10 
ng/ml) for 5 days. F4/80+ cells were isolated by MACS and 1.0 × 106 cells were 
injected into recipient mice through tail vein. Two days after injection, sections from 
the large and small intestines of the recipient mice (total of 4 mice in 2 different 
times) were viewed through a fluorescent microscope as described in Methods. 
Images in the bottom row show representative fluorescent microscopy results. Images 
in the top row are representative overlays of phase contrast microscopic digital 
images with their corresponding fluorescent images from the same tissue section area. 
Arrows indicate EGFP+ cells. (B) Average numbers of EGFP+ cells per 40× field of 
view (>20) from the small and large intestine tissue sections were counted and 
plotted. Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 by Student’s t-test). (C) 
Similarly, the small and large intestine tissue sections after indicated days of adoptive 
transfer (2.0 × 105 cells) were prepared and viewed as (A). 	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Figure 3.8 
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3.3.8 Gr-1high and Gr-1low intestinal resident macrophages 
(Ly6Clow/CD11c+/F4/80+) are reduced in G-CSFR-/- 
mice. 
Since G-CSF enhanced tissue localization of M-BMCs, we examined whether G-
CSFR-/- mice are defective in populating mononuclear phagocytes in the intestine 
during steady state. Lamina propria leukocytes of the intestine were isolated from G-
CSFR+/+ and -/- mice and examined for the surface expression of different markers. 
Based on the same flow cytometry analysis scheme used for in vitro BMCs, intestinal 
lamina propria leukocytes isolated from wild-type mice contained F4/80+/Gr-
1low/Ly6Clow/CD11c+ (~22%, P1), F4/80+/Gr-1high/Ly6Clow/CD11c+ (~10%, P2) and 
F4/80-/Gr-1+/Ly6Clow/CD11c- (~20%, P3) cells (Fig. 3.9A-B). Cells from G-CSFR-/- 
mice contained significantly lower numbers of P1 (~10%) and P2 (~4%) cells than 
those from G-CSFR+/+ mice, whereas no differences were detected in the numbers of 
P3 cells (Fig. 3.9C). These data suggest that G-CSFR plays a key role in populating 
both P1 and P2 mononuclear phagocytes in the intestine in vivo. 
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Figure 3.9. G-CSFR-/- mice harbour reduced numbers of Gr-1high and Gr-1low 
macrophage-like (Ly6Clow/CD11c+/F4/80+) cells in the intestinal lamina propria 
compared to those of wild-type mice. The intestinal lamina propria cells were 
isolated from wild-type and G-CSFR-/- mice and hematogenous cells enriched on a 
percoll step gradient. (A) Based on the Gr-1 and F4/80 expression characteristics, 
cells were divided into 3 populations: P1, Gr-1low/F4/80+; P2, Gr-1high/F4/80+; P3, Gr-
1+/F4/80-. (B) Each cell population was further characterized based on the expression 
of Ly6C and CD11c. (C) Percentage of each cell population was quantified and 
plotted. Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 by Student’s t-test). 	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Figure 3.9 	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3.4 DISCUSSION 
Although G-CSF has been dubbed the “generator and activator of granulocytes” due 
to its best known activities toward neutrophils, early in vitro bone marrow cell 
cultures and G-CSFR-/- mouse studies suggested that G-CSF is also involved in the 
generation of monocytes/macrophages. Here, we show that in a single CSF bone 
marrow cell culture model, G-CSF specifically supported persistent growth of M-
BMCs but not GM-BMCs (Fig. 3.1C & D). GM-CSF alone was able to support 
generation of at least four heterogeneous cell populations, including Gr-1+/F4/80- 
neutrophil-like cells (Fig. 3.3), whereas M-CSF gave rise to a more homogeneous cell 
population than GM-CSF, mainly Gr-1low/Ly6Clow/F4/80+/CD11b+/CD11c+ 
macrophage-like (P1) cells (Fig. 3.2). Enhanced growth of M-BMCs by G-CSF 
mainly attributes to the generation of Gr-1high/F4/80+/Ly6C+/CD11b+/CD11c+ (P2) 
macrophage-like and Gr-1+/Ly6C+/F4/80-/CD11blow/CD11c- (P3) neutrophil-like cell 
populations (Fig. 3.2). These results were consistent with in vivo roles of GM-CSF 
and M-CSF in supporting granulocyte/macrophage progenitors and macrophage/DC 
precursor cells, respectively, in bone marrow [10]. The macrophage-DC precursor 
cells, derived from granulocyte-macrophage progenitors, lose their granulocyte 
potential and give rise to monocytes and common DC precursors [2, 45-48]. 
Subsequently, certain populations of monocytes migrate to tissues and differentiate 
into tissue macrophages, such as CD103-/CD11b+/F4/80+ cells in the gut [49, 50]. 
DCs can further differentiate to either classical or plasmacytoid DCs, which can 
constitute CD103+ or CD103- DCs in the gut [45, 51]. M-CSF is also involved in the 
transition of Ly6Chigh monocytes to Ly6Clow monocytes [52-54]. Consistent with 
these studies, we found that BMCs cultured with M-CSF for more than 8 days 
reduced expression of Ly6C, regardless of the presence of G-CSF (data not shown). 
Therefore, M-CSF may support growth of macrophage-DC precursors and maturation 
of Ly6Chigh cells to Ly6Clow monocytes, which are detected in the circulation at 
steady state [10] and the intestine (Fig. 3.9B). Unexpectedly, M-CSF together with G-
CSF was able to generate both Gr-1+/F4/80- neutrophil-like (P3) and Gr-1high/F4/80+ 
macrophage-like (P2) cells, when G-CSF alone supported neither P2 nor P1 cells 
(Fig. 3.2A). These results are consistent with the fact that G-CSF induces cell 
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differentiation commitment [55], and suppresses apoptosis of progenitor and mature 
cells [56]. Furthermore, addition of G-CSF to BMCs after culturing 4 days with M-
CSF suppressed apoptosis of P2 and P3 cells induced by sub-optimal concentrations 
of M-CSF (Fig. 3.5C). Although previous studies suggested that G-CSF has only 
apoptosis suppressive effects without proliferation-inducing activities [55, 56], 
signalling via the G-CSFR was shown to induce cell differentiation and proliferation 
through two distinct domains of the receptor [57]. Therefore, it is possible that 
synergistic effects of two separate signalling cascades induced by the M-CSF-
receptor (M-CSFR) and G-CSFR may be required for the generation of P2 and P3 
cells in in vitro bone marrow cell cultures. Particularly, G-CSF enhanced generation 
of P2 cells from P1 cells in M-BMCs, which was abolished by nocodazole (Fig. 3.6). 
Therefore, both cell-specific suppression of apoptosis and promotion of proliferation 
could contribute to the expansion of P2 cells in M-BMCs.  
Previous studies showed that BMCs treated with GM-CSF or M-CSF produce distinct 
M1- and M2-like cytokine profiles, respectively, in response to microbial components 
such as LPS [11, 58, 59]. Consistent with their reports, GM-BMCs produced high 
levels of IL-23 and TNF-α, and low levels of CCL2 in response to LPS (Fig. 3.7A). 
Addition of G-CSF in the culture media had no effects on their production profiles. In 
contrast, M-BMCs produced high levels of IL-10 and CCL2, and low levels of IL-23 
in response to LPS. Addition of G-CSF in the culture media slightly reduced 
production of IL-10 and CCL2. The decrease of CCL2 production was likely due to 
an increase of P3 cells in the culture, since P3 cells fail to produce CCL2 (Fig. 3.7B). 
P1 and P2 cells were equipotent in producing IL-10 and CCL2, suggesting that both 
P1 and P2 cells were M2-like macrophages. However, when M-BMCs were activated 
by IL-4/IL-13, expression levels of M2-specific surface markers were greater in P2 
than P1 cells (Fig. 3.7C). Morphologies of both P1 and P2 cells were similar, showing 
typical macrophage-like ultra-structures with large vacuoles and limited membrane 
ruffles (Fig.3. 7D). Based on these results, we believe that G-CSF enhanced the 
generation of M2-like macrophages in conjunction with M-CSF. Further studies are 
required to unravel the distinctive characteristics and function of P2 cells in 
comparison to P1 cells.  
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M-CSF was shown to control macrophage populations in peritoneal macrophages and 
Kupffer cells [10, 53, 60], and differentiation of specific DC subsets such as 
epidermal Langerhans cells, kidney, lung and intestinal macrophages/DCs [51, 61, 
62]. Considering its known biological functions, we expected that M-BMCs would be 
distributed to these tissues after adoptive transfer of M-BMCs. However, M-CSF-
treated lys-EGFP-ki F4/80+ BMCs were mainly localized in the small intestinal 
lamina propria of recipient mice (Fig. 3.8A). When these cells were treated with G-
CSF, significantly more numbers of cells were localized in both the small and large 
intestines, and survived more than 30 days (Fig. 3.8). G-CSF also enhanced numbers 
of gut-homing M-BMCs even after 6 h of adoptive transfer (Appendix A.3B-C), 
suggesting that G-CSF enhanced gut-homing tropism of M-BMCs. In line with the 
effect of G-CSF, the lamina propria of the intestine from G-CSFR-/- mice were also 
shown to harbor greatly reduced numbers of Gr-1high and Gr-1low mononuclear cells 
(Ly6Clow/CD11c+/F4/80+), very similar to those of P2 and P1 macrophage-like cells, 
respectively, based on the four surface marker expression profiles (Fig. 3.9). 
However, no differences were detected in the numbers of intestinal Gr-1+/F4/80- 
neutrophil-like (P3) cells between G-CSFR+/+ and -/- mice (Fig. 3.9). These results are 
quite surprising, considering the substantial decrease in the proportion of neutrophils 
in the spleen and bone marrow of G-CSFR-/- mice (Appendix A.4). At this moment, it 
is unknown whether these transferred cells differentiated to typical resident 
macrophages after they arrived in the intestine. Previously, adoptive transfer of 
CCR2+/CX3CR1lo inflammatory monocytes were short-lived, but CCR2-/CX3CR1high 
regulatory monocytes persisted longer and cells that could be recovered had a 
CD11c+/MHC-II+ DC-like phenotype [63]. Also Ly6Chigh monocytes gave rise to 
CX3CR1+ small intestinal lamina propria mononuclear phagocytes and failed to 
differentiate into classical splenic DCs [46]. Therefore, it will be interesting to 
examine whether M-BMCs treated with G-CSF, particularly P2 cells, share similar 
surface marker expression and function of CCR2-/CX3CR1+ mononuclear cells in the 
intestinal lamina propria. In addition, Gr-1+/CD11b+ cells are found during early 
lineage-committed precursors of myeloid cells [64] and comprise 20-30% of BMCs 
[65]. Gr-1+/CD11b+ cells are also known as myeloid-derived suppressor cells [66, 67] 
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and adoptive transfer of these cells protects allergen-induced airway inflammation 
[68] and colitis [69]. Therefore, it will be interesting to see if G-CSF-induced P2 cells 
exhibit similar functions as these myeloid-derived suppressor cells.  
G-CSF was shown to have anti-inflammatory and anti-apoptotic roles in immune 
cells, including macrophages, DCs and T/B lymphocytes [70-72]. In the intestine, G-
CSF may be important for guarding against invading pathogens, maintaining 
tolerance to indigenous microbes and supporting cell survival in the presence of 
various gut luminal stresses [25]. Supporting this notion, the administration of 
recombinant G-CSF was shown to have beneficial effects in both animal colitis 
models [73, 74] and open-label pilot studies in inflammatory bowel disease patients 
[75, 76]. The in vitro bone marrow cell culture model used here will not represent the 
much more complex and heterogeneous monocytes/macrophage cell populations in 
vivo; however, simplistic cell cultures using a single CSF will provide valuable 
information on the role of specific cytokines under examination. Using the M-CSF or 
GM-CSF bone marrow cell culture models, we found that G-CSF also appeared to 
specifically support the survival of M-BMCs, which showed M2-like cytokine 
production profiles and gut-homing characteristics after adoptive transfer. These 
results suggest a novel function of G-CSF in the differentiation of macrophages to 
M2-like characteristics and in the homing of these cells to the intestine.  
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4.1 INTRODUCTION 
Granulocyte colony-stimulating factor (G-CSF) is primarily known for its role in the 
generation, mobilization and function of neutrophils [1-3] which are key innate 
immune cells fighting against invading microbes [4-7]. G-CSF also plays an 
important role in regulating both innate and adaptive immune responses through 
modulating activation of macrophages and dendritic cells (DCs) [8-10], and 
promoting generation of tolerogenic DCs [11] and regulatory T cells [12]. These dual 
modalities of G-CSF in immune regulation could be important in maintaining 
intestinal immune homeostasis, where both avid immune surveillance and tolerance 
against infiltrating commensal microbes are required. Previous studies have 
demonstrated that administration of recombinant G-CSF ameliorates colitis in acute 
and chronic experimental colitis [13, 14] and Crohn’s disease patients [15-17], 
suggesting its beneficial role in immune homeostasis of the intestine. However, the 
role of endogenous G-CSF in intestinal immune homeostasis is largely unknown. 
Intestinal macrophages are highly populated in the intestinal lamina propria, residing 
underneath the single epithelial layer, and Peyer’s patches [18, 19]. These cells form 
an intestinal immune barrier for invading microbes, and also orchestrate immune and 
wound repair responses that prevent inadvertent development of colitis [20-22]. 
However, in pathologic conditions, monocytes/macrophages, rapidly recruited into 
the inflamed intestines, can mediate inflammatory responses through releasing pro-
inflammatory cytokines or promoting inflammatory T cell differentiation [23, 24]. 
Unlike most tissue macrophages derived from local progenitor cells [25, 26], 
intestinal macrophages are mainly refurnished by circulating monocytes originated 
from bone marrow cells (BMCs) [19, 27]. Circulating monocytes released from the 
bone marrow migrate to the intestine where they differentiate into resident 
macrophages under the influence of local cytokine milieu [24]. Recruited monocytes 
or resident macrophages can then be polarized to either classically activated (M1) or 
alternatively activated (M2) macrophages in response to lipopolysaccharide 
(LPS)/interferon (IFN)-γ or interleukin (IL)-4/IL-13, respectively [28-31]. M1 
macrophages are characterized as inflammatory macrophages by their high capacity 
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to produce pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, IL-
1β, IL-12, IL-23, and inducible nitric oxide synthase (iNOS) [29, 32]. In contrast, M2 
macrophages highly express regulatory cytokines, such as transforming growth factor 
(TGF)-β and IL-10 [32], and various markers, including Arginase I [33], chitinase-
like 3 (Ym1) [34], found in inflammatory zone 1 (FIZZ1) [34, 35], cluster of 
differentiation (CD)71, CD206 [36] and programmed death ligand 2 (PDL2) [37], 
which are involved in anti-inflammatory, wound-healing or anti-parasitic responses 
[28, 29, 31]. 
In addition to the generation of neutrophils, G-CSF was also shown to be involved in 
the generation of macrophages. It was shown to support the survival of macrophage 
progenitor cells in in vitro bone marrow cell cultures [1, 38] and mice deficient in G-
CSF harbor ~50% reduced circulating monocytes, compared to wild-type mice [39]. 
Recently, we showed that G-CSF plays an important role in the generation of 
regulatory Gr-1high/F4/80+ macrophages, which are localized mainly in the intestine 
after adoptive transfer [40]. Here, we further examined the role of endogenous G-CSF 
in intestinal immune homeostasis using a dextran sulfate sodium (DSS)-induced acute 
colitis model in G-CSFR-/- mice. We found that G-CSFR-/- mice were more 
susceptible to DSS-induced colitis than G-CSFR+/- or G-CSFR+/+ mice. Macrophages 
derived in the presence of G-CSF enhanced expression of several M-like markers, 
such as PLD2, CD71 and CD206, and suppressed LPS/IFN-γ-induced expression of 
iNOS, CD80 and CD86. Adoptive transfer of these macrophages significantly 
ameliorated the severity of colitis in G-CSFR-/- mice. These results suggest that 
endogenous G-CSF plays a protective role from developing inadvertent colitis, likely 
through generating gut-homing macrophages. 
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4.2 MATERIALS AND METHODS 
4.2.1 Mice 
C57BL/6j wild-type mice were obtained from The Jackson Laboratory (Bar Harbor, 
ME, USA). Homozygote G-CSFR-/- mice with C57BL/6j background were obtained 
originally from Dr. D. C. Link (Washington University Medical School, St. Louis, 
MO, USA) and maintained in the animal care and veterinary facility at the University 
of Western Ontario (London, ON, Canada) under conventional conditions. C57BL/6j 
and G-CSFR-/- were crossed, and G-CSFR+/- offspring were then crossed to generate 
G-CSFR+/+, +/- and -/- littermates for use in experimental procedures. G-CSFR+/+, +/-, 
and -/- were housed in conventional conditions, and were intermixed randomly during 
experiments such that each would be co-housed with other mice of different 
genotypes. Aged-matched mice between 6 to 12 weeks of age were used in all 
experimental procedures. All experimental protocols were approved by the University 
of Western Ontario Animal Use Subcommittee, which follows the regulations of the 
Animals for Research Act (Ontario) and the Canadian Council on Animal Care. 
4.2.2 Reagents, Antibodies and Cytokines 
ELISA for TNF-α, IL-1β and IL-10 were obtained from eBioscience (San Diego, CA, 
USA). LPS from Escherichia coli O111:B4 was obtained from List Biological 
Laboratories (Campbell, CA, USA). FITC-anti-mouse F4/80, PE-Cy7-anti-mouse Gr-
1, PE-anti-mouse CD71, PE-anti-mouse PDL2, APC-anti-mouse CD206, APC-anti-
mouse CD80 and PE-anti-mouse CD86 antibodies were purchased from eBioscience 
(San Diego, CA, USA). IL-4, IL-13 and IFN-γ cytokines were obtained from 
PeproTech (Rocky Hill, NJ, USA). The murine recombinant M-CSF and G-CSF were 
obtained from eBioscience (San Diego, CA, USA). 
4.2.3 DSS Colitis Mouse Model 
1.5% weight/volume DSS (molecular weight: 40,000-50,000 Da, USB Corporation, 
Cleveland, Ohio) was dissolved in autoclaved drinking water and administered ad 
libitum to the mice for 5 days. Control mice were given normal drinking water. On 
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day 5, the DSS solution was replaced with water without DSS for an additional 4-5 
days. Mice were monitored daily for weight loss, diarrhea and rectal bleeding. 
Disease activity scoring was performed as follows: weight loss (percentage of starting 
weight): < 10% = 1, < 15% = 2, < 20% = 3; diarrhea: slightly loose feces and/or slight 
rectal prolapse = 1, loose feces and/or obvious prolapse = 2, watery diarrhea and/or 
severe prolapse = 3; bleeding: spotty blood in feces or around anus = 1, slightly 
bloody feces or moderate blood around anus = 2, bloody stool or severe bleeding 
around anus = 3; activity: still moving spontaneously but reduced = 1, little 
spontaneous movement = 2, moves only with gentle touch = 3. The sum of the all 
values constitutes the colitis score. Mice were euthanized if the total score reached 
higher than 9 or if more than 20% body weight loss was observed. 
4.2.4 Histology and Immunohistochemistry 
After the mice were sacrificed, the caecum was removed and the remaining colon 
tissue was cut into 0.5 cm pieces. Tissues were then fixed in 10% neutral buffered 
formalin, paraffin-embedded, sectioned (5 µm), and stained with hematoxylin and 
eosin (H&E) for visualization of intestinal tissue damage, or used for 
immunohistochemical staining for myeloperoxidase (MPO). H&E stained sections 
were evaluated by a pathologist in a blinded fashion. Histological scoring was 
performed as follows (modified from [41]): 0 = normal; 1 = lesions that are not 
transmucosal; 2 = 0-25% of mucosa affected; 3 = 25-50% of mucosa affected; 4 = 
>75% of mucosa affected. Immunohistochemical staining was performed after heat-
induced epitope retrieval by heating slides to 95°C in 10 mM Tris buffer (pH 10) 
containing 0.05% Tween-20. Staining was performed using the Santa Cruz ABC 
staining kit (Santa Cruz Biotechnology, Santa Cruz, California) according to the 
manufacturer’s instructions. Briefly, slides were incubated in 1% hydrogen peroxide 
in phosphate-buffered saline (PBS) for 5 minutes to quench endogenous peroxidase 
activity. Slides were then incubated in 1.5% blocking serum in PBS for 1 hour, 
followed by overnight incubation at 4°C with 10 µg/mL anti-MPO antibody (R&D 
Systems, Minneapolis, Minnesota). Staining was developed the next day and slides 
were counterstained with hematoxylin. For counting of the number of MPO positive 
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cells per field of view, a single tissue section containing the highest degree of staining 
on the slide was chosen, and densely stained cells in each field of view at 100× 
magnification were counted. 
4.2.5 Generation of BMDM and G-BMDM 
Macrophage-CSF (M-CSF)-treated bone marrow-derived macrophages (BMDM) and 
G-CSF- and M-CSF-treated bone marrow-derived macrophages (G-BMDM) were 
generated as previously described [40]. Briefly, BMCs were harvested from femurs 
and tibia of G-CSFR+/+ and/or G-CSFR-/- mice using a 25.5-gauge needle and PBS. 
Red blood cells were lysed using ammonium chloride and EDTA. BMCs were then 
cultured in RPMI 1640 medium (Sigma-Aldrich), supplemented with 10% heat-
inactivated fetal bovine serum (Sigma-Aldrich), 100 U ml-1 penicillin, 0.1 mg ml-1 
streptomycin (Sigma-Aldrich), 5 mM sodium pyruvate (Sigma-Aldrich), 5 mM MEM 
non-essential amino acids (Sigma-Aldrich), and M-CSF (20 ng/ml) or M-CSF and G-
CSF (10 ng/ml). Cells were then maintained at 37°C in a humidified atmosphere with 
5% CO2 for 7 days. The culture media was replaced with fresh media every 2 days. 
4.2.6 Flow cytometry 
BMDM and G-BMDM were harvested, washed twice, surface labeled with 
fluorescently conjugated antibodies against F4/80, Gr-1, PDL2, CD206, CD71, CD80 
and CD86. Labeled cells were washed and analyzed with a FACSCalibur flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) using the CellQuest 
software (Becton Dickinson, Franklin Lakes, NJ, USA). Flow cytometry analysis was 
done using FlowJo software (version 7.6.5; TreeStar, Ashland, OR, USA). 
4.2.7 Adoptive transfer of BMDM/G-BMDM and estimation 
of the number of cells localized in the intestine 
5 × 106 BMDM or G-BMDM were injected intraperitoneally into G-CSFR-/- recipient 
mice 1 day before and 2 days after DSS treatment. Blood samples were obtained 
immediately after sacrifice from each mouse in a 1.5 ml tube via cardiac puncture and 
allowed to clot at room temperature for 30 min. The blood samples were then 
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centrifuged (2000 g, 4°C, 10 min) and the serum was collected and stored at −80°C 
until analyzed for serum cytokine levels. In addition, colon tissue was excised (feces 
was gently forced out), washed extensively with PBS, and measured for weight and 
length. The entire colon tissues were then opened longitudinally, cut into 0.5 cm 
pieces and then 150 mg of the tissues were weighed and kept in TRIzol reagent (Life 
Technologies) for further quantitative real-time PCR (qRT-PCR) screening. The 
number of BMDM and G-BMDM were calculated by extrapolating from a standard 
curve generated by series of dilutions of G-CSFR transcripts obtained from 1 × 106 
BMDM or G-BMDM injected, using qRT-PCR. Estimation of % of recovered 
BMDM and G-BMDM in intestinal tissues were then calculated from the total 
numbers of cells present in random intestinal tissue samples (~150 mg) using the 
same qRT-PCR procedures. 
4.2.8 Quantitative Real-Time PCR 
Total cellular RNA was isolated from the colon tissues using TRIzol according to 
manufacturer’s instructions. 1 µg of total RNA was then reverse-transcribed with 
M‐MuLV reverse transcriptase (New England BioLabs) according to the 
manufacturer’s instruction in the presence of oligo (dT) primer. cDNA was then used 
for qRT-PCR analysis using the Brilliant SYBR Green PCR Master Mix (Applied 
Biosystems) on the Rotor-Gene RG3000 quantitative multiplex PCR instrument. 
Mouse oligonucleotide primers used in qRT-PCR analysis are listed in Table 4.1.  
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Table 4.1. List of primers used for qRT-PCR with corresponding amplicon sizes 
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Table 4.1	  
 
Gene Forward primer Amplicon (bp) 
GAPDH 
Forward: 5`-GCATTGTGGAAGGGCTCATG-3` 
361 
Reverse: 5`-TTGCTGTTGAAGTCGCAGGAG-3` 
TNF-α 
Forward: 5`-CTTGGAAATAGCTCCCAGAA-3` 
299 
Reverse: 5`-CATTTGGGAACTTCTCATCC-3` 
IL-10 
Forward: 5`-TGCTATGCTGCCTGCTCTTA-3` 
243 
Reverse: 5`-TCATTTCCGATAAGGCTTGG-3` 
Arginase I 
Forward: 5`-CAGAAGAATGGAAGAGTCAG-3` 
250 
Reverse: 5`-CAGATATGCACGGAGTCACC-3` 
TGF-β Forward: 5`-GGAGAGCCCTGGATACCAAC-3` 148 
Reverse: 5`-CAGGGTCCCAGACAGAAGTT-3` 
Ym1 
Forward: 5`-CATGATGCAGAATGCGCTGTGGAA-3` 
100 
Reverse: 5`-AGGGCCCTTATTGAGAGGAGCTTT-3` 
FIZZ1 
Forward: 5`-ACTGCCTGTGCTTACTCGTTGACT-3` 
83 
Reverse: 5`-AAAGCTGGGTTCTCCACCTCTTCA-3` 
IL-1β 
Forward: 5`- GCTTCAGGCAGGCAGTATCAC-3` 
239 
Reverse: 5`-CGACAGCACGAGGCTTTTT-3` 
iNOS 
Forward: 5`-CAGCTGGGCTGTACAAACCTT-3` 
95 
Reverse: 5`-CATTGGAAGTGAAGCGTTTCG-3` 
G-CSF receptor 
WT (exon 4 and 5) 
Forward: 5`-CATCCAACCTGGGGACAGAC-3` 
171 
Reverse: 5`-CTGGCAGGGGGATAGCCT-3` 
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4.2.9 Statistical Analysis 
Statistical analysis was carried out using Prism 5.0c for Mac OS X (GraphPad 
Software, La Jolla, CA, USA). Student’s t-tests, one-way ANOVA with Tukey’s 
multiple comparison post hoc test and two-way ANOVA with Bonferroni post-test 
were performed as described in the figure legends. 
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4.3 RESULTS 
4.3.1 G-CSFR deficiency exacerbates DSS-induced colitis in 
mice. 
To examine the role of endogenous G-CSF in colitis, we first examined susceptibility 
of G-CSFR-/- and G-CSFR+/- mice to DSS-induced acute colitis in comparison to G-
CSFR+/+ mice. As shown in Fig. 4.1A, non-DSS-treated G-CSFR-/- mice (dotted lines) 
showed no difference in body weights relative to G-CSFR+/- mice. Treatments of DSS 
through drinking water (ad libitum) for 5 days started causing severe body weight loss 
in Day 6 in all mice; however, G-CSFR-/- mice showed more pronounced and rapid 
body weight loss than G-CSFR+/+ and +/- mice by Day 7, and some G-CSFR-/- mice 
lost more than 20% of their starting body weight by Day 8 (Fig. 4.1A, upper panel). 
Consistent with these results, DSS-treated G-CSFR-/- mice exhibited higher diarrhea, 
rectal bleeding and lethargy scores during the course of DSS treatment (Day 7), 
which then decreased to the levels of G-CSFR+/+ mice on Day 9 (Fig. 4.1A, bottom 
left panel). The reason for the decrease observed on Day 9 was due to early 
termination of these mice because of high scores on Day 8, rather than recovery from 
colitis. In agreement with these results, overall colitis scores including body weight, 
diarrhea, rectal bleeding and lethargy were significantly higher in G-CSFR-/- than G-
CSFR+/+ or G-CSFR+/- mice toward to end of DSS-treatment (Fig. 4.1A, bottom right 
panel).  
Colons from mice euthanized on Day 9 were stained with H&E for histological 
evaluation. Non-DSS-treated G-CSFR+/- and -/- mice retained intact colonic structure 
(Fig. 4.1B, upper panels), whereas all DSS-treated mice had extensive epithelial cell 
destruction, crypt loss and tissue infiltration (Fig. 4.1B, lower panels). However, 
colons from DSS-treated G-CSFR-/- mice showed more extensive tissue damage than 
those from DSS-treated G-CSFR+/+ and +/- mice. In agreement with these results, DSS 
treatment led to a significant increase in histopathological scores (0-4, 4 being the 
most tissue damage) of G-CSFR-/- colons compared to their G-CSFR+/+ counterparts 
(Fig. 4.1C). Indeed, all examined G-CSFR-/- colons scored 2 to 4, while G-CSFR+/+ 
tissue scores ranged from 0-4. Additionally, 3 out of the 5 G-CSFR-/- mice examined 
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histologically also revealed the formation of a pseudomembranous structure (Fig. 
4.1B, lower right panel), which appeared to be admixed with a large population of 
bacteria and pockets of bacterial clusters surrounded by infiltrating cells (arrow). 
These results suggest the presence of a secondary bacterial infection in the DSS-
treated G-CSFR-/- mice. In contrast, no pseudomembranous structures or bacterial 
infections were detected in any of the colon segments from G-CSFR+/+ or +/- mice. 
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Figure 4.1. G-CSFR deficiency exacerbates DSS-induced colitis in mice. (A) G-
CSFR+/+, +/- or -/- mice were administered 1.5% dextran sulfate sodium (DSS) in the 
drinking water for 5 days, and fresh water thereafter. Body weight loss, 
diarrhea/rectal bleeding/lethargy scores, and overall colitis scores (encompassing 
weight loss, stool consistency, rectal bleeding and loss of activity) were plotted from 
Day 0 to 9. Figures show pooled data of more than 3 independent experiments (n ≥ 10 
per group, except Day 9 (n = 5 for G-CSFR+/- and -/-, n = 2 for G-CSFR+/+)). *, p < 
0.05 by two-way ANOVA with a Bonferroni post-test. Symbols represent mean ± 
SEM. (B) Colon sections stained with H&E. Non DSS-treated G-CSFR+/- and -/- colon 
tissue showed healthy and normal appearance. Nine days after DSS treatment, colon 
tissue of all mice groups showed intestinal tissue damage; however, G-CSFR+/+ and +/- 
tended to show a lesser degree of tissue damage than G-CSFR-/-. DSS-treated G-
CSFR-/- mice showed the presence of a pseudomembranous structure with clusters of 
bacteria, digitally magnified inset of DSS-treated G-CSFR-/-; bacteria indicated by 
arrow. Original images were obtained at 400× magnification. (C) Histological 
damage scores (0-4, 4 being the most tissue damage) from 4-6 tissue sections of each 
group were plotted. All G-CSFR-/- tissues examined scored 2 to 4, whereas G-CSFR+/+ 
scores ranged from 0-4. *, p < 0.05 by Student’s t-test.  	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Figure 4.1 	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4.3.2 G-CSFR-/- mice harbor lower basal levels of F4/80+ 
macrophage-like cells without alterations in F4/80-/Gr-
1+ neutrophil-like cells in basal and DSS-exposed 
intestines. 
We then examined whether F4/80+ macrophage-like and F4/80-/Gr-1+ neutrophil-like 
cells are similarly populated in the intestine between G-CSFR+/+ and G-CSFR-/- mice. 
As shown in Fig. 4.2A, G-CSFR-/- cells were similarly populated in neutrophil-like 
cells (~20% of all gut lamina propria cells), but significantly lower in macrophage-
like cells (~10%), when compared to those (~20% in both cell types) of G-CSFR+/+ 
mice. To determine whether circulating neutrophil deficiency participated in the 
exacerbation of inflammatory conditions in the DSS-treated G-CSFR-/- mice, we 
evaluated neutrophil infiltration into the intestine of DSS-treated mice using 
immunohistochemical staining for MPO. Non-DSS-treated mice showed on average 
less than one positive cell per entire tissue section (data not shown). However, the 
average number of MPO+ cells in colon segments from DSS-treated G-CSFR-/- mice 
(Fig. 4.2B; right panels shows a digitally magnified inset of left column, arrows 
indicate example MPO+ cells) showed a trend for slightly higher numbers of MPO+ 
cells relative to DSS-treated G-CSFR+/+ or +/- mice (Fig. 4.2C), although this did not 
reach statistical significance. Taken together, these data imply that reduced 
macrophage, but not neutrophil, infiltration may be responsible for the increased 
DSS-induced colitis susceptibility in G-CSFR-/- mice. 
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Figure 4.2. G-CSFR-/- mice harbor lower basal levels of F4/80+ macrophage-like 
cells without alterations in Gr-1+/F4/80- neutrophil-like cells in basal and DSS-
exposed intestines. (A) The intestinal lamina propria cells were isolated from G-
CSFR+/+ and G-CSFR-/- mice and hematogenous cells were enriched on a Percoll step 
gradient. Percentage of F4/80+ macrophage-like and F4/80-/Gr-1+ neutrophil-like cells 
were quantified and plotted. Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 by 
Student’s t-test). (B and C) G-CSFR+/+ and -/- mice colon tissue sections prepared 9 
days after the initiation of 1.5% dextran sulfate sodium (DSS) treatment were stained 
for myeloperoxidase (MPO). (B) While G-CSFR+/+ tissue sections showed a few 
number of cells but with strong MPO staining (digitally magnified inset of DSS-
treated G-CSFR+/+; MPO staining = brown color; arrow indicates example MPO+ 
cell), G-CSFR-/- showed high number of MPO+ cells but with weak staining (digitally 
magnified inset of DSS-treated G-CSFR-/-; arrow indicates example MPO+ cell). 
Original images were obtained at 400× magnification. (C) Quantification of MPO+ 
cells per field of view from more than 4 tissue sections from each group was plotted. 
Line represents the mean. No significant changes in between groups were detected. 	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Figure 4.2 
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4.3.3 G-CSF enhances expression of several M2-like cell 
surface markers in BMDM in response to IL-4/IL-13. 
To examine the effects G-CSF on macrophage activation, primary macrophages were 
generated by culturing BMCs with M-CSF (BMDM) or G-CSF and M-CSF (G-
BMDM) 5 days and treated with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for an 
additional 2 days. On day 7, expression of M2 cell surface markers including PDL2, 
CD71 (transferrin receptor) and CD206 (mannose receptor, C type 1) were examined. 
As shown in Fig. 4.3A, IL-4/IL-13 significantly induced expression of PDL2, CD206 
and CD71 in both BMDM and G-BMDM. However, expression levels of these 
markers were significantly higher in G-BMDM than BMDM. Similar experiments 
using G-CSFR-/- mice showed no such G-CSF effects on these markers in G-CSFR-/- 
BMDM, suggesting that G-CSFR was the receptor responsible for exogenous G-CSF 
responses in BMDM. We further quantified mRNA expression levels of intracellular 
M2 markers in these cells, including Arginase I, TGF-β, Ym1 and FIZZ1. However, 
unlike surface markers, expression levels of these intracellular markers were not 
significantly different between G-BMDM and BMDM (Fig. 4.3B). These results 
suggest that G-CSF generated a distinct macrophage population with different 
capabilities in responding to M2-stimuli. 
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Figure 4.3. G-CSF enhances expression of several M2-like cell surface markers 
in BMDM in response to IL-4/IL-13. G-CSFR+/+ (WT) and G-CSFR-/- (KO) BMCs 
were treated with M-CSF (20 ng/ml) (BMDM) or M-CSF + G-CSF (10 ng/ml) (G-
BMDM) for 5 days. Then, cells were treated with IL-4 (20 ng/ml) + IL-13 (20 ng/ml) 
for an additional 2 days. (A) Mean fluorescence intensity (MFI) of PDL2, CD71 and 
CD206 cell surface markers of WT and KO M- and G-BMDM were examined. (B) 
mRNA expression of Arginase I, TGF-β, Ym1, and FIZZ1 was analyzed in IL-4/IL-
13-treated WT M- or G-BMDM. Data shown as mean ± SEM [n ≥ 3; *, p < 0.05 by 
one-way ANOVA with Tukey’s multiple comparison post hoc test; columns 
accompanied by the same letter (a, b or c) are not significantly different from each 
other].  	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Figure 4.3 
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4.3.4 G-BMDM are less responsive to M1-stimuli in 
expressing iNOS, CD80 and CD86 than BMDM. 
To examine the effects of G-CSF on the response of BMDM to M1-stimuli, BMDM 
were similarly cultured as above, except with IFN-γ (20 ng/ml) and LPS (50 ng/ml) 
for an additional 2 days, and examined for the expression of M1 markers including 
IL-1β, iNOS, CD80 and CD86. G-BMDM expressed significantly lower levels of 
iNOS and CD86, but not IL-1β, when compared with those of BMDM (Fig. 4.4). 
Although the expression levels of CD80 in G-BMDM were slightly but not 
significantly higher than those of BMDM, treatments of IFN-γ and LPS induced 
CD80 expression in BMDM, but not in G-BMDM. 
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Figure 4.4. G-BMDM are less responsive to M1-stimuli in expressing iNOS, 
CD80 and CD86 than BMDM. G-CSFR+/+ BMCs were treated with M-CSF (20 
ng/ml) (BMDM) or M-CSF + G-CSF (10 ng/ml) (G-BMDM) for 5 days. Then, cells 
were treated with IFN-γ (20 ng/ml) + lipopolysaccharide (LPS; 50 ng/ml) for an 
additional 2 days. mRNA expression of IL-1β and iNOS and mean fluorescence 
intensity (MFI) of CD80 and CD86 cell surface markers were examined. Data shown 
as mean ± SEM [n ≥ 3; *, p < 0.05 by one-way ANOVA with Tukey’s multiple 
comparison post hoc test; columns accompanied by the same letter (a, b or c) are not 
significantly different from each other]. 	  
	  	  
139	  
Figure 4.4 	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4.3.5 Adoptive transfer of G-BMDM exert a protective effect 
on DSS-induced mouse colitis in G-CSFR-/- mice. 
Next, we examined the role of G-BMDM in murine DSS-induced colitis in mice. To 
this end, 5 × 106 G-BMDM or BMDM were adoptively transferred into G-CSFR-/- 
mice twice, 1 day before and 2 days after starting DSS treatments. Adoptive transfer 
of G-BMDM significantly prevented body weight loss, which was comparable to that 
of G-CSFR+/+ mice, whereas BMDM had no effects on body weight loss (Fig. 4.5A, 
upper panel). Consistent with these results, adoptive transfer of G-BMDM, but not 
BMDM, into DSS-treated G-CSFR-/- mice also showed significantly lower diarrhea 
and rectal bleeding, and overall colitis scores which were similar to those of DSS-
treated G-CSFR+/+ mice (Fig. 4.5A, bottom panels). In addition, DSS caused more 
extensive colon shortening, which is an additional disease severity indicator in colitis, 
in G-CSFR-/- than G-CSFR+/+ mice. However, adoptive transfer of G-BMDM into G-
CSFR-/- mice prevented the colon shortening to a similar extent of G-CSFR+/+ mice 
(Fig. 4.5B). We estimated that about 28% of total adoptively transferred G-BMDM 
(2.8 × 106 G-BMDM/mouse) were localized in the intestine of these mice, based on 
qRT-PCR-based estimation as described in the Materials and Methods (Fig. 4.5C). 
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Figure 4.5. Adoptive transfer of G-BMDM exert a protective effect on DSS-
induced mouse colitis in G-CSFR-/- mice. G-CSFR+/+ and -/- mice were given 1.5% 
dextran sulfate sodium (DSS) in the drinking water for 5 days, and fresh water 
thereafter. G-CSFR-/- mice were injected with 5 × 106 M-CSF (20 ng/ml)-treated 
(BMDM) or M-CSF + G-CSF (10 ng/ml)-treated (G-BMDM) cells 1 day before and 
2 days after DSS treatment. (A) Body weight loss, diarrhea/rectal bleeding and 
overall colitis scores (encompassing weight loss, stool consistency, rectal bleeding, 
and loss of activity) were plotted from Day 0 to 10. *, p < 0.05 by one-way ANOVA 
with Tukey’s multiple comparison post hoc test. Symbols represent mean ± SEM. (B) 
Colon length of mice after 10 days of DSS treatment was measured and plotted. (C) 
Gut-homing phenotype of the adoptive transferred-M- and G-BMDM in DSS-treated 
G-CSFR-/- mice was evaluated by investigating the presence of mRNA expression of 
G-CSF receptor wild-type (G-CSFR exon 4 and 5) in colon tissues. Data shown as 
mean ± SEM [n ≥ 3; *, p < 0.05 by one-way ANOVA with Tukey’s multiple 
comparison post hoc test; columns accompanied by the same letter (a, b or c) are not 
significantly different from each other].  	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Figure 4.5 
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4.3.6 Adoptive transfer of G-BMDM suppresses pro-
inflammatory cytokines and iNOS in DSS-treated G-
CSFR-/- mice. 
Since adoptive transfer of G-BMDM protected DSS-induced colitis, we further 
examined the expression of cytokines and iNOS in serum and/or colon tissues from 
day 10 samples of DSS- and non-treated G-CSFR+/+ and G-CSFR-/- mice. As shown 
in Fig. 4.6A, DSS treatment significantly induced TNF-α, IL-1β and iNOS mRNA in 
colon tissues, which was more pronounced in G-CSFR-/- than G-CSFR+/+ mice. G-
CSFR-/- colon tissues adoptively transferred with G-BMDM showed lower expression 
of these inflammatory markers, which were comparative to those of G-CSFR+/+ 
colons. Similarly, production of the pro-inflammatory cytokines TNF-α and IL-1β 
were enhanced in G-CSFR-/- mice, when compared with those in G-CSFR+/+ mice, 
and adoptive transfer of G-BMDM to G-CSFR-/- mice suppressed expression of these 
cytokines to the levels of G-CSFR+/+ (Fig. 4.6B). However, no significant changes 
were detected in the levels of IL-10 production regardless of DSS treatment (Fig 6B; 
right panel). Overall, these results indicate that endogenous G-CSF plays a protective 
role in DSS-induced colitis in mice, which is at least in part mediated by generating 
gut-homing macrophages. 
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Figure 4.6. Adoptive transfer of G-BMDM suppresses pro-inflammatory 
cytokines and iNOS in DSS-treated G-CSFR-/- mice. G-CSFR+/+ and -/- mice were 
given 1.5% dextran sulfate sodium (DSS) in the drinking water for 5 days, and fresh 
water thereafter. G-CSFR-/- mice were injected with 5 × 106 M-CSF (20 ng/ml) + G-
CSF (10 ng/ml)-treated (G-BMDM) cells 1 day before and 2 days after DSS 
treatment. (A) mRNA expression of TNF-α, IL-1β and iNOS was measured using 
qRT-PCR from colon tissues of mice with or without adoptive transfer of G-BMDM. 
Data shown as mean ± SEM [n ≥ 3; by one-way ANOVA with Tukey’s multiple 
comparison post hoc test; columns accompanied by the same letter (a, b, or c) are not 
significantly different from each other]. (B) Cytokine levels of TNF-α, IL-1β and IL-
10 were measured from serum of mice using ELISA. *, p < 0.05 by Student’s t-test. 
Each point represents an individual mouse, line shows the mean. Pooled data of two 
independent experiments. 	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Figure 4.6 
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4.4 DISCUSSION 
Systemic administration of recombinant G-CSF induces immune suppressive and 
wound healing responses [41-43], which can render beneficial effects on animal and 
human colitis [16, 44-47]. However, the role of endogenous G-CSF in immune 
homeostasis of the intestine is not well understood. Here, we show that G-CSFR-/- 
mice did not develop spontaneous colitis, but these mice developed 
pseudomembranous structures and more severe colitis than G-CSFR+/+ or G-CSFR+/- 
mice when 1.5 % DSS was administered (Fig. 4.1), suggesting a protective role of 
endogenous G-CSF in acute colitis. In fact, it is often the case for mice genetically 
mutated in key innate immune factors only when phenotypes are manifested after 
certain challenges such as DSS or microbial infections [48-50]. Different intestinal 
microflora and/or the presence of unique pathogenic microbes could have contributed 
to the phenotypes of G-CSFR-/- mice [51, 52]. However, G-CSFR-/- mice were housed 
intermixed with G-CSFR+/+ and +/- mice during the course of the experiment; 
therefore, G-CSFR deficiency, rather than differences in microbial exposure, was 
likely responsible for the development of pseudomembrane structures and severe 
colitis. 
G-CSFR-/- mice did not show apparent defects in the numbers of resident (Fig. 4.2A) 
and recruited neutrophils (MPO+ cells; Fig. 4.2B & C). These results are consistent 
with previous studies shown that, although circulating neutrophil counts are decreased 
up to 85%, emergency generation neutrophils and their recruitments to local 
infection/inflammatory sites during infection or inflammation are not compromised in 
G-CSF-/- or G-CSFR-/- mice [53-55]. However, G-CSF also enhances bactericidal 
function of neutrophils, development of severe colitis and formation of 
pseudomembranous structures in G-CSFR-/- mice could be due to functional defects 
of intestinal neutrophils. Indeed, low intensities of MPO staining in G-CSFR-/- mice 
may indicate a functional defect in G-CSFR-/- neutrophils, as MPO is important for 
the bactericidal activity of neutrophils [56] and their ability to produce neutrophil 
extracellular traps [57]. Further studies are required to explore whether and how these 
defects influence the outcome of severe colitis in G-CSFR-/- mice. Unlike neutrophils, 
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we found lower numbers of intestinal macrophages in G-CSFR-/- mice than wild-type 
mice (Fig. 4.2A). This observation is consistent with the facts that G-CSF-/- mice 
harbors ~50% lower circulating monocytes than wild-type mice [39], resident 
intestinal macrophages are mainly originated from circulating monocytes [19, 27], 
and G-CSF promotes generation of gut-homing Gr-1high/F4/80+ monocytes [40]. 
Therefore, we further examined the characteristics of macrophages cultured in the 
presence of G-CSF and their role in colitis. 
Of more than 20 soluble hematopoietic factors, M-CSF and granulocyte/macrophage-
CSF (GM-CSF) play crucial roles in the generation and characteristic differentiation 
of myeloid cells in the bone marrow [58, 59]. In general, M-CSF is involved in the 
generation and maintenance of “M2-like” macrophages, which potently produce anti-
inflammatory/regulatory cytokines upon activation; whereas, GM-CSF generates 
“M1-like” DCs or macrophages skewed toward pro-inflammatory responses [59, 60]. 
Previously, we showed that G-CSF enhances the generation of M-CSF-derived, but 
not GM-CSF-derived, macrophages which are mainly localized in the colon after the 
adoptive transfer [40]. In line with this observation, macrophages cultured together 
with G-CSF expressed higher levels of M2 markers (PDL2, CD71 and CD206; Fig. 
4.3), but lower levels of M1 markers (iNOS and CD80/86; Fig. 4.4), in response to 
IL-4/-13 and IFN-γ/LPS, respectively. However, it had no effects on the expression of 
several other M1 and M2 markers, such as Arginase I, Ym1, FIZZ1, TGF-β and IL-
1β, suggesting an effect of G-CSF on macrophages distinct from a generalized 
dichotic view of macrophage activation/differentiation. At this moment, it is not clear 
whether G-CSF directly induced expression or suppression of these markers, and/or 
contributed to the proliferation of specific subsets of macrophages. Since, G-CSF did 
not induce such effects in fully differentiated macrophages (data not shown), we 
suspect that G-CSF promoted generation of macrophages with unique characteristics. 
Further experiments using cell proliferation inhibitors or mutant G-CSFR specifically 
defective in the cell proliferation or differentiation signaling cascade [61, 62] will 
likely provide information on these questions.   
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Regardless the mechanism of G-CSF in inducing M2-like responses, we examined the 
role of macrophages in colitis and found that G-BMDM, but not BMDM, protected 
G-CSFR-/- mice from DSS-induced acute colitis (Fig. 4.5). DSS treatments induced 
higher levels of TNF-α, IL-1β and iNOS in the colon, and TNF-α and IL-1β in the 
serum in G-CSFR-/- mice than wild-type mice, which were prevented by adoptively 
transferring G-BMDM (Fig. 4.6). Since these pro-inflammatory cytokines are main 
mediators of colitis in DSS-induced colitis in animals and inflammatory bowel 
disease patients [63-66], we tempt to speculate that G-CSF at least in part positively 
contribute to immune homeostasis of the intestine through enhancing intestinal 
localization of immune regulatory macrophages and suppressing production of pro-
inflammatory cytokines. However, it is still unknown how and whether directly or 
indirectly G-BMDM rendered the colitis ameliorating effects. Since resident 
macrophages, which are tolerant to microbes in inducing pro-inflammatory responses, 
actively involved in phagocytosis of invading microbes, and immune modulating and 
wound healing processes [67-70], we suspect that adoptively transferred G-BMDM 
likely conferred beneficial effects during DSS-induced colitis through enhancing 
immune barrier function (eg. phagocytosis and killing microbes) without overt 
inflammation and/or wound healing processes. Consist with the beneficial effects of 
G-CSF, we previously showed that G-BMDM comprise mainly with Gr-1+/CD11b+ 
cells [40], which are known as myeloid-derived suppressor cells [71, 72] and adoptive 
transfer of these cells protects allergen-induced airway inflammation [73] and colitis 
[74].  
In summary, this study demonstrates that G-CSFR-/- mice were more susceptible to 
DSS-induced acute colitis than wild-type mice and adoptive transfer of G-BMDM 
protected G-CSFR-/- mice from the colitis. These results suggest that endogenous G-
CSF plays an important role in maintaining intestinal immune homeostasis and 
preventing colitis, likely through enhancing population of immune regulatory 
macrophages in the intestine. 
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5.1 INTRODUCTION 
Microorganisms induce diverse immune responses, which can be either harmful or 
beneficial to the host. Unlike pathogenic microbes, probiotics are microorganisms 
usually isolated from fermented food or healthy individuals, and confer a health 
benefit on the host when administered in adequate amounts [1, 2]. Among various 
probiotic bacteria, Lactobacillus, a Gram-positive facultative anaerobic bacterium, is 
a common constituent of the indigenous microbiota in the human intestinal and 
urogenital tracts [3, 4], and has been used as a probiotic for preventing or treating 
infectious and inflammatory diseases [5, 6]. However, different Lactobacillus species 
and strains elicit strikingly different immune responses from a variety of immune 
cells and experimental systems [7-10]. L. rhamnosus GG (LGG) is a well-studied 
strain that can induce inflammatory responses in dendritic cells (DCs) and aggravate 
dextran sulfate sodium (DSS)-induced acute colitis in mice [11, 12]. LGG also has 
anti-inflammatory effects on mouse and human macrophage cell lines [7, 13], and 
renders beneficial effects on chronic DSS-induced mouse colitis and pouchitis in 
human [14, 15]. Two soluble factors from LGG, referred to as p75 and p40, prevent 
apoptotic cell death of intestinal epithelial cells through activating the epithelial 
growth factor receptor [16, 17] and are beneficial in ameliorating DSS-induced acute 
colitis, as well as oxazolone and trinitrobenzenesulfonic acid-induced chronic colitis 
in mice [18]. L. rhamnosus GR-1 (GR-1), which is closely related to LGG, colonize 
both the intestinal and urogenital tracts after oral supplements [19-21]. Previously, 
GR-1 was shown to increase IL-10 and granulocyte-colony stimulating factor (G-
CSF) production, and suppress tumor necrosis factor (TNF)-α production in human 
placental trophoblast cells [22, 23]. GR-1 also renders anti-inflammatory effects on 
macrophages [24, 25] and DCs [26], and promotes the generation of regulatory T 
cells in humans [27]. However, detailed immune responses and signaling mechanisms 
elicited by GR-1 remain largely unknown.  
Macrophages are key innate immune cells, orchestrating immune responses through 
releasing various pro- and anti-inflammatory cytokines. These cells are highly 
populated in the gut lamina propria, interacting directly with microorganisms that 
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have crossed the gut barrier [28]. Macrophages detect microbe-associated molecular 
patterns (MAMPs) through pattern recognition receptors (PRRs) such as Toll-like 
receptors (TLRs). Although probiotics harbor MAMPs, they rarely cause infections 
and inflammatory diseases, and discretely modulate host immune responses through 
inducing distinct cytokine and chemokine profiles [7-10, 29]. Although details remain 
to be elucidated, several strains of probiotic bacteria have been shown to have 
immunomodulatory activities through selectively activating PRRs or regulating 
signaling cascades initiated by PRRs. For example, cell wall components such as 
lipoteichoic acid (LTA) [30-32], cell wall associated polysaccharide [33], S layer 
protein A [34], bacteriocins [35, 36], pilus [37] and histamine [38, 39] have each been 
shown to modulate pro-inflammatory responses in macrophages and DCs through 
activating specific or unidentified receptors. Also, several probiotic bacteria were 
shown to suppress pro-inflammatory cytokine expression or promote anti-
inflammatory cytokines by inhibiting activation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) [31, 40, 41], c-Jun N-terminal kinases (JNKs) 
[42] and extracellular regulated kinases (ERKs) [31, 41]. The present study examined 
cytokines produced, signaling cascades activated, and bacterial factor(s) released by 
GR-1 in macrophages. We found that a protein-like factor released by GR-1 
specifically and potently induced immunomodulatory G-CSF through activating NF-
κB, ERKs and protein kinase B (also known as Akt), but not JNKs, in a TLR2-
dependent manner.  
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5.2 MATERIALS AND METHODS 
5.2.1 Mice 
C57BL/6j wild-type mice were obtained from The Jackson Laboratory (Bar Harbor, 
ME, USA). Mice were maintained in the animal care and veterinary facility at the 
University of Western Ontario (London, ON, Canada) under conventional conditions. 
Male and female mice, aged 4-10 weeks, were used in all experimental procedures. 
All experimental protocols were approved by the University of Western Ontario 
Animal Use Subcommittee, which follows the regulations of the Animals for 
Research Act (Ontario) and the Canadian Council on Animal Care. 
5.2.2 Cell cultures, bacteria and reagents 
Immortalized mouse bone marrow-derived macrophages (BMDM) with C57BL/6j 
background were originally obtained from Dr. Bharat Aggarwal (MD Anderson 
Cancer Center, University of Texas, Houston, TX) and cultured in RPMI 1640 
medium (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum 
(Sigma-Aldrich), 100 U ml-1 penicillin, 0.1 mg ml-1 streptomycin (Sigma-Aldrich), 5 
mM sodium pyruvate (Sigma-Aldrich), 5 mM MEM non-essential amino acids 
(Sigma-Aldrich) (referred to as complete (c)-RPMI). Cells were then maintained at 
37°C in a humidified atmosphere with 5% CO2. L. rhamnosus GR-1, obtained from 
Dr. Gregor Reid (The Canadian Research and Development Centre for Probiotics, 
Lawson Health Research Institute, London, ON, Canada), was grown anaerobically in 
De Man, Rogosa and Sharpe (MRS) agar (Becton Dickinson) using anaerobic packs 
(Becton Dickinson) at 37°C for 24 h. For cell culture challenge, L. rhamnosus GR-1 
were grown from a single colony in MRS broth (Becton Dickinson) at 37°C for 48 h. 
Uropathogenic E. coli GR-12, originally isolated from the urine of a patient with 
pyelonephritis [43], and Staphylococcus aureus str. Newman were grown aerobically 
overnight in Luria-Bertani (LB) medium (Becton Dickinson) and brain-heart infusion 
(BHI) broth (Becton Dickinson), respectively, with agitation at 37°C. All bacteria 
were harvested by centrifugation at 6000 g for 10 min, washed three times with 
phosphate-buffered saline (PBS) (pH 7.4), and diluted to obtain a final optical density 
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of 1.0 at 600 nm (representing approximately 109 CFU/ml) in PBS. 
Lipopolysaccharide (LPS) from E. coli O111:B4 was purchased from List Biological 
Laboratories (Campbell). PAM2CSK4 (PAM2) and PAM3CSK4 (PAM3) were 
purchased from Invivogen. LTA from S. aureus, lipase (from Candida rugosa) and 
RNase A were obtained from Sigma-Aldrich. DNase was purchased from Roche. 
LY294002, Akt inhibitor II, NF-κB activation inhibitor, wortmannin, SB202190, 
U0126, and JNK inhibitor II were purchased from Calbiochem (EMD Biosciences). 
Antibodies for phospho-p38 (p-p38), p-ERKs, p-SAPK/JNKs, p-Akt, p-inhibitory κB 
(IκB) and β-actin were purchased from Cell Signaling Technology (NEB 
Biosciences).  
5.2.3 Generation of primary BMDM 
Bone marrow cells (BMCs) were harvested from femurs and tibia of mice using a 
25.5-gauge needle and PBS. Isolated cells were cultured in c-RPMI supplemented 
with murine recombinant macrophage (M)-CSF (20 ng/ml; eBioscience). Cells were 
then maintained at 37°C in a humidified atmosphere with 5% CO2 for 7 days. The 
culture media was replaced with fresh media every two days after culture initiation. 
5.2.4 Crude LTA purification 
Crude LTA was extracted from LGG and S. aureus using the butanol extraction 
method as previously described [44]. Briefly, bacterial cells were sonicated for 15 
min, re-suspended in n-butanol/water (1:1, v/v) and stirred for 30 min at room 
temperature. The suspension was then centrifuged at 8000 g for 30 min, resulting in a 
two-phase system. The aqueous phase was lyophilized to give crude LTA. 
Subsequently, the lyophilized sample was re-suspended in PBS and used for further 
experiments. 
5.2.5 Macrophage cell challenge and cytokine determination 
Macrophages were challenged for 4 h and 24 h in a 96-well plate format with live 
bacteria (if not indicated otherwise, 20 colony forming units (CFU)/cell), bacterial 
spent culture supernatant (SCS; 1/25 dilution), LTA (10 µg/ml), and LPS (100 
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ng/ml). Samples for TNF-α and G-CSF analysis by enzyme-linked immunosorbent 
assays (ELISA) were obtained from cell culture supernatant after 4 and 24 h 
challenge, respectively, and stored at -20°C until use.  
5.2.6 ELISA 
To measure the TNF-α and G-CSF levels in cell culture supernatant, ELISA kits were 
purchased from eBioscience (San Diego, CA) and R&D Systems (Minneapolis, MN), 
respectively. Standard curves were generated using recombinant proteins provided by 
the manufacturer.   
5.2.7 Western blot 
Total cell lysate extraction and Western blot analysis were performed as previously 
described [45]. Briefly, total cell lysates were extracted using ice-cold lysis buffer 
containing 20 mM MOPS, 15 mM EGTA, 2 mM EDTA, 1 mM Na3VO4, 1 mM DTT, 
75 mM β-glycerophosphate, 0.1 mM PMSF, 1 μg/mL aprotinin, 10 μg/mL pepstatin 
A, 1 μg/mL leupeptin, and 1% Triton X-100. Following the incubation of cells with 
lysis buffer on ice for 5 min, cell lysates were extracted by centrifuging the 
homogenate at 18000 g for 15 min. Extracts were then mixed with SDS-PAGE 
loading buffer, heated to 100°C for 5 min, resolved on 11% SDS-PAGE 
polyacrylamide gels (Bio-Rad), and transferred onto nitrocellulose membranes. 
Following that, membranes were blocked with 5% w/v skim milk for 30 min, 
immunoblotted with antibodies, and visualized using an enhanced chemiluminescence 
detection system (ECL; Pierce Bioscience). Band intensity quantification was 
performed using ImageJ (Rasband, W.S., ImageJ, U.S. National Institutes of Health, 
Bethesda, MD, USA, 1997–2009, http://rsb.info.nih.gov/ij/) [46]. 
5.2.8 Cytokines and Chemokines PCR Array 
Total RNA was isolated using RNeasy Mini kit (QIAGEN Canada) according to the 
manufacture’s recommendations. Reverse transcription was conducted using the RT2 
First Strand Kit (QIAGEN) according to the manufacture’s protocol. The Q-PCR was 
performed using a RT2 Profiler PCR Array System Kit-mouse cytokines and 
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chemokines PCR array (QIAGEN) on an Applied Biosystems StepOnPlus instrument 
according to the manufacturer guidelines.  
5.2.9 Statistical analysis 
Pooled results of several independent experiments were used in all analyses. Results 
are reported as mean ± SEM. Student’s t-test or one-way analysis of variance 
(ANOVA) with Tukey’s multiple comparison post hoc test were used to determine 
significance at p < 0.05 among experimental groups using Prism 5.0c for Mac OS X 
(GraphPad Software, La Jolla, CA). 
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5.3 RESULTS 
5.3.1 Production of G-CSF is the most prominent among 84 
cytokines and chemokines examined in GR-1-treated 
macrophages. 
We previously showed that the probiotic GR-1 potently induces G-CSF but poorly 
induces TNF-α production in macrophages [47]. To further examine production of 
other cytokines and chemokines induced by GR-1 and their levels in comparison to 
other stimuli, immortalized BMDM were treated with live GR-1 (20 CFU/cell), the 
TLR4 ligand LPS (1 µg/ml), TLR2/6 ligand PAM2 (1 µg/ml) and TLR1/2 ligand 
PAM3 (1 µg/ml) for 5 h, and the expression of 84 cytokines and chemokines were 
examined using the RT2 Profiler PCR Array System Kit. As shown in Fig. 5.1 (upper 
left panel) and Appendix A.5, GR-1 potently induced expression of G-CSF mRNAs 
(>60-fold of those induced in non-treated cells), whereas all others were induced less 
than 5-fold. LPS also induced G-CSF mRNA to ~80-fold; however, it also potently 
induced other cytokines and chemokines, including C-C motif ligand (CCL)5, 
CCL12, C-X-C motif ligand (CXCL)1, CXCL3, CXCL9, CXCL10, CXCL11, IL-
1α/β, IL-6, IL-12, TNF-α and TNF superfamily member 10 more than 50-fold. PAM2 
and PAM3 also potently induced G-CSF more than 100-fold; however, they also 
induced IL-1α/β, IL-16 and TNF-α more than 50-fold. These results demonstrate that 
GR-1 induced a distinct cytokine expression profile from LPS, PAM2 and PAM3. 
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Figure 5.1. Production of G-CSF is the most prominent among 84 cytokines and 
chemokines examined in GR-1-treated macrophages. Cytokine mRNA levels were 
measured in immortalized BMDM treated with GR-1 (20 colony forming units 
(CFU)/cell), lipopolysaccharide (LPS; 1 µg/ml), PAM2CSK4 (PAM2; 1 µg/ml), and 
PAM3CSK4 (PAM3; 1 µg/ml) using PCR array. The graph plots the log10 of 
normalized gene expression levels in a control condition (x-axis) versus an 
experimental condition (y-axis). 
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Figure 5.1 
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5.3.2 Preferential G-CSF production by GR-1 is unique 
among tested bacteria in primary BMDM. 
We further examined whether preferential production of G-CSF was also observed in 
other bacteria and also in non-transformed cells. Macrophages derived from BMCs of 
C57BL/6j mice in the presence of M-CSF were treated with live GR-1, E. coli GR-12 
and S. aureus with 1-200 CFU/cell, and production of TNF-α (in 4 h) and G-CSF (in 
24 h) were measured using ELISA. Both E. coli and S. aureus induced TNF-α as low 
as 1 CFU/cell, whereas GR-1 did not induce TNF-α even at 10 CFU/cell (Fig. 5.2A). 
GR-1 with higher than 20 CFU/cell induced TNF-α, but the levels was less than one-
half of those induced by E. coli and S. aureus. Unlike TNF-α, G-CSF was 
significantly produced by GR-1 as low as 10 CFU/cell and maximally at 50 CFU/cell 
(Fig. 5.2B). E. coli maximally produced G-CSF even at 1 CFU/cell, whereas S. 
aureus gradually induced more G-CSF production starting at 1 CFU/cell and 
maximally at 20 CFU/cell. Further examination on the kinetics of the production of 
these cytokines showed that GR-1 induced G-CSF 12 h after treatment at similar 
levels induced by LTA (Fig. 5.2C; right panel). Unlike G-CSF, production of TNF-α 
was induced as early as 4 h of LTA treatment. However, GR-1 did not induce TNF-α 
until 12 h post-treatment and the levels were significantly lower than those induced 
by LTA (Fig 5.2C; left panel). Nonetheless, the levels of TNF-α were significantly 
lower than those induced by LTA. Similar results were also obtained in immortalized 
BMDM. These results suggest that live GR-1 preferentially produced G-CSF with 
similar kinetics as LTA, but induced TNF-α significantly less efficiently than LTA. 
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Figure 5.2. Preferential G-CSF production by GR-1 is unique among other 
bacteria in primary BMDM. (A-B) Primary BMDM treated with live S. aureus, live 
E. coli GR-12 or live GR-1 at the indicated bacteria:macrophage (colony forming 
units (CFU/cell) ratios. Production of TNF-α (A; in 4 h) and G-CSF (B; in 24 h) was 
measured from spent cell culture media using ELISA. [n ≥ 3; p < 0.05 by one-way 
ANOVA with Tukey’s multiple comparison post hoc test; columns accompanied by 
the same letter (a, b or c) are not significantly different from each other]. (C) Primary 
BMDM treated with live GR-1 (20 CFU/cell) or lipoteichoic acid  (LTA; 10 µg/ml) 
for indicated time points. Production of TNF-α (in 4 h) and G-CSF (in 24 h) was 
measured from spent cell culture media using ELISA. Data shown as mean ± SEM [n 
≥ 3]. 
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Figure 5.2 
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5.3.3 Activation of ERKs, NF-κB and Akt but not JNKs by 
GR-1 plays a key role in the preferential production of 
G-CSF over TNF-α. 
To examine signaling pathways activated by GR-1, immortalized BMDM were 
treated with GR-1 at 20 CFU/cell for different time points and Western blots against 
phosphorylated IκB, Akt and MAPKs (ERKs, p38 and JNKs) were performed. 
Consistent with previous studies, LTA activated all MAPKs, Akt and NF-κB 
signaling cascades after 15-30 min of treatment (Fig. 5.3A). GR-1 also potently 
activated ERKs, but weakly p38, Akt and NF-κB. However, no activation of JNKs by 
GR-1 was detected. To further examine which of these signaling cascades were 
involved in G-CSF and TNF-α production, these cells were pretreated with various 
inhibitors, and then treated with GR-1 or LTA. As shown in Fig. 5.3B, production of 
G-CSF by GR-1 and LTA was inhibited by the NF-κB inhibitor (NF-κB activation 
inhibitor), ERKs inhibitor (U0126), phosphatidylinositol 3-kinase (PI3K) inhibitor 
(wortmanin or LY94002) and Akt inhibitor (Akt inhibitor II), but not by the p38 
inhibitor (SB203580) and JNKs inhibitor (JNK inhibitor II) (Fig. 5.3B, left panel). 
Unlike G-CSF, the production of TNF-α by LTA was inhibited by all the MAPK 
inhibitors (U0126, SB203580 and JNK inhibitor II), but not by the PI3K and Akt 
inhibitors (wortmanin, LY94002 and Akt inhibitor II) (Fig. 5.3B, right panel). These 
results suggested that GR-1 preferentially induces G-CSF production in macrophages 
through selectively activating ERKs, NF-κB and Akt, but not JNKs, in a TLR2-
dependent manner. 
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Figure 5.3. Activation of ERKs, NF-κB and PI3K/Akt but not JNKs by GR-1 
plays a key role in the preferential production of G-CSF over TNF-α. (A) 
Immortalized BMDM were treated with live GR-1 (20 colony forming units 
(CFU)/cell) or lipoteichoic acid  (LTA; 10 µg/ml) for 15, 30 and 60 min. 
Phosphorylation of MAPKs (ERKs, p38 and JNKs), Akt and I-κB was analyzed by 
Western blot using phospho- or anti-peptide antibodies against indicated proteins. Bar 
graphs demonstrate band intensity quantification (ratio of protein phosphorylation to 
β-actin) using ImageJ. Data shown as mean ± SEM [n ≥ 3]. (B) Immortalized BMDM 
treated with GR-1 (20 CFU/cell) or LTA (10 µg/ml) in the presence or absence of 
various inhibitors (NF-κB-NF-κBi; 10 µM, p38-SB203580; 10 µM, JNKs-JNK 
inhibitor II; 250 nM, MEK/ERKs-U0126; 25 µM, Akt-Akt inhibitor II; 1 µM, PI3K-
wortmannin; 10 µM and PI3K-LY94002; 10 µM). Production of TNF-α (in 4 h) and 
G-CSF (in 24 h) was measured from spent cell culture media using ELISA. Data 
shown as mean ± SEM (n ≥ 3; *, p < 0.05 by Student’s t-test). 
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Figure 5.3 
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5.3.4 TLR2 plays a key role in inducing G-CSF in GR-1-
treated primary BMDM. 
GR-1, as a Gram-positive bacterium, harbors several MAMPs including 
lipoproteins/LTA, which activate TLR2. To examine if this receptor is involved in 
GR-1-induced G-CSF production, primary BMDM derived from TLR2-deficient 
(TLR2-/-) mice were treated with GR-1 or PAM3. G-CSF production was 
undetectable in TLR2-/- BMDM in response to either GR-1 or PAM3 (Fig. 5.4A). 
TLR2-/- BMDM failed to produce TNF-α by either GR-1 or PAM3. Consistent with 
these results, TLR2-/- BMDM did not activate ERKs, p38, Akt and NF-κB in response 
to GR-1 (Fig. 5.4B). GR-1 activated JNKs in neither wild-type nor TLR2-/- BMDM 
(data not shown), as in immortalized BMDM (Fig. 5.3A). These data suggest that 
production of G-CSF and activation of ERKs, p38, Akt and NF-κB by GR-1 was 
mediated through TLR2.  
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Figure 5.4. TLR2 plays a key role in inducing G-CSF in GR-1-treated primary 
BMDM. (A) Primary BMDM from wild-type (WT) and TLR2-/- mice were treated 
with live GR-1 (20 colony forming units/cell (CFU/cell)) or Pam3CSK4 (PAM3; 1 
µg/mL). Production of TNF-α (in 4 h) and G-CSF (in 24 h) was measured from spent 
cell culture media using ELISA. Data shown as mean ± SEM [n ≥ 3]. (B) Primary 
BMDM from WT and TLR2-/- mice were treated with live GR-1 (20 CFU/cell) for 15, 
30 and 60 min. Phosphorylation of MAPKs (ERKs, p38 and JNKs), Akt and I-κB was 
analyzed by Western blot using phospho- or anti-peptide antibodies against indicated 
proteins. Bar graphs demonstrate band intensity quantification (ratio of protein 
phosphorylation to β-actin) using ImageJ. Data shown as mean ± SEM [n ≥ 3]. 
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Figure 5.4 
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5.3.5 A heat-labile protein-like molecule(s) secreted by GR-1 
preferentially induces G-CSF production. 
Since TLR2 activation was required for G-CSF production by GR-1, we first 
examined whether LTA/lipoproteins isolated from GR-1 induced a similar G-CSF 
preferential production effect in immortalized BMDM. LTA/lipoproteins from GR-1 
were ~ 10-fold less effective in inducing both G-CSF and TNF-α than those from S. 
aureus (Fig. 5.5A). However, unlike live GR-1, LTA/lipoproteins from GR-1 induced 
both TNF-α and G-CSF at similar levels, suggesting that LTA/lipoproteins were not 
the factor responsible for the G-CSF preferential production effect. We then 
examined whether a factor(s) released from GR-1 had a similar effect on G-CSF 
production as in live GR-1. As shown in Fig. 5.5B, GR-1 cell free SCS, but not the 
media (MRS) alone, preferentially produced G-CSF over TNF-α, and the production 
of G-CSF was abolished in SCS treated with heat (95oC for 3 h), trypsin and 
proteinase K, but not with lipase, DNase and RNase (Fig. 5.5B). Treatments of 
trypsin or proteinase K had no effects on LPS-induced TNF-α and G-CSF production, 
indicating that inhibition of G-CSF production in GR-1-SCS was not due to residual 
effects of these proteases on macrophages. To estimate the molecular size(s) of the 
GR-1 molecule(s), GR-1-SCS was filtered through different sizes of membranes. As 
shown in Fig. 5.5C, the molecule(s) passed through 100 kDa membranes but not 30 
kDa membranes, suggesting that the GR-1 molecule(s) was between 100 and 30 kDa 
in native size. Collectively, these results indicate that the GR-1 factor(s) responsible 
for preferential G-CSF production in macrophages is a heat-labile protein-like 
molecule(s) of 30-100 kDa in native size. 	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Figure 5.5. A heat-labile protein-like molecule(s) secreted by GR-1 preferentially 
induces G-CSF production. (A) Immortalized BMDM were treated with indicated 
concentrations of GR-1- or S. aureus-n-butanol-extracted crude LTA/lipoproteins. 
Production of TNF-α (in 4 h) and G-CSF (in 24 h) was measured from spent cell 
culture media using ELISA. Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 by 
Student’s t-test). (B) Immortalized BMDM were treated with GR-1 spent culture 
supernatant (SCS; 1/25 dilution) or MRS culture media (1/25 dilution) which had 
been treated with proteinase K (200 μg/mL), lipase (200 μg/mL), trypsin (200 
μg/mL), DNase (200 μg/mL), RNase (200 μg/mL), and heat (95oC for 3 h). 
Production of TNF-α (in 4 h) and G-CSF (in 24 h) was measured from spent cell 
culture media using ELISA. Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 by 
Student’s t-test). (C) Immortalized BMDM were treated with MRS culture media 
(1/25 dilution), GR-1-SCS (1/25 dilution) or GR-1-SCS which had been fractioned 
using Centricon centrifugal filter devices with a 100 or 30 kDa molecular weight 
cutoffs. Production of TNF-α (in 4 h) and G-CSF (in 24 h) was measured from spent 
cell culture media using ELISA. Data shown as mean ± SEM [n ≥ 3]. 
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Figure 5.5	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5.4 DISCUSSION 
Here, we showed that among 84 cytokines and chemokines examined, GR-1 potently 
induced G-CSF (Fig. 5.1 and Appendix A.5), and the production of G-CSF by GR-1 
was as efficient as other known pro-inflammatory stimuli in both kinetics and 
amounts (Fig. 5.2). This observation is consistent with our previous studies in 
macrophages [24, 26] and placental trophoblast cells that showed high levels of G-
CSF production by GR-1 [22, 23]. GR-1 at higher than 20 CFU/cell or after 12 h 
post-exposure was able to induce TNF-α, albeit at significantly lower levels than 
those induced by E. coli GR-12 or S. aureus (Fig. 5.2). Therefore, GR-1 could induce 
pro-inflammatory cytokines, but much less efficiently when compared to other 
bacteria or LTA.  
Inefficient production of TNF-α by GR-1 was likely due to poor stimulatory effects of 
GR-1 cell wall components. LTA prepared from GR-1 was ~10-fold less efficient in 
inducing TNF-α when compared to LTA from S. aureus (Fig. 5.5A). Previous studies 
have shown that LTA purified from several strains of Lactobacillus, including L. 
plantarum str. WCFS1 [30], L. casei str. YIT9029 [31], L. fermentum str. YIT0159 
[31] and LGG [48] are inefficient in producing pro-inflammatory cytokines such as 
TNF-α, IL-1β and IL-6. It is still unknown why LTA from several strains of 
Lactobacillus are inefficient in inducing pro-inflammatory cytokines. Interestingly, 
mutant L. plantarum WCFS1 and LGG that lacks D-alanylated LTA induces more 
anti-inflammatory but less pro-inflammatory cytokines in monocytes than wild-type 
LTA [30], and rendered protective effects on colitis [12, 30]. However, in another 
study, alanylation of LTA had no role in the production of pro-inflammatory 
cytokines in LGG-treated macrophages and peripheral mononuclear cells [48]. 
Regardless the levels of alanylation, GR-1 LTA is not likely involved in the G-CSF 
preferential effect of GR-1, as GR-1 LTA at high doses induced both TNF-α and G-
CSF at similar extents (Fig. 5.5A).  
At this moment, the identity of GR-1 factor(s) responsible for the preferential 
production of G-CSF is elusive. This study suggested that a protein-like factor, which 
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is sensitive to heat and proteases, such as trypsin and proteinase K, with a molecular 
weight between 30 and 100 kDa, is responsible for G-CSF preferential production by 
GR-1 (Fig. 5.5B-C). To date, probiotic proteins known to preferentially induce anti-
inflammatory cytokines include surface layer proteins from L. reuteri, L. casei, [49] 
and L. acidophilus NCFM [34], and bacteriocins released from L. plantarum strains 
[36, 50]. Immunomodulation elicited by surface layer proteins likely acts through 
DC-specific ICAM3-grabbing non-integrin (DC-SIGN) [49, 51], which is distinct 
from the GR-1 factor(s) that required TLR2 (Fig. 5.4A). Various Lactobacillus 
species including L. rhamnosus release bacteriocins, which can directly modulate 
immune responses [50, 52, 53]. Therefore, bacteriocin-related proteins released by 
GR-1 may have been involved in the G-CSF production. Further studies on the 
possible involvement of bacteriocin-related proteins in G-CSF production are 
warranted. 
GR-1 was shown to release factors that have immunomodulatory effects on non-
immune cells. GR-1-SCS significantly induced G-CSF and macrophage inflammatory 
protein 1α/β, but suppressed various LPS-induced pro-inflammatory cytokines 
including TNF-α in human decidual cells [54] and in CD-1 pregnant mice [55]. 
However, in urinary bladder cells, GR-1-SCS enhanced activation of NF-κB [56] and 
production of TNF-α, but not IL-6 and IL-8, induced by E. coli [57]. In these studies, 
GR-1 or GR-1-SCS alone induced NF-κB but little TNF-α production, which is 
consistent with our results (Fig. 5.3A and 5.4B). Although it is unknown whether 
these responses are mediated by the same factor, molecular characteristics in a 
protein-like entity with native molecular size above 30 kDa appear to be common in 
both studies (Fig. 5.5) [56]. 
We further examined the signaling pathways required for G-CSF preferential 
production in GR-1-treated macrophages. GR-1 activated ERKs, p38, Akt and NF-
κB, but not JNKs, in immortalized and primary BMDM in a TLR2-dependent manner 
(Fig. 5.3A and 5.4B). Based on experiments using specific inhibitors, activation of 
ERKs, Akt and NF-κB pathways were involved in G-CSF production, whereas 
activation of ERKs, p38, JNKs and NF-κB pathways were required for TNF-α 
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production (Fig. 5.3B). These results are consistent with previous reports showing 
that p38 and JNKs are required for production of pro-inflammatory cytokines, such as 
TNF-α, IL-1β, IL-6 and IL-8 [58, 59]. Also, the p38 and JNKs, but not ERKs, 
pathways are involved in the signal transduction of LPS-induced TNF-α and IL-1β 
production by Kupffer cells [60] and RAW 264.7 macrophages [61]. Therefore, lack 
of JNKs activation in GR-1-treated macrophages likely contributed to the inefficient 
production of pro-inflammatory cytokines. The PI3K/Akt signaling axis can suppress 
TNF-α production through multiple pathways [62], particularly through inactivating 
NF-κB but activating cAMP response-binding protein (CREB), resulting in 
suppression of IL-12 and induction of IL-10 production [63]. We showed that the 
inhibitors specific for Akt or PI3K inhibited TNF-α, but not G-CSF, production (Fig. 
5.3B). These results are consistent with previous studies showing that activation of 
ERKs, NF-κB and PI3K/Akt pathways are crucial for G-CSF expression [64, 65]. 
Recent studies also showed that activation of PI3K/Akt is required for TLR-mediated 
G-CSF production, through inducing expression of the transcription factor octamer-
binding factor-2 (Oct-2) [66, 67]. Therefore, activation of PI3K/Akt and ERKs 
pathways by GR-1 likely contributed to G-CSF-specific production by GR-1-treated 
macrophages.  
An intriguing fact is that GR-1-induced G-CSF production required TLR2 (Fig. 
5.4A). At this moment, it is unknown how activation of TLR2 by GR-1 led to ERKs 
and p38 activation without JNKs activation, resulting in G-CSF production without 
inducing pro-inflammatory cytokines. However, the anti-inflammatory responses by 
activating TLR2 are not restricted to GR-1. Bifidobacterium pseudocatenulatum 
CECT7765 was recently shown to produce anti-inflammatory cytokines such as IL-10 
and suppress TNF-α production through TLR2 [68]. Even purified LTA or whole 
cells from lactobacilli were previously shown to modulate TNF-α expression through 
a TLR2-dependent mechanism [30, 31, 69, 70]. Further experiments delineating 
mechanisms of TLR2 in activating immunomodulatory responses is of great interest. 
In addition to the primary function of G-CSF in the generation and mobilization of 
neutrophils, G-CSF enhances anti-microbial function of mature neutrophils [71-73], 
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and regulates immune responses through suppressing production of various pro-
inflammatory cytokines in myeloid cells [24, 25], generating regulatory gut-homing 
macrophages [74], promoting maturation of tolerogenic DCs [26, 75, 76], and 
generation of IL-10-secreting CD4+ type 1 T regulatory cells [77]. Therefore, G-CSF 
production by GR-1 may play an important role in enhancing anti-bacterial activities 
of neutrophils and preventing cell death of intestinal/urogenital epithelial cells 
induced by various stresses, without inducing inflammatory responses. Beneficial 
effects of probiotics are not limited in the intestine. Interestingly, a recent study 
showed that administration of L. plantarum 299v or GR-1 protected cardiac failure 
and hypertrophy in the rat heart [78, 79]. Since G-CSF also renders cytoprotective 
effects against various stresses in neuronal and cardiac cells [80-82], we are tempted 
to speculate that G-CSF may also contribute to the cardio-protective effects of L. 
plantarum 299v or GR-1.  
In summary, this study demonstrated that a protein-like factor(s) from GR-1 
preferentially and potently produced G-CSF in macrophages through selectively 
activating ERKs, NF-κB and Akt in a TLR2-dependent manner. 
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6.1 SUMMARY OF RESULTS 
Several in vitro and in vivo studies have shown that G-CSF has a role in the 
generation of monocytes/macrophages [1, 2]. Additionally, G-CSF induced by the 
probiotic strain of L. rhamnosus GR-1 down-regulates expression of inflammatory 
cytokines in activated macrophages [3]. However, details on the mechanisms of these 
observations had remained to be explored. The first part of this thesis focused on 
examining the immune regulatory effects of G-CSF in the gut through macrophages 
(Chapters 3 and 4). I have established that G-CSF induced the generation of gut-
homing M2-like macrophages in BMDM. I also showed that G-CSF was an important 
factor in the regulation of the gut immune system, as demonstrated in the DSS-
induced acute colitis mouse model. The second part of this thesis elucidated the 
signaling mechanisms involved in the preferential production of G-CSF in GR-1-
exposed macrophages  (Chapter 5). I have shown that GR-1 induced high levels of 
immunomodulatory G-CSF production with low levels of pro-inflammatory cytokines 
in macrophages through activating TLR2, and subsequent NF-κB, ERKs and 
PI3K/Akt signaling pathways. The GR-1 factor responsible for the G-CSF 
preferential effect was a heat-labile protein-like molecule(s) of 30-100 kDa in size. 
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6.1.1 Chapter 3: G-CSF preferentially supports the 
generation of gut-homing Gr-1high macrophages in M-
CSF-treated bone marrow cells  
Chapter 3 describes the role of G-CSF in the generation of macrophages. Since G-
CSF alone was not able to sustain continued survival/proliferation of BMCs (Fig. 
3.1C and Fig. 3.2A; left panel), I investigated its impact on BMCs in the presence of 
other CSFs, M-CSF and GM-CSF. I found that the addition of G-CSF mainly 
promoted the growth of BMCs in the presence of M-CSF (Fig. 3.1C), but not GM-
CSF (Fig. 3.1D). M-CSF alone generated a homogenous cell population, mainly Gr-
1low/F4/80+ macrophage-like cells, from BMCs (Fig. 3.2). G-CSF and M-CSF induced 
Gr-1high/F4/80+ macrophage-like (Fig. 3.2 and Fig. 3.7D) and Gr-1+/F4/80- neutrophil-
like cell populations (Fig. 3.2). G-CSF prevented cell death (Fig. 3.4 and Fig. 3.5) and 
enhanced cell proliferation of Gr-1high/F4/80+ macrophage-like cells (Fig. 3.6). In 
addition, I also established that these Gr-1high/F4/80+ macrophage-like cells have M2-
like cytokine (3.7A-B) and cell surface marker expression profiles (3.7C). Adoptive 
transfer of F4/80+ BMCs that were treated with G-CSF resulted in higher localization 
of BMCs in the intestinal lamina propria of recipient mice (Fig. 3.8) but not in other 
tissues examined (Appendix A.3). Accordingly, the number of intestinal Gr-
1high/F4/80+ and Gr-1low/F4/80+ cells was reduced in G-CSFR-/- mice compared to their 
wild-type counterparts with no differences in the number of Gr-1+/F4/80- neutrophil-
like cells. These results suggested that G-CSF can contribute to the survival and 
proliferation of M-CSF-exposed BMCs, which showed M2-like cytokine production 
and cell surface marker profiles and gut-homing characteristics following adoptive 
transfer.  
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6.1.2 Chapter 4: Protective role of endogenous G-CSF in 
dextran sulfate sodium-induced acute colitis through 
generating gut-homing macrophages  
As shown in Chapter 3, G-CSF seemed to be involved in gut-homing of M-CSF 
derived macrophages. In Chapter 4, therefore, I first aimed to elucidate the 
endogenous role of G-CSF in gut immune regulation using the DSS-induced acute 
colitis model. Mice (G-CSFR+/+, -/+ and -/-) received DSS (1.5% w/v) in their drinking 
water and were monitored for the severity of colitis. Following DSS treatments, all 
mice showed significant body weight loss, diarrhea, colitis scores (Fig. 4.1A) and 
tissue damage (Fig 4.1B-C), but these effects were more pronounced in G-CSFR-/- 
mice (Fig 4.1A-B), which also showed a decreased ability to clear infections after 
DSS treatment, reflected by formation of pseudomembranous structures (Fig 4.1B, 
lower right panel). Since no development of spontaneous colitis was observed in G-
CSFR-/- mice (Fig. 4.1A), it can be postulated that the G-CSF signaling defect may 
not be a primary factor of colitis induction but rather a driving factor in colitis 
progression. Next, I tested whether G-CSFR-/- mice with low circulating neutrophil 
counts had similar deficiency in the gut neutrophil populations. Interestingly, I found 
no difference in the neutrophil-like cell population in the steady-state (Fig. 4.2A; left 
panel) or in the infiltration of these cells in inflammatory state after DSS treatment 
(Fig. 4.2B-C). These observations indicated that emergency generation of neutrophils 
during inflammation and recruitment to local inflammatory sites were not defective in 
these mice and neutrophils might not be involved in the G-CSFR-/- DSS-induced 
colitis phenotype.   
 As shown in Fig. 3.7, macrophages treated with G-CSF had M2-like characteristics, 
reflected by their cytokine and cell surface marker expression profiles. To investigate 
further the G-CSF-treated BMDM characteristics, I continued to analyze the M1- and 
M2- cell surface marker and mRNA expression of these cells in response to M1 and 
M2 stimuli. There appeared to be a significant increase in expression of M2-cell 
surface markers (Fig. 4.3A); however, there was no such effect in the mRNA 
expression of M2-specific genes in G-CSF-treated BMDM in response to M2 stimuli 
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(Fig. 4.3B). In contrast, G-CSF significantly reduced M1 markers, iNOS mRNA and 
CD86 cell surface marker expressions on G-CSF-treated BMDM in response to M1 
stimuli (Fig. 4.4). These results indicated that G-CSF-treated BMDM may not readily 
fall into all M2 macrophage characteristics, but are regulatory and modulatory in 
nature (the reason why we called them M2-like cells).  
Since G-CSF induced the generation of gut-homing M2-like macrophages (Chapter 
3), G-CSFR-/- mice had less F4/80+ macrophages, but not neutrophils (Fig. 3.9 and 
Fig 4.2) and G-CSFR-/- mice were more susceptible to DSS-induced acute colitis (Fig. 
4.1), I explored the effects of adoptively transferred G-BMDM during DSS-induced 
acute colitis. I found that adoptive transfer of G-BMDM, but not BMDM, rendered 
disease-ameliorating effects in DSS-induced acute colitis in G-CSFR-/- mice (Fig. 4.5 
and Fig. 4.6). Collectively, these findings pointed out that G-CSF plays an important 
role in the regulation of gut immune response in DSS-induced acute colitis model.	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6.1.3 Chapter 5: Activation of TLR2-dependent signaling 
cascades and preferential production of G-CSF by a 
protein-like Lactobacillus rhamnosus GR-1 secretory 
factor.  
In Chapter 5, I aimed to reveal the mechanism underlying the G-CSF production in 
GR-1-exposed macrophages. I found that GR-1 induced high levels of G-CSF mRNA 
expression in macrophages, whereas all other pro-inflammatory cytokines and 
chemokines mRNA were minimally expressed or absent (Fig. 5.1). Next, I showed 
that this cytokine profile was unique to GR-1 as other bacteria (Fig. 5.2) or other TLR 
stimuli (Fig. 5.1) potently induced G-CSF and pro-inflammatory cytokines. 
Accordingly, I showed that preferential production of G-CSF was mainly mediated 
through ERKs, NF-κB and PI3K/Akt but not JNKs  signaling pathways (Fig 5.3). I 
further showed that activation of all ERKs, NF-κB and PI3K/Akt signaling pathways 
were mediated through TLR2 (Fig. 5.4). Given that GR-1-SCS induced preferential 
production of G-CSF in macrophages similar to live GR-1 (Fig. 5.4C), I sought to 
characterize the responsible factor(s). I found that GR-1 responsible factor(s) 
involved in preferential G-CSF production was a heat-labile protein like molecule(s) 
(Fig. 5.4B) of 30-100 kDa in size (Fig. 5.4C). Taken together, I showed that GR-1 
induced preferential G-CSF production in a TLR2/ERKs/NF-κB/PI3K/Akt-dependent 
pathway by means of a protein like molecule(s) of 30-100 kDa in size. 
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6.2 CONCLUSION 
The main findings and conclusion of this thesis are summarized as follows: 
• G-CSF promoted the generation of gut-homing M2-like Gr-1high/F4/80+ 
macrophages in M-CSF-treated BMCs. 
• G-CSF had a disease ameliorating effect in DSS-induced acute colitis.   
• L. rhamnosus GR-1 preferentially induced G-CSF production through 
activation of TLR2-dependent NF-κB and PI3K/Akt signaling pathways. 
• The L. rhamnosus GR-1-secreted factor(s) responsible for preferential G-CSF 
production in macrophages was a heat-labile protein-like molecule(s) of 30-
100 kDa in size.  
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6.3 FUTURE DIRECTIONS 
The work presented in Chapters 3 and 4 provide many new and exciting avenues of 
research for examining the role and mechanism of G-CSF in gut immune regulation 
through macrophages. Further investigating the role of G-CSF in macrophage 
development and gut immune regulation can be aims of future research.  
In Chapter 3, I demonstrated that G-CSF promoted growth of Gr-1+/F4/80+ 
macrophages in only M-CSF, but not GM-CSF-exposed macrophages (Fig. 3.2 and 
Fig. 3.3). This indicates that G-CSF could potentiate the macrophage generation 
function of M-CSF in BMC culture. Activation of both M-CSF receptor and GM-CSF 
receptor induce similar signaling pathways, including JAK/STAT, Ras/ERKs and 
PI3K/Akt pathways [4-8]. Whether G-CSF activates a specific signaling pathway(s), 
such as JAK2-STAT5 [9], that are absent in M-CSF signaling but present in GM-CSF 
signaling or potentiates a specific signaling pathway, such as Ras/ERKs, that are 
differently regulated by M-CSF or GM-CSF [10], would be a matter of interest to 
investigate. G-CSF enhanced homing of adoptively transferred macrophages to the 
gut (Fig. 3.8 and Appendix A.3); however, whether these transferred cells were 
differentiated to resident macrophages after arriving in the gut is still unknown. Gut 
resident macrophages marked by CX3CR1high/Ly6C- have been shown to be recruited 
from CX3CR1low Ly6Chigh blood monocytes [11]. Therefore, it would be interesting to 
see the effects of G-CSF on the expression of CX3CR1 in BMDM after adoptive 
transfer. Moreover, Gr-1+/CD11b+ cells were shown to be myeloid-derived 
suppressor cells [12, 13] with colitis protective effects [14]. Therefore, it would be 
interesting to examine whether G-CSF-induced Gr-1+/F4/80+ macrophages exhibit 
similar functions as these myeloid-derived suppressor cells. Their suppressive effects 
can be assessed by examining proliferation of T cells in the presence or absence of 
purified Gr-1+/F4/80- cells or their condition media.  
Furthermore, G-CSF also increased Gr-1+/F4/80- cells in M-CSF-exposed BMCs (Fig. 
3.2). Since Gr-1 is transiently expressed in the myeloid lineage [15], it is not clear 
whether this cell population represent neutrophils or macrophage precursor cells. 
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Further characterization of Gr-1+/F4/80- cells in their morphology and neutrophil 
functions such as LPS/phorbol myristate acetate-induced formation of neutrophil 
extracellular traps (NETs) assay [16] will reveal whether these cells are bona fide 
neutrophils.  
In Chapter 4, I showed that G-CSF played a protective role in DSS-induced acute 
colitis model (Fig. 4.1). As the DSS model mainly involves innate immunity, the role 
of G-CSF in other colitis models should also be examined. The TNBS model of acute 
colitis is also used due to its efficiency in inducing colitis and convenience in 
handling [17, 18]. In contrast to the DSS model, the TNBS model involves adaptive 
immunity for the development of colitis. Since the adaptive immune system also 
plays an important role the development of colitis, examining the role of G-CSF by 
using G-CSFR-/- mice in the TNBS model will unravel the function of G-CSF in the 
context of gut adaptive immunity. Another suitable model to study the role of G-CSF 
in the gut inflammation is the CD4+CD45RBhigh T cell transfer model [19]. 
CD4+CD45RBhigh cells can be adoptively transferred into newly generated G-CSFR-/-
RAG-/- (lacking adaptive immunity) mice for the induction of colitis. This model will 
further evaluate the role of G-CSF in non-adaptive immune cells in the growth of a T 
cell dependent colitis. I also determined in Chapter 4 that adoptive transfer of G-CSF-
exposed macrophages reduced the severity of colitis in G-CSFR-/- mice (Fig. 4.5 and 
Fig. 4.6). The CD4+CD45RBhigh T cell transfer model can be used for co-transfer of 
G-CSF-exposed macrophages and CD4+CD45RBhigh cells to assess the importance of 
G-CSF-exposed macrophages in gut immune regulation.  
The IL-10-/- mouse model is a well-characterized spontaneous colitis model that 
indicates the importance of the anti-inflammatory cytokine IL-10 in maintenance of 
gut homoeostasis [20]. In addition, depletion of phagocytes in IL-10-/- mice 
ameliorates the colitis conditions in these mice [21]. Having observed the 
immunomodulatory role of G-CSF in down-regulating inflammatory cytokines [3, 22, 
23] and robust production of pro-inflammatory cytokines by macrophages in IL-10-/- 
mice [24], it would be best to evaluate the function of adoptively transferred G-CSF-
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exposed macrophages with an M2-like cytokine profile in newly generated G-CSFR-/- 
IL-10-/- mice.  
In addition, I found in Chapter 3 that G-CSF-exposed BMCs contained 3 different 
cell populations, Gr-1-/F4/80+, Gr-1+/F4/80+ and Gr-1+/F4/80- (Fig. 3.2A). Finding the 
responsible population in reducing severity of colitis in G-CSFR-/- mice might 
provided more insight into the mechanisms underlying the beneficial effects of G-
CSF.  
In Chapter 4, only DSS-treated G-CSFR-/- mice, but not G-CSFR+/+ and +/- mice, 
formed a pseudomembranous structure admixed with a large population of bacteria, 
suggesting that these mice were defective in controlling bacterial infection following 
DSS-induced tissue damage. It is still undetermined whether and how these features 
affect the outcome of severe colitis in G-CSFR-/- mice. Since all mice were kept under 
conventional housing conditions, using specific-pathogen free conditions would offer 
unique opportunities to study the effects of these structures on the outcome of colitis 
in G-CSFR-/- mice.    
In Chapter 5, there were no differences in IκB phosphorylation and degradation in 
between GR-1 and LTA treatments, indicating that GR-1 induces IκB degradation. I 
and others [25-28] have shown that NF-κB signaling pathway is important for 
expression of TNF-α, IL-12 and G-CSF, but how GR-1-dependent NF-κB activation 
induces only G-CSF is still undetermined. It is, therefore, important to examine 
whether GR-1 can inhibit or reduce the nuclear translocation of NF-κB or NF-κB 
DNA binding activity, leading to preferential G-CSF production by other pathways.  
Given that PPAR-γ involves in nuclear export of RelA subunit of NF-κB, it would 
also be pertinent to investigate whether GR-1 inhibit NF-κB transcription activity. It 
is also interesting to investigate whether GR-1 can manipulate the non-canonical 
pathway of NF-κB in order to induce preferential G-CSF production. GR-1 also 
activated PI3K/Akt pathway with minimal effects on JNKs activation. Activation of 
PI3K/Akt pathway has been shown to negatively regulate MAPKs- and NF-κB-
dependent inflammatory cytokine production in macrophages through inhibition of 
	  	  
198	  
key inflammatory transcription factors including NF-κB, AP-1 and Egr-1 [29]. 
However, we ruled out such possibilities due to the fact that inhibition of PI3K/Akt 
pathway did not result in increased production of TNF-α (Fig 5.3). It is possible that 
GR-1 preferentially produce G-CSF over TNF-α through directly inhibiting the 
activation of JNKs. To date, several molecules have been shown to be involved in the 
JNKs specific inhibition. The X-link inhibitor of apoptosis (XIAP) and growth arrest 
and DNA damage induced protein (Gadd45β) prevent JNKs activation by ubiquitin-
mediated degradation of TAK1 [30] and directly binding and inhibiting MKK7 
activity [31], respectively. Therefore, it will be interesting to investigate the activation 
of common upstream activator of JNKs, such as MKK7, or XIAP and Gadd45β, in 
GR-1-treated macrophages.  
I have not yet identified the GR-1 factor responsible for the preference production of 
G-CSF. Given that the GR-1 factor(s) was a secreted protein-like molecule(s) of 30-
100 kDa in size, using a size-exclusion and anion or cation column chromatography 
would further purify the GR-1 factor(s). In fact, I have tried to identify the GR-1 
factor(s) through gradient fast protein liquid chromatography (FPLC) on the 80% 
ammonium sulfate fraction and the Centricon precipitated GR-1-SCS samples that 
had the preferential G-CSF production activity. However, the results were not 
promising as the factor would not bind to the Mono Q column and induces G-CSF 
and to some extend TNF-α in almost all fractions in BMDM (data not shown). 
However, I observed that released products from GR-1 cultured in PBS for 2 h would 
not be able to induce preferential G-CSF production (data not shown). Further mass 
spectrophotometry analysis on the GR-1-PBS incubated culture supernatant and GR-
1-SCS revealed only one recognized protein with high homology score to fibrinogen 
binding protein (FBP) from L. rhamnosus. However, the recombinant FBP produced 
from E. coli BL21 with histidine-tagged fusion showed no preferential G-CSF 
activity in BMDM. Two dimensional gel electrophoresis and subsequent tandem mass 
spectrometry of the released proteins from GR-1 or GR-1 cultured in PBS would help 
us to find secreted candidate protein. Once complete sequences of candidate proteins 
are revealed, the recombinant protein can be expressed in E. coli and purified 
recombinant protein can be tested for further confirmation of its G-CSF stimulating 
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activity. Similar to GR-1-SCS, LGG-SCS has been shown to strongly induce G-CSF 
production in macrophages. LGG secreted proteins, p40 and p75, have been both 
shown to activate Akt [32-34]. By using GR-1 mutant in p75 SCS, we, however, 
ruled out that this protein is involved in preferential G-CSF production by GR-1 in 
macrophages (Appendix A.6). 
One of the strategies by which probiotics elicit their effects is by increasing anti-
inflammatory cytokines such as IL-10 and G-CSF, while decreasing pro-
inflammatory cytokines such as TNF-α [3, 22]. Thus, the anti-inflammatory capacity 
of probiotics may be useful in treatment of IBD. I showed that G-CSFR-/- mice 
exhibited more severe inflammatory conditions in a DSS-induced acute colitis model 
than wild-type mice (Fig. 4.1), indicating an importance role of G-CSF in intestinal 
immune regulation. I also showed that the GR-1 or its SCS was able to induce G-CSF 
in macrophages. Given that G-CSF is able to down-regulate inflammatory cytokines, 
it is expected that the production of G-CSF by oral administration of GR-1 or 
intraperitoneal injection of GR-1-SCS would reduce inflammatory responses in 
colitis. This will extend our understanding on the mechanistic basis of the proposed 
probiotic GR-1 health effects. While results from previous studies on therapeutic 
implication of LGG for IBD remain controversial [35-37], further detailed and 
extensive experiments would reveal the role of GR-1 in colitis. 
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Appendix A.1. BMCs from lys-EGFP-ki transgenic mice were expressing EGFP. 
BMCs from lys-EGFP-ki transgenic (right panel) and wild-type (left panel) mice were 
cultured in the presence of M-CSF (20 ng/ml) + G-CSF (10 ng/ml). On day 5, F4/80+ 
cells were sorted using MACS and were analyzed for EGFP expression before 
intravenously injecting to G-CSFR+/+ mice using flow cytometry. 
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Appendix A.2. BMCs from wild-type and G-CSFR-/- mice show no differences in 
Gr-1 and F4/80 surface marker expression in the presence of M-CSF or GM-
CSF. BMCs from wild-type and G-CSFR-/- mice were treated with GM-CSF (10 
ng/ml) or M-CSF (20 ng/ml) for five days. (A and B) Based on the Gr-1 and F4/80 
expression characteristics, cells were divided into 3 populations: P1, Gr-1low/F4/80+; 
P2, Gr-1high/F4/80+; P3, Gr-1+/F4/80-.  (C and D) Percentage of each cell population 
was quantified and plotted. Data are average of two independent experiments. 	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Appendix A.3. G-CSF increases localization of F4/80+ M-BMCs in the intestine. 
BMCs from lys-EGFP-ki transgenic mice were treated with M-CSF (20 ng/ml) + G-
CSF (10 ng/ml) for five days. F4/80+ cells were isolated by MACS and 1.0 × 106 cells 
were injected to the recipient mice through tail veins. (A) After two days of adoptive 
transfer (1.0 × 106 cells), spleen, liver, kidney, lung, heart and bone marrow tissue 
sections were prepared and viewed through a fluorescent microscope. (B) Six hours 
after injection, sections from the large and small intestines of the recipient mice (total 
of four mice in two different times) were viewed through a fluorescent microscope. 
Images show representative fluorescent microscopy results. (C) Average numbers of 
EGFP+ cells per 40× field of view (> 20) from the small and large intestine tissue 
sections were counted and plotted. Data shown as mean ± SEM (n ≥ 3; *, p < 0.05 by 
Student’s t-test). 
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Appendix A.4. Numbers of macrophages and neutrophils are significantly 
reduced in spleen and bone marrow in G-CSFR -/- mice compared to those of 
wild-type mice. Splenocytes (A-B) and BMCs (B-C) were prepared from wild-type 
and G-CSFR-/- mice. Based on the Gr-1 and F4/80 expression characteristics, cells 
were divided into different populations. (B and D). Percentage of each cell population 
was quantified and plotted. Data shown as mean ± SEM (n = 3; *, p < 0.05). 	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Appendix A.5. Induction of expression of cytokine and chemokine genes in 
immortalized BMDM treated with GR-1and TLR2/4 agonists. 
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Appendix A.5       
 
Gene 
Symbol Gene of Interest
* 
Fold Change 
GR-1  
(20 CFU/cell) 
PAM2  
(1 µg/ml) 
PAM3 
(1µg/ml) 
LPS  
(1 µg/ml) 
Ccl1 Chemokine (C-C motif) ligand 1 N.D
1 N.D N.D 48 
Ccl12 Chemokine (C-C motif) ligand 12 2 53 15 229 
Ccl19 Chemokine (C-C motif) ligand 19 -1 -3 2 1 
Ccl2 Chemokine (C-C motif) ligand 2 1 12 4 8 
Ccl22 Chemokine (C-C motif) ligand 22 -1 16 3 33 
Ccl24 Chemokine (C-C motif) ligand 24 -2 -2 -2 -6 
Ccl3 Chemokine (C-C motif) ligand 3 2 14 7 16 
Ccl4 Chemokine (C-C motif) ligand 4 2 34 9 48 
Ccl5 Chemokine (C-C motif) ligand 5 -1 3 7 452 
Ccl7 Chemokine (C-C motif) ligand 7 2 40 7 38 
Cd70 CD70 antigen N.D N.D N.D 27 
Cntf Ciliary neurotrophic factor -1 1 1 -1 
Csf1 
Colony stimulating 
factor 1 
(macrophage) 
-1 2 -1 2 
Csf2 
Colony stimulating 
factor 2 
(granulocyte-
macrophage) 
3 12 24 8 
Csf3 
Colony stimulating 
factor 3 
(granulocyte) 
61 161 142 124 
Cx3cl1 Chemokine (C-X3-C motif) ligand 1 -1 4 1 7 
Cxcl1 Chemokine (C-X-C motif) ligand 1 N.D N.D N.D 85 
Cxcl10 Chemokine (C-X-C motif) ligand 10 2 4 18 1183 
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Cxcl11 Chemokine (C-X-C motif) ligand 11 N.D N.D N.D 250 
Cxcl13 Chemokine (C-X-C motif) ligand 13 N.D N.D N.D 11 
Cxcl16 Chemokine (C-X-C motif) ligand 16 1 25 2 22 
Cxcl3 Chemokine (C-X-C motif) ligand 3 5 155 24 163 
Cxcl9 Chemokine (C-X-C motif) ligand 9 N.D N.D N.D 457 
Gpi1 Glucose phosphate isomerase 1 -1 2 -1 -2 
Il10 Interleukin 10 4 5 2 24 
Il12a Interleukin 12A N.D N.D N.D 159 
Il12b Interleukin 12B N.D N.D N.D 269 
Il15 Interleukin 15 -1 -1 1 11 
Il16 Interleukin 16 1 3 -1 6 
Il17f Interleukin 17F 1 -1 1 1 
Il18 Interleukin 18 1 -1 2 4 
Il1a Interleukin 1 alpha 4 84 50 249 
Il1b Interleukin 1 beta 6 118 84 448 
Il1rn Interleukin 1 receptor antagonist 2 10 4 18 
Il23a Interleukin 23, alpha subunit p19 1 1 3 5 
Il24 Interleukin 24 N.D N.D N.D 11 
Il27 Interleukin 27 1 5 3 43 
Il6 Interleukin 6 7 214 154 1121 
Il7 Interleukin 7 N.D -1 N.D 7 
Lif Leukemia inhibitory factor N.D 34 26 45 
Lta Lymphotoxin A 1 2 3 4 
Ltb Lymphotoxin B 1 6 1 4 
Mif 
Macrophage 
migration inhibitory 
factor 
-1 -1 1 -2 
Osm Oncostatin M 1 4 2 3 
Pf4 Platelet factor 4 -1 5 1 -1 
Ppbp Pro-platelet basic protein 1 4 2 3 
Spp1 Secreted phosphoprotein 1 1 3 2 1 
Tgfb2 Transforming growth factor, beta 2 1 -3 2 N.D 
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Tnf Tumor necrosis factor 2 90 114 156 
Tnfsf10 
Tumor necrosis 
factor (ligand) 
superfamily, member 
10 
N.D N.D N.D 298 
Tnfsf13b 
Tumor necrosis 
factor (ligand) 
superfamily, member 
13b 
1 2 1 2 
Vegfa Vascular endothelial growth factor A 1 4 -1 -1 
1 Genes that were not amplified or not detectable in the PCR array were marked as 
'N.D' (not detectable). 
* Genes that were not amplified or not detectable in the PCR array of all treatments 
were not reported. For the complete list of genes refer to 
http://www.sabiosciences.com/ArrayList.php?pline=PCRArray (cytokines and 
chemokines PCR Array).    
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Appendix A.6. GR-1 mutant in p75 (Msp1) has similar capability to GR-1 WT in 
inducing preferential G-CSF production over TNF-α. Production of TNF-α (in 4 
h) and G-CSF (in 24 h) was measured from spent cell culture media of BMDM 
treated with GR-1-spent culture supernatants (SCS; 1/25 dilution) of wild-type (WT) 
and Δp75 GR-1 using ELISA. Data shown as mean ± SEM. 
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